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Polyketides are a remarkable class of compounds. In addition to exhibiting a 
great structural and functional diversity, they often possess drug activity that has 
been used for decades in many pharmaceutical fields. They are biosynthesized by 
highly complex machineries called polyketide synthases. Therefore, these enzymes 
represent a very promising tool for the production of compounds with either new or 
enhanced drug activity. Mycobacterium tuberculosis uses polyketides as virulence 
factors, and thus polyketide synthases also represent potential drug targets. 
Tuberculosis is the second cause of death due to a single infectious agent and is still 
considered as a global health concern. Nowadays, the need for new drugs targeting 
new pathways is critical. 
PpsC is a type-I mono-modular polyketide synthase essential for the synthesis 
of the well-characterized phthiocerol dimycocerosates virulence factors in 
Mycobacterium tuberculosis. In an attempt to both help the search for new 
antituberculosis drugs, and decipher the complex mechanism used by polyketide 
synthases, we have undertaken the functional and structural study of PpsC using X-
ray crystallography. Type-I polyketide synthases are made of several domains, each 
possessing a different catalytic activity. Due to their size and intrinsic flexibility these 
enzymes are difficult to characterize in their full-length form. We have then used the 
recently developed domain trapping method to identify soluble fragments 
representing each domain of PpsC. The study of these fragments has led to the 
structural determination of the acyltransferase domain, the dehydratase domain, and 
the nucleotide-binding subdomain of the enoylreductase domain of PpsC. In 
addition, we have deciphered the catalytic mechanism of the dehydratase domain, 
with the help of the structure of a substrate-enzyme complex and in vitro enzymatic 
tests. 
Polyketide synthases need to be activated by the transfer of a prosthetic group 
onto their acyl carrier protein domain, catalyzed by 4’-phosphopantetheinyl 
transferases. In Mycobacterium tuberculosis, PptT is responsible for the activation of 
polyketide synthases and is thus essential to its virulence. Therefore, we were also 
interested in the functional and structural characterization of this promising drug 
ABSTRACT 
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target. Using the split-GFP technology, we have designed a protocol for the 
production and purification of PptT, where its co-factors play an essential role for its 
stability both in vivo and in vitro. Activity of the enzyme was assessed by in vitro 
transfer of the prosthetic group onto the acyl carrier protein domain of PpsC. Finally, 
we have solved the three dimensional structure of PptT at 1.4 A resolution using X-
ray crystallography, which will allow the structure-based design of inhibitors. 

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Polyketides make good drugs 
 
Of the ~10,000 known polyketides, 1% possess drug activity 
From standard pharmaceutical screens, the typical hit rate is <0.001%. 
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A. POLYKETIDES 
 
 
1. PHARMACEUTICAL INTEREST 
 
Polyketides cover a large variety of structure and shape. They can adopt 
aliphatic, aromatic or macrolidic structures with multiple modes of folding and ring 
formation (Figure 1). They can be as small as the 6 carbons triacetic acid lactone or 
up to 164 carbons like the 3422 Da maitotoxin, they possess variable molecular 
properties and occupy a large chemical space. Polyketides have therefore found 
applications in numerous pharmaceutical fields as antibacterial, anticholesterolemic, 
immunosuppressant, antifungal, anti-cancer, antiparasitic, insecticide and probably 
other activities that remain to be characterized. The lovastatins are the most 
successful cardiovascular drugs of all time. Erythromycin has been in clinical usage 
for 53 years while its derivative azithromycin is one of the best-selling antibiotics in 
the world. Rifampicin is one of the most commonly used antibiotics to treat the 
second most common cause of death from an infectious disease, i.e. tuberculosis. The 
enediyines, especially calicheamicins, are among the most powerful anti-cancer 
agents yet discovered. By targeting the bacterial ribosome, tetracycline and its 
derivatives have been widely used as broad-spectrum antibiotics. There are numerous 
examples of pharmaceutical success stories concerning polyketides (Table 1). In fact, 
more than one third of natural products and derivative compounds approved as 
drugs between 2005 and 2007 were polyketides. As testimony to their importance, 
polyketide-derived pharmaceuticals comprise 20% of the top-selling drugs and 
annual sales routinely reach US$20 billion. 
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2. A BIT OF HISTORY 
 
In 1893 at London University, James Collie serendipitously discovered a 
remarkable set of synthetic reactions. While working on the elucidation of the 
structure of dehydroacetic acid by degradation chemistry [1], he discovered that 
boiling dehydroacetic acid with barium hydroxide yielded an aromatic compound, 
orcinol, as one of the reaction products. Collie showed that orcinol and related 
compounds did not fit into any of the previously described chemical classes, and 
therefore proposed a new chemical class named polyketides which contain the 
structure: CH3-CO-(CH2-CO)n-X. Later, Collie proposed a rough mechanism for the 
synthesis of orcinol and related compounds, based solely on their structure, implying 
repetitive condensation or polymerization reactions [2]. 
However, Collie’s hypotheses were met with indifference until the 1950s, when 
Arthur Birch came up with the theory that polyketides could be generated from 
acetate units by repeated condensation reactions. He applied his theory to the 
synthesis of the polyketide 6-methyl-salicylic acid (6-MSA) produced by the fungus 
Penicillium patulum. The linkage of four acetate units would be necessary to generate 
a first intermediate, followed by a sequence of aldol condensation, dehydration and 
enolization that would finally lead to the aromatic natural product. To test this 
hypothesis, he fed a polyketide-producing organism with a 14C radiolabelled version 
of his proposed precursor. Then he isolated the generated products and subjected 
them to radioactivity measurement. The results were consistent with his predictive 
pattern of incorporation [3]. This new methodology inaugurated a great activity in 
the natural product community. Subsequent experiments established not only that 
many polyphenolic aromatic molecules were biosynthesized from acetate units but 
also that many non-aromatic compounds were also formed by further 
transformations of such products. 
The results on natural product biosynthesis coincided with the development of 
nuclear magnetic resonance and mass spectrometry as powerful new techniques for 
the structural elucidation of complex molecules. A structural study that might take 
several years of intensive work using the decomposition methodology, might be 
solved in only a matter of weeks or even days by the new spectroscopic technologies. 
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These emerging technologies were applied to understand the biosynthesis of 
chemically well-characterized polyketides such as nargenicin [4] and erythromycin 
[5], and pointed to a biosynthetic route to the reduced aliphatic polyketide. In this, 
each successive addition of a building block is immediately followed by reductive 
modification of the newly-formed keto group (so-called ‘processive’ biosynthesis), as 
opposed to construction of a polyketone chain followed by reduction. 
 
3. NEW CHALLENGES FOR 
POLYKETIDE DRUGS 
 
Discovering analogues of widely used polyketides with improved 
pharmaceutical properties or totally new structures with novel properties has always 
been a challenge. Efforts in medicinal chemistry have focused on two main strategies, 
(1) the identification of new compounds from the biosphere or (2) the semi-synthetic 
modification of existing ones. The latter strategy has proven to be valuable for the 
development of today best-selling drugs such as azithromycin (erythromycin-
derived), simvastatin (lovastatin-derived) or doxycyclin (tetracyclin-derived). 
However, these semi-synthetic drugs are restrained to the same mechanism of action 
than their parental compound and, in the case of antibiotics, are often subjected to 
previously-developed bacterial resistance. 
Identification of new naturally occurring compounds has recently become a 
much simpler approach. Indeed, development of high-throughput sequencing 
techniques and whole genome sequencing allowed the mapping of genes coding the 
enzymes responsible for the biosynthesis of polyketides: the polyketide synthases 
(PKSs). The genomic era allowed researchers to accumulate hundreds of pks genes 
for which the resulting polyketide is to-be-assigned are now available (Figure 2). 
However, such a data-mining analyze is time-consuming and requires to precisely 
know the complex biosynthesis mechanism used by the concerned PKS in order to 
confidently attribute a structure to the polyketide.  
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Alternatives to the so-called semi-synthetic modification approach to develop 
new compounds have arisen from the growing biochemical knowledge on polyketide 
biosynthesis. These new strategies consist either in exploiting existing PKS 
machineries, or genetically engineering the pks genes. The first strategy is 
exemplified by the whole-cell biosynthesis of simvastatin [6], a compound normally 
synthesized by a chemical modification of the lovastatin polyketide. The authors 
successfully used the substrate versatility of the PKS responsible for the biosynthesis 
of the lovastatin to directly produce the simvastatin in an engineered E. coli strain. 
This method represents an interesting alternative to the expensive and time-
consuming chemical modification. The latter strategy is commonly referred to as 
“combinatorial biosynthesis”. In addition to classic point mutations targeting amino 
acids of interest, it requires design of patchwork PKS genes from two or more genes 
spliced together. Using this strategy, enzymatic activities from a given PKS could be 
added or exchanged to another PKS. First reports of successful applications to 
develop new compounds were published in the mid-1990s [7], [8] with the synthesis 
of a few novel triketide lactones. A decade later, encouraging advances have been 
made [9], [10], [11], which permitted, for example, the biosynthesis of more efficient 
geldanamycin analogues anti-cancer drugs (Figure 3). In 2005, with the arising of 
generic approaches to design synthetic pks genes [12], directed engineering of 
modular PKSs had resulted in the production of a total of more than 200 new 
polyketides, but key challenges remain before the potential of combinatorial 
biosynthesis can be fully realized. Indeed, these low efficient and labor-intensive 
experiments cannot be brought up to high-throughput industrial drug discovery. 
Also, in all the different enzymatic activities catalyzed by PKSs, only the ones 
responsible for the incorporation, but not modification, of the building blocks have 
been successfully engineered. Besides, PKSs chosen so far to design patchworks could 
be considered as “case studies” since they often share high similarity and are 
therefore easier to manipulate, but do not offer a wide variety of new biosynthesized 
polyketides. 
All the recently developed strategies to identify or create new compounds have 
been hindered by the lack of precise knowledge concerning the molecular and 
structural features that govern the biosynthesis mechanism of polyketides. Such 
knowledge would hopefully allow a more rational design of various polyketides by 
combinatorial biosynthesis, and help the development of improved methods to 
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identify naturally occurring polyketides from uncharacterized pks genes sequences. 
Therefore, in parallel to the development of new tools for genetic engineering [13] 
and heterologous expression [12] to efficiently biosynthesize polyketides, research is 
now focusing on deciphering the structure and function of the complex machineries 
that are PKSs.  
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B. POLYKETIDE SYNTHASES 
 
 
1. POLYKETIDE BIOSYNTHESIS 
 
Polyketide synthases are the enzymes responsible for the biosynthesis of 
polyketides. In order to provide a wide variety of polyketides and to adapt to different 
environments, these enzymes have evolved to different types. To better characterize 
and classify polyketide synthases, it is appropriate to digress into the field of fatty 
acid biosynthesis. Indeed, polyketide and fatty acid biosynthesis are highly related, 
both in the nature of the chemistry used in the chain extension and in the character of 
the enzymes that are used for chain assembly. Interestingly, the earliest publications 
addressing the origins of fatty acids and polyketides actually appeared in the same 
issue of the Journal of the Chemical Society in 1907 [2], [15]. 
 
a) Fatty Acid Biosynthesis 
 
GENERAL REACTION OF THE FATTY ACID BIOSYNTHESIS 
Fatty acids are assembled from C2 units by head-to-tail linkage using an 
iterative mechanism. A starter acyl unit (usually acetyl) is attached via a Claisen 
condensation (Figure 4A) to a “building block” (which will now be referred to as an 
“elongation unit”), i.e. a malonyl unit. This condensation reaction results in a β-keto 
ester, which is then successively modify to give a saturated chain. Several enzymes 
are involved in this pathway and can be grouped into two classes depending on their 
function: the condensation enzymes and the modification enzymes. All of these 
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represented activities are either coded as domains in a multi-domain protein or as 
individual enzymes assembling into a complex. 
 
THE REACTION SEQUENCE 
The condensation reaction takes place with the help of three different enzymes 
(Figure 4B). First, the acyltransferase (AT) recruits an acetyl (from acetyl 
coenzyme-A) as the starter unit and transfers it to the acyl carrier protein (ACP) 
which in turn loads it into the cysteine thiol of the KS. Then, the AT recruits an 
elongation unit from an acyl-coenzyme-A precursor and transfers it to the ACP. The 
condensation reaction is then catalyzed by the KS and results in a β-keto ester bound 
to the ACP. The modification reactions, which will now be referred as “β-carbon 
processing”, also involves three enzymes: a ketoreductase (KR), a dehydratase (DH) 
and an enoylreductase (ER). The β-keto ester first undergoes a reduction by the KR to 
yield a hydroxyl, and then is dehydrated by the DH resulting in a carbon-carbon 
double bond formation. Finally the growing fatty acid is reduced again by the ER to 
yield a saturated carbon chain longer than the original by two methylene units. The 
product is released as a free acid or an ester by a thioesterase (TE). 
 
THE ROLE OF ACP AND ITS ACTIVATION 
The ACP has a central role in fatty acid biosynthesis. It is often referred to as a 
“shuttle” because it carries the acyl to be extended and brings it to the other enzymes 
to realize condensation and β-carbon processing. But the acyl is not carried by a thiol 
in the primary chain of the ACP, instead it is the terminus of a flexible arm added to 
the protein in a post-translational modification. This ACP activation is catalyzed by 
phosphopantetheinyl transferases (PPTases) that use coenzyme-A (CoA) and a 
divalent cation as cofactors. It consists in the covalent linkage of a 4’-
phosphopantetheine moiety from CoA to a conserved serine residue of the ACP [16]. 
The 4’-phosphopantetheine (P-pant) carries the growing chain and delivers it to the 
various enzymes responsible for chain extension. This post-translational modification 
has been shown to be essential to fatty acid biosynthesis, polyketide biosynthesis and 
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non-ribosomal peptide biosynthesis [17], [18]. The activation process is detailed in 
the chapter dedicated to PPTases (section I.B.2). 
 
THE DIFFERENT FAS SYSTEMS 
All the represented activities that lead to fatty acid biosynthesis can be 
genetically and structurally coded in different manners depending on the function to 
achieve and mainly on the type of organism. Generally, in bacteria the fatty acid 
synthase consists of a complex composed by a set of discrete proteins that can be 
isolated, we refer to it as the FAS-II system. In mammals, on the other hand, all the 
enzymes are covalently linked to form a large multifunctional protein: FAS-I. 
However, in some organisms, these two systems can be simultaneously expressed and 
serve different functions. Interestingly, a eukaryotic FAS-II system is also present in 
mitochondria of eukaryotic cells (for review [19]). While FAS-I mainly produce 
saturated palmitate and reaction intermediates, FAS-II is more versatile as it can 
synthesize products with variable chain lengths and different degree of unsaturation 
or hydroxylation. 
 
b) Polyketide Biosynthesis 
 
THE DIFFERENT TYPES OF PKS 
Polyketide synthases can also be divided into type-I and type-II, similarly to 
the FAS systems. Indeed, type-I and type-II PKS types correspond to a unique 
polypeptide chain bearing all enzymatic activities or multiple discrete enzymes, 
respectively. In general, type-I PKSs biosynthesize macrolides, e.g. erythromycin, or 
long aliphatic chains, whereas type-II PKSs often biosynthesize aromatic molecules 
produced by iterative cycles, e.g. tetracycline (Figure 1).  
Type-I PKSs can be further sub-divided into two categories: 
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x Iterative type-I which synthesize a polyketide by iterative cycles. At the end 
of a cycle the extended acyl is transferred back to the KS to realize another 
cycle, just like FAS does (Figure 4). 
x Modular type-I, which are consecutive PKSs organized in modules, each 
module being responsible for the condensation of an elongation unit with 
the intermediate (equivalent to a cycle). Instead of being subjected to 
iterative condensation cycles, the acyl is streamed through the different 
modules until it is released by a thioesterase activity, usually included in 
the terminal module. PKSs can be mono-modular (one module per PKS), or 
multi-modular (several modules per PKS). 
In addition to type-I and type-II, PKSs can also exist as type-III, which are 
self-contained enzymes that form homodimers and catalyze the priming, extension, 
and cyclization reactions iteratively to form polyketide products. They do not use an 
ACP and hence, do not require post-translational activation by PPTase. Resulting 
polyketides are often small molecules comprising one or two aromatic cycles Best 
known examples are flavonoids that constitute the major pigments in plants and are 
synthesized by chalcone synthases type-III PKSs. Due to their divergence with type-I 
PKSs, the primary focus of this manuscript, type-III PKSs will not be described. 
However, excellent reviews are available on the subject: [20], [21], [22]. 
Together with non-ribosomal peptide synthases (NRPSs), type-I PKS and type-
I FAS form the megasynthases class of enzymes. Megasynthases are large proteins 
containing all the catalytic activities required for the biosynthesis of their respective 
products on a single polypeptide chain. Catalytic activities are borne by domains 
separated by linkers on the polypeptide chain. These enzymes also have in common 
the use of a carrier protein (CP) domain, named acyl carrier protein (ACP) for FASs 
and PKSs, and peptidyl carrier protein (PCP) for NRPSs because of the nature of the 
carried intermediate. All these carrier proteins must be activated by the transfer of a 
P-pant moiety by PPTases. NRPSs also possess condensation and modification 
domains, but due to the peptidic nature of their substrates these domains are not 
homologous to FASs and PKSs domains, and thus will not be discussed. 
Despite their architectural and functional similarities, FAS and PKSs also 
possess striking differences in their composition. While type-I FASs necessarily 


 
 
include KS, AT, DH, ER, KR, ACP and TE domains to carry out their function, a 
distinction between essential and optional domain exists in PKSs: 
x Essential (or core) domains are responsible for condensation: KS, AT and 
ACP 
x Optional domains in different combinations: KR, KR-DH, or KR-DH-ER, 
that gradually process the previously formed β-keto ester to give a 
hydroxyl, a carbon-carbon double bond, or a saturated chain, respectively 
x The thioesterase activity can be borne by a domain or a trans-active enzyme 
x Additional domains can also be included in PKSs such as methyltransferase 
and sulfhydrolase 
Partial β-carbon processing of the intermediate, involving KR and DH domains, will 
then allow the presence of hydroxyl and keto substitutions or the formation of a 
permanent carbon-carbon double bond with all associated stereochemistries. In 
addition to the variability in domain composition, AT domains from PKSs cover a 
wide range of possible elongation units and a given AT domain can sometimes even 
accept different elongation units. 
The possible organization of PKSs into modules permits a great number of 
combinations in terms of domain composition, substrate specificity and selectivity for 
each round of condensation/β-carbon processing. This overall flexibility in PKSs 
allows the synthesis of a wide variety of polyketides. Besides, accounting for the 
potential action of trans-acting enzymes to further modify the resulting polyketide, 
possibilities for the nature of the final product are then almost infinite. For these 
reasons, type-I PKSs and especially modular ones represent very interesting targets 
with regard to biotechnological aspects such as combinatorial biosynthesis. Indeed, 
the presence of all domains on the same polypeptide chain makes PKSs easier to 
manipulate. 
 
ERYTHROMYCIN BIOSYNTHESIS: A PARADIGM OF MODULAR 
PKSs 
The biosynthesis of erythromycin has been extensively studied since the 
discovery of this macrolide polyketide in 1949 by Eli Lilly and co-workers (U.S. patent 
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2,653,899; 1953). It is now well characterized and represents the paradigm for the 
understanding of the structure and biochemical function of modular polyketide 
synthases. 
Eryrthromycin biosynthesis can be divided into two phases. In the first phase 
the PKSs catalyze sequential condensations of one unit of propionyl-CoA and six 
units of methylmalonyl-CoA to give 6-deoxyerythronolide B (6-deB), the first 
enzyme-free intermediate. In the second phase, 6-deB is modified by a series of 
“tailoring” enzymes which include hydroxylases, glycosyltransferases, and 
methyltransferases. Though the modifying steps are essential to produce the active 
antibiotic erythromycin, the rest of this chapter will focus on the biosynthesis 
catalyzed by modular PKSs, the 6-deoxyerythronolide B synthases (DEBS). 
6-deoxyerythronolide B biosynthesis is catalyzed by 3 DEBS subunits (Figure 
5). Each homodimeric DEBS subunit contains two 160–200 kDa protein modules, 
each responsible for a single round of polyketide chain extension and β-carbon 
processing. Within each module are present several catalytic domains that are 
analogous in structure, function, and organization to the corresponding FAS 
components. All six DEBS modules contain the three core domains but their 
composition in optional β-carbon processing domains is variable. Additionally, at the 
N-terminus of the most upstream module is a loading didomain (AT-ACP) that 
primes the KS domain of module 1 with the propionyl starter unit. Finally, cyclization 
and release of the 6-dEB is controlled by a thioesterase (TE) domain located at the C-
terminus of the most downstream module. 
 
OUTSTANDING ISSUES 
As highlighted above, the DEBS example shows the striking collinearity that 
exists between the organization of the domains encoded by the PKSs genes and the 
order of the biochemical reactions that generate the polyketides. Indeed, the chain 
length, substitution pattern, and oxidation level of the initially generated linear 6-
dEB, are the direct consequence of both the number of DEBS modules and the 
domain composition of these modules. Nonetheless, such straightforward 
correlations have proven to be elusive for many modular PKSs-based biosynthesis 
mechanisms. Presence in individual PKS modules of inactive β-carbon processing 
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domains [23], [24], [25], trans-acting domains [26], [27], [28], [29], multiple AT or 
ACP domains [30], [31], “broken modules” [32], [33], as well as module skipping 
[34], [35] and stuttering [36], [37] hinder the establishment of a clear relationship 
between pks gene sequences and biochemical function. Also, unusual AT domain 
specificity toward elongation units such as chloroethylmalonyl-CoA [38] or 
hexylmalonyl-CoA [39] eventually adds further complexity to the process. 
In addition to these “abnormalities” in PKS modules, there still are a number 
of outstanding issues about polyketide biosynthesis that mainly concern:  
x Elongation unit selectivity by AT domains 
x Recognition of the growing polyketide by KS domains. 
x Substrate specificity of the β-carbon processing domains. 
x Stereochemistry induced by β-carbon processing of the β-keto ester 
x Domain-domain interactions required for both stabilizing PKS structure 
and mediating ACP specificity toward the other domains 
x Module-module interactions that allows efficient and error-prone 
streaming of the intermediate to the next module. 
x Overall structural architectures of isolated modules (mono-modular PKS) 
or iterative PKS that could be different depending on their domain 
composition. 
x Overall structural architecture of multiple modules on multi-modular PKS 
(DEBS-like) 
x Interactions with enzymes acting in trans 
x Shuttling with other metabolite biosynthesis pathways 
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c) Review of Structural and Functional Data on 
Polyketide Synthases 
 
(1) CONDENSATION DOMAINS 
 
In the last two decades, efforts have focused on both structural and functional 
studies of PKSs-mediated biosynthesis and yielded great advances in the 
understanding of these complex machineries. X-ray or NMR structures of each 
individual domain from PKSs are now available and some issues highlighted in the 
previous section have been at least partially solved. Yet, structures of multiple 
domains on a single polypeptide chain are almost inexistent though they are essential 
to decipher the complex mechanism required for polyketide biosynthesis. For that 
matter, biochemical and structural information on sequence- and structure-related 
FASs remain invaluable for PKSs studies. Furthermore, in addition to the functional 
analysis of isolated domains, recent results on linkers, inactive domains, docking 
domains or dimerization motifs indicate an essential role of these structural 
constituents in the structure and function of PKSs and are therefore mentioned in 
this chapter. 
 
THE KETOSYNTHASE DOMAIN 
Among PKS domains, the ketosynthase domain is the most conserved. All KS 
domains, either from PKSs or FASs, adopt a thiolase fold (Figure 6A). This fold 
consists in alternative layers of α-helices and β-sheets to form an α/β/α/β/α 
architecture. Several 3D structures of KS-AT didomains are available from type-I PKS 
[40], [41] and type-I FAS [42]. 
KS is a homodimer composed of ~400-450 residue-long monomers with an 
extensive dimer interface stabilized by a pair of hydrogen-bonded, antiparallel β-
strands, which creates a 14-stranded β-sheet spanning both monomers. It is thought 
to stabilize dimerization of the entire megasynthase [43]. KS is responsible for the 
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chain extension of the growing polyketide, and thus features a substrate-binding 
tunnel divided into two halves: an acyl-binding region to bind the ACP-acyl to be 
extended, and a P-pant-binding region to bind the elongation unit. The P-pant-
binding region stretches from the enzyme surface to the active-site cysteine and is 
relatively well conserved, reflecting its universal role in binding the P-pant moiety. 
The reactive cysteine is positioned on a ‘‘nucleophilic elbow’’ such that the positive 
dipole of the α-helix decreases its pKa and increases its nucleophilicity [44]. In 
addition to this cysteine (from a TACSSS motif), the catalytic machinery also 
comprises two histidine residues (from EAHGTG and KSNIGHT motifs). The acyl-
binding region, on the other hand, can vary significantly between different KS 
domains. While type-I FAS domains are highly specific toward saturated acyl chains 
[44], type-I modular KS domains have a wider range of substrate specificities that 
vary in length from diketide to decaketide. Also, some PKS KS domains have been 
shown to possess specificity with regard to different β-carbon status [45]. Indeed, the 
acyl-binding pockets of PKS KS domains are amphipathic and allow hydrogen-
bonding interactions with the carbonyl groups of the growing polyketide chain [40], 
[41] whereas FAS KS domains have a hydrophobic, narrow pocket of a suitable size to 
specifically accommodate their corresponding fatty acyl substrates [46]. Hence, 
substrate specificity may rather arise from selective ACP recognition, as seen in DEBS 
modules [47]. 
A putative condensation mechanism has been described based on a 
comprehensive structural study of the FabF enzyme, a type-II KS, either inhibitor-
bound (Figure 6B) or covalently linked to a dodecanoic acid. In both cases, the 
catalytic cysteine had been mutated to a glutamine [48]. First, a trans-
thioesterification reaction would take place between the acyl-ACP and the reactive 
cysteine inside the substrate tunnel with the help of an oxyanion hole. Then, the ACP 
bearing an elongation unit would dock to the acylated KS which generate, by a 
decarboxylation process, an enolate that could finally attack the thioester carbonyl to 
elongate the polyketide. This putative mechanism is based on a single comprehensive 
study and needs to be confirmed or at least completed. The lack of (physiological) 
substrate-bound KS structures hinders the understanding of the detailed reaction 
mechanism of decarboxylation, acyl transfer, and KS-ACP interaction. It is also 
noteworthy that other inhibitors of KS activity, such as cerulenin and thiolactomycin, 
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identified almost half a century ago, have been structurally characterized [49], [50] 
but are still not clinically used. 
 
THE ACYLTRANSFERASE DOMAIN 
The acyltransferase is a ~300 residue domain (Figure 7A) connected to the 
KS domain through a ~140 residue “KS-AT” linker. ATs contain two subdomains: a 
~240 residue catalytic subdomain that possesses an α/β hydrolase fold and ~60 
residue ferredoxin-like subdomain. All reported structures are highly similar (rmsd 
<2 Å). These include DEBS modules 3 [41] and 5 [40], and human FAS [42] as 
didomains together with KS domain but also FabD, the FAS-II acyltransferase from 
Escherichia coli [51], and the malonyl-CoA:ACP transacylase from Streptomyces 
coelicolor [52]. 
AT domain catalyzes the transfer of a starter/extender unit to its cognate ACP, 
it is responsible for the selection of this unit and is then often referred to as the 
“gatekeeper” of polyketide biosynthesis. Transfer to ACP occurs by a ping-pong bi-bi 
mechanism through a covalently bound acyl-intermediate to the catalytic serine. 
Once the catalytic serine has been activated by the neighboring histidine, 
starter/extender unit is recruited and it results in formation of an acyl-AT. Such acyl-
enzyme complex has been observed when soaking FabD with malonyl-CoA (Figure 
7B). In addition to confirming the role of an invariant arginine (R117 in FabD) in 
interacting with the substrate carboxylate, the acyl-FabD structure has also greatly 
helped in understanding the catalytic mechanism [53]. In FabD, the catalytic serine 
S92 attacks the malonyl-CoA thioester carbonyl and forms an intermediate stabilized 
in the oxyanion hole mediated by Q11 and L93. Then, the imidazole side chain of 
H201 positions the hydroxyl function of S92 for subsequent nucleophilic substrate 
attack by the free thiol group of the P-pant carried by the ACP domain. Interactions 
with the P-pant moiety from CoA are also described and involve the carbonyls of 
S163, P164 and G165, and the side chains of N160 and Q166 (Figure 7B). 
Several AT domains which possess specificity toward malonyl- and 
methylmalonyl-CoA have been structurally and functionally characterized and 
correlated motifs for the selection of the extender unit have emerged. Two sequence 
motifs lying in close proximity to the catalytic residues, GHSXG and XAXH, 



)LJXUH$F\O$&3FRQIRUPDWLRQVDQG$&3'+GRFNLQJPRGHO
$&RPSDULVRQEHWZHHQW\SH,,)$63'%FRGH)$&DQGW\SH,3.63'%FRGH
/,:$&3DF\OV,Q)$6,,WKHDF\OLVEXULHGLQWRDFHQWUDOFDYLW\DQGVWDELOL]HGE\
VHYHUDOK\GURJHQERQGVZKHUHDV LQ W\SH,3.6 WKHDF\O LV VWDFNHGDJDLQVW WKH$&3
VWUXFWXUH YLD D VLQJOH K\GURJHQ ERQG % )LJXUH 'RFNLQJ PRGHO RI WKH '+$&3
LQWHUDFWLRQZLWK SXWDWLYH UHVLGXHV HQJDJHG LQ WKH LQWHUDFWLRQ UHSUHVHQWHG LQ VWLFNV
)URP$QDQGHWDO
 

 
 
(catalytic residues are in bold), have been identified to specifically bind either 
malonyl-CoA (GHSQG and HAFH) or methylmalonyl-CoA (GHS(I/V)G and YASH). 
Unfortunately, these motifs are not universally conserved and it is sometimes very 
difficult to guess which extender unit is selected by analyzing the amino acid 
sequence only. Also, some ATs are specific for substrates other than malonyl- and 
methylmalonyl-CoA and no general pattern could be assigned to these domains yet. 
Nonetheless, the arginine that forms a salt-bridge with the substrate carboxylate in 
extending AT domains is often replaced by a non-polar amino acid in loading 
domains which are selective for shorter substrates. For example, the AT domain from 
the DEBS1 loading module (Figure 5) contains a tryptophan instead of an arginine 
and is selective for acetyl-CoA. 
While the catalytic mechanism has been defined in good details thanks to 
structural information, assigning the substrate specificity on a sequence basis only, 
still remains a challenging task. Indeed, substrate specificity is likely to be a 
combinatorial result of different structural elements that interact throughout the 
entire protein fold, rather than an influence of a limited number of residues. Thus, 
additional structures of native or mutated AT domains in complex with their 
substrate may be required to clear this specificity problem out. 
 
THE ACYL CARRIER PROTEIN DOMAIN 
ACP covalently shuttles starter/extender units and growing intermediates to 
the other domains. This ~80-residue long domain consists in a four-helix bundle and 
is usually located at the C-terminal end of a PKS module. NMR structures are 
available for two modular type I PKS: DEBS module 2 [54] and curacin PKS CurA 
[55]. Despite low sequence identity between ACP domains, the overall fold and the 
motif “DSL” at the end of helix α2 which contains the catalytic serine are always 
conserved. However, the position of the bound acyl may change, as illustrated by 
either crystal structures of acyl-ACPs from type-II FASs [56] with fatty acyl groups 
pointing toward the inner cavity, or NMR structures of acyl-ACPs from rat type-I FAS 
[57] and type-I PKS CurA [55] where the bound substrates are rather stacked against 
the helical bundle (Figure 8A). 
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Since ACP domain acts as a shuttle, it must communicate with all other 
domains. Characterization of the interactions that mediate communication between 
ACP and other domains is critical to understand how the corresponding activities are 
regulated. Nonetheless, to date, no complex involving a condensation or a β-carbon 
processing domain and an ACP domain from type-I PKS has been experimentally 
determined. Instead, modeling studies have been carried out where ACP docking 
poses are proposed for KS-AT didomain [58], DH and KR domains [59]. These 
studies have allowed the identification of putative residues involved in ACP 
interaction/recognition. For example, the DH/ACP (from DEBS module 4) modeling 
study [59] has allowed confirmed the role of two putative interacting residues on DH, 
previously reported as hindering dehydration activity of acyl-ACP when mutated 
(Figure 8B) [60]. Another example is the successful engineering of a modified PKS 
resulting in a module that catalyzes two rounds of condensation instead of one [47]. 
This very promising work is based on mutations in the ACP domain that have been 
guided by KS-AT/ACP modeling [58]. According to these docking studies, ACP 
interactions with other domains are very labile and seem to be mediated by a little set 
of residues that are not universally conserved among PKSs and might then not 
account for a universal interaction mechanism. 
 
(2) ΒETA-CARBON PROCESSING DOMAINS 
 
THE KETOREDUCTASE DOMAIN 
The ketoreductase domain is monomeric and ~450 residue long. It comprises 
a ~200 residues “structural” (non-catalytic) sub-domain and a ~250 residues 
catalytic sub-domain, both of which possessing a Rossmann-like fold. KR belongs to 
the SDR (short-chain dehydrogenase/reductase) superfamily and is structurally and 
functionally related to the FAS-II FabG ketoreductase. Within both FASs and type I 
PKSs containing a full set of β-carbon processing domains, the structural sub-domain 
(named KRs in PKSs or ΨKR in FASs) is distantly located from the catalytic sub-
domain in the primary structure (Figure 9A) though these are very close in the 
tertiary structure (Figure 9B). The structural sub-domain seems to stabilize the 
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catalytic subdomain, thereby enabling the entire KR domain to be located away from 
the 2-fold axis of the megasynthase [46]. 
The KR domain is responsible for the reduction of the β-ketone from the 
elongation unit incorporated by the upstream module using NADPH as a co-factor. It 
also sets the stereochemistry of the resulting hydroxyl group. KRs can be divided into 
three types: A-type and B-type depending on the stereochemistry of the generated β-
hydroxyl, or C-type if they are inactive. Modules that contain others β-processing 
enzymes in addition to KR usually contain a B-type KR. Some KRs can also epimerize 
the α-substituent and are then further divided into subtypes 1 and 2 based on the 
orientation of the α-substituent thus yielding A1-, A2-, B1- and B2- subtypes. High-
resolution crystal structures are available for each of these KR-types isolated from 
type-I PKS [61], [62], [63], [64]. Fingerprints have been identified to distinguish 
between the different KR types based on their amino acid sequence. The most 
obvious one is a B-type characteristic “LDD motif” that allows to differentiate B-type 
KRs from A-type KRs, in which this motif is absent. More intuitively, C-types lack 
either the catalytic tyrosine or the NADPH binding site that are present in A- and B-
types. Remarkably, in some iterative type I PKSs, the KR switches between A-type 
and B-type depending on the intermediate it is reducing [65]. 
While almost all the reported structures are composed of a binary complex 
with the co-factor NADPH (Figure 9B), no structure of a ternary complex involving 
a bound polyketide has been deposited in the PDB yet. However, putative catalytic 
residues have been identified and consist in a tyrosine (from a YAAAN motif), a 
lysine, and a serine. The hydroxyls of serine and tyrosine would be in charge of 
activating the polyketide β-ketone. When the NADPH attacks this β-ketone, the 
lysine-stabilized tyrosine would give its proton and then generate a β-hydroxyl 
polyketide. Other residues are also thought to play a role in binding the polyketide. 
Interestingly, a few point mutations on isolated KRs are sufficient to switch from a 
KR type to another, but when these mutants are introduced back into a full-length 
PKS, the programmed polyketide is not produced [61], [66]. 
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THE DEHYDRATASE DOMAIN  
Dehydratase domain catalyzes the dehydration of a polyketide intermediate to 
yield a double bond between the α- and β-carbons. Interestingly, when isolated from 
a type-I PKS it is also able to catalyze the reverse reaction, even if this function is 
apparently not used in the context of full-length PKSs. Hydrated product might be 
counter-selected by downstream KS. 
A few 3D structures of DH domains from type-I PKSs are available: the DH 
domain from DEBS module 4 [60] and DH domains from the curacin PKSs [67]. 
They all possess a double hotdog fold (Figure 10A) similar to the homodimers of 
FAS-II FabA, each FabA monomer being a single hotdog [68]. For this reason, DH 
domain monomers from type-I FASs and type-I PKSs are thought to arise from 
ancestral gene duplication of type-II FASs. However, while FabA contains two active 
sites – one by monomer – DH domains from FASs or PKSs only contain a single one.  
Dehydratase activity requires a catalytic dyad composed by an aspartic acid 
and a histidine. It is noteworthy that in some cases, the aspartic acid is replaced by a 
glutamic acid. The aspartic acid is thought to donate a proton to the β-hydroxyl, and 
the histidine is thought to abstract one, thus catalyzing the elimination of a water 
molecule and generating a carbon-carbon double bond (Figure 10B). Most 
generated products bear a trans double bond but when DH domains are preceded by 
A-type KR domains it results in the formation of a cis double bond [67]. Some DHs 
are also known to possess an isomerase activity that shifts a double bond from the α- 
and β-carbons to the β- and γ-carbons [69]. However, sequence alignments of DHs 
have not permitted to identify patterns that distinguish between DHs that (1) catalyze 
the formation of cis versus trans double bonds, (2) serve as epimerases, or (3) are 
nonfunctional. 
Details about P-pant-bound substrate stabilization and the dehydration 
mechanism are still needed. For example, conserved active site residues have been 
identified but no function has been attributed to them yet [60]. A structure of a 
binary complex between FAS-II FabA and the mechanistic inhibitor 3-decynoyl-N-
acetylcysteamine is available though. However, this ligand presents a cis double 
bond, it is not a DH substrate since it covalently binds the catalytic histidine and 
therefore probably adopts a biased conformation (Figure 10C). Another 
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controversial aspect concerns the dimerization interface of DH domains inside PKSs. 
Indeed, all reported structures from isolated DH domains describe a linear dimer 
(Figure 10A) whereas the DH dimer in the mammalian FAS-I is bent ~60° [46]. 
Interestingly, the dimerization interface of PKS DH domains is mainly built by the 
~20 N-terminal residues which are not present in the mammalian FAS DH (Figure 
10A). 
 
THE ENOYLREDUCTASE DOMAIN 
ER belongs to the acyl-CoA reductase family of the medium-chain 
dehydrogenase/reductase (MDR) superfamily and is structurally related to the 
bacterial quinone oxidoreductase [70]. Its active site is located in a cleft between the 
~140-residue nucleotide-binding sub-domain and the ~170-residue substrate-
binding sub-domain (Figure 11A). It employs NADPH to stereoselectively reduce 
trans-α,β-double bonds generated by DHs. 
Structural determination of the NADP+-bound ER domains from porcine FAS 
[46] and spinosyn PKS module 2 [71] have helped the identification of putative 
catalytic residues. They reveal an invariant lysine-aspartate pair ~6 Å from the 
NADPH although the aspartate is not identically positioned in the two structures. An 
additional tyrosine has been proven to play a role in setting an S configuration on the 
α-carbon (when substituted) but is present in only half of the ER domains from 
modular PKSs [71]. The spinosyn ER domain shows a decreased activity on a short 
substrate-analogue when Y421 and K422 are mutated to alanines. On the contrary, 
D444 does not seem to participate to the catalytic mechanism of the spinosyn ER 
domain, since the catalytic activity is not altered when this residue is mutated to an 
alanine. However, it may participate in the FAS catalytic mechansim, since it is 
strictly conserved among mammalian FASs [46]. ER domains bind NADPH in a deep 
cleft located between the subdomains (Figure 11A). A pyrophosphate-binding motif 
GGVGMA has been identified, along with conserved residues lysine and arginine that 
form salt bridges with the adenine ribose phosphate. Eventually, a ternary complex 
involving a bound polyketide intermediate is missing to (1) determine which residues 
are involved in stabilizing the substrate and (2) decipher the catalytic mechanism. 
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One striking difference between mFAS and spinosyn PKS structures is the 
oligomerization state of the ER domain (Figure 11B). Indeed, as seen in mFAS, 
MDR enzymes usually dimerize through hydrogen bonds and form a 12-stranded β-
sheet spanning the whole dimer. Instead, the spinosyn PKS ER domain crystallizes as 
a monomer, a state already observed for the trans-acting lovastatin ER [72]. In 
addition, interaction with KR domain is very different to the one described in the 
porcine FAS structure. Also, in multi-modular type-I PKSs, it is thought that 
dimerization of ER domains would hinder movement of the cognate ACP which is 
already restricted by the downstream module [71]. This feature is obviously not 
relevant in FASs or mono-modular type-I PKSs whose mobility is not restricted in 
such manner. 
 
(3) OVERALL ARCHITECTURE OF FATTY ACID 
SYNTHASES 
 
No structure of a type-I PKS is yet available but clues on the overall 
architecture of PKS can be derived from structural information on mammalian FAS. 
Indeed, (1) domain organization is preserved between the two megasynthases, (2) 
both mFAS and type-I PKSs are homodimeric [73], [74], and (3) sequence and 
especially structure analysis of individual domains reveal higher similarity between 
mFAS and PKS than between mFAS and bacterial FAS-II. In addition, there is 
evidence for a common evolution between mFASs and PKSs. An active 
methyltransferase (MT) domain from a common ancestor of PKSs and mFASs may be 
at the origin of both the non-functional MT domain found in mFAS, and the active 
ones found in several PKSs [75], [76]. mFAS can then be considered as a single PKS 
module specialized for iterative fatty acid synthesis [46]. Although no structure of a 
full-length type-I PKS is available, didomains from PKS have been structurally 
determined. These structures show a similar architecture to mFAS but also some 
differences in the organization of the domains. This chapter will then summarize 
structural data coming from mFAS (both crystal [46] and electron microscopy [77]) 
and from mono- and multi-domain structures of PKSs [40], [41], [60], [67], [71]. 
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As seen in Figure 12, mFAS assembles into a homodimer resembling an “X” 
shape where the lower legs of the “X” are represented by the KS and AT domains, and 
the upper legs are represented by the β-carbon processing domains DH, ER and KR 
[46], [77]. ACP and TE domains are not clearly defined in density and thus were not 
positioned in the overall architecture. Two additional non-catalytic domains are 
found in the β-carbon processing part of the structure: a pseudo-methyltransferase 
(referred as ΨME) and a non-catatlytic KR (referred as ΨKR, similar to the 
“structural” KR sub-domain described in several structures of PKSs). mFAS 
homodimer is stabilized by the dimerization interfaces of KS and ER domains, and to 
a lesser extent, by the DH domain and the linker between AT and DH domains. These 
interactions are responsible for the 5400 Å² dimer surface contact area. 
The condensation part seems to be particularly well conserved between mFAS 
and PKSs [40], [41], [46] (Figures 6A and 12). Indeed, in both cases, KS mediates 
homodimerization at the 2-fold axis of the megasynthase and is connected through a 
structured linker to AT which is located on the periphery. The only difference is the 
presence of a helical insertion in the KS-AT linker in PKS that does not influence the 
relative positions of the KS and AT domains. The structure continues with a ~20 
residue linker which account for the connection between the condensation and the β-
carbon processing part of the megasynthase. This feature is well conserved between 
mFAS and PKSs.  
To date, only the structure of mFAS [46] describes the organization of the full 
β-carbon processing part (DH-ER-KR) from a megasynthase. However, a structure of 
an ER-KR didomain from the module 2 of the spinosyn PKS is available and show 
important differences in the organization of the domains compared to mFAS [71]. On 
the one hand, in mFAS, the ER domain dimerizes along the 2-fold axis of the 
megasynthase and forms interactions with both DH and KR domains. On the other 
hand, ER-KR didomain structure from the spinosyn PKS, reveals a monomeric ER 
domain (Figure 11B) and a completely different interface between ER and KR 
domains (Figure 9B). These preliminary data show that different architectures may 
be possible among the β-carbon processing part of megasynthases. It has also been 
suggested that the mFAS architecture would not be compatible with the multi-
modular PKS mechanism [71]. Indeed, in multi-modular PKSs, ACP domain is 
tethered to a dimeric domain, either a downstream KS or a terminal TE (in contrast 
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to the monomeric TE in mFAS) and is then less mobile than its mFAS counterpart, a 
feature that would not allow it to access all the β-carbon processing domains. This 
ACP-tethering is obviously not observed in mono-modular PKSs, which can then 
possibly adopt the same architecture than mFAS. 
In any case, ACP domain, with help of the flexible KR-ACP linker and its post-
translationally added P-pant arm, seems to possess enough mobility to reach other 
domains active sites without significant architecture reorganization. However, some 
of these sites are distantly located and are not present on the same face of the mFAS 
“X” architecture (Figure 12). Additionally, earlier studies had provided biochemical 
evidences indicating that the ACP domains from FASs [78], [79] and PKSs [73], [80], 
[81] were able to make functional contacts with the KS and AT domains from both 
monomers of the megasynthase. Thus, overall architecture flexibility is required for 
the ACP to efficiently shuttle the substrate to the other domains in both mFAS and 
PKSs. 
Such flexibility has been studied in the case of the rat FAS using single particle 
electron microscopy and a combination of different catalytic mutations and 
substrates [77]. It reveals the pliability of FAS that result in multiple conformations 
(Figure 13A). These conformations have been classified using three main movement 
criteria: (1) in-plane rotation between the top and bottom portions of the structure, 
(2) re-organization resulting in progressive asymmetry in the upper half of the 
structure, and (3) off-plane rotation between the top and bottom portions. This work 
suggests a direct correlation between conformation and specific enzymatic activities.  
It provides direct evidence that FAS can adopt a conformation in which the lower part 
of the structure is rotated 80-100° relative to the upper part of the structure. Thus, 
rotation of ~90° in either direction would allow ACP domain to interact preferentially 
with KS or AT domains depending on the rotation direction and would restore the 
stable “X” shape conformation seen in the crystal structure of porcine FAS. Using 
inactive mutants of the KS and DH activities and their respective substrates, the 
different classes of conformations can also be correlated to the condensation and 
dehydration activities (Figure 13). Furthermore, rotation motions are apparently 
coordinated with rearrangement of β-carbon processing domains, possibly resulting 
in asynchronous chain extension and β-carbon processing reactions between the two 
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reaction chambers formed by the two monomers. FAS flexibility has been estimated 
to contribute ~20% to the overall rate of fatty acid biosynthesis [78]. 
 
(4) LINKERS AND OTHER STRUCTURAL MOTIFS 
 
Linkers have long been considered as semi-flexible tethers that hold adjacent 
domains in proximity [82]. In contrast, KS-AT linker has been recently referred to as 
“not just a swinging arm” [40]. Indeed, along with post-AT linker, KS-AT linker plays 
an important structural role in fixing the relative positions of the KS and AT domains 
using both hydrophobic and hydrogen bonding interactions. The KS domain, the KS-
AT linker, the AT domain, and the post-AT linker are packed together in an 
apparently rigid arrangement that precludes significant movement of the KS and AT 
domains relative to one another. Based on recent biochemical [83] and molecular 
docking [58] studies, KS-AT linker and post-AT linker have been proposed to play a 
crucial role in ACP binding for subsequent KS and AT activities in both FASs and 
PKSs (Figure 14A). 
Some linkers are also specific to PKSs. This is the case of sequences located at 
the N- (~35-residue long) and C-termini (~90-residue long) of modular PKSs. These 
linkers have been demonstrated to form compatible pairs that play a role in the 
specificity of inter-modular interactions between modules from different 
polypeptides and have been named “docking domains” [82]. In addition to the 
partially specific recognition between ACP (module n) and KS (module n+1), these 
docking domains provide specific interactions in order to stream the growing 
polyketide to the correct module. NMR studies have helped in identifying the module 
specificity behind these docking domains [84], and the solution structures of 
compatible docking domains from DEBS modules 2 and 3 has also been solved 
[85].(Figure 14B). 6 helices provided by the C-terminal docking domain of the 
dimeric DEBS module 2, and 2 helices provided by the N-terminal docking domain of 
the dimeric DEBS module 3 assemble together into a complex. The structure reveals 
that all eight helices are required to stabilize the homodimeric PKS structure. 
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Other structural motifs are thought to play a role in stabilizing some PKSs 
dimers. As observed in mFAS, apart from the KS domain, the β-carbon processing 
domains DH and ER are able to mediate dimerization of the megasynthase. In PKSs, 
when the β-carbon processing part is composed by the monomeric KR domain only, 
the KS domain remains the sole domain able to mediate dimerization. In this context, 
a motif has been identified in ~50% of these KR-reducing PKS modules that would 
aid KS domains in dimerizing the PKS and has been therefore called a “dimerization 
element” (DE). The DE from the spinosyn PKS module 3 has been structurally 
determined (Figure 14C) [86]. A model representing a module containing the KS-
AT-KR-ACP domains from a multi-modular PKS has also been constructed, with help 
of the KS-AT didomain [40] and ACP domain [54] structures. Interestingly, the 
previously reported structures of the DH domain [60] (Figure 10A) and the ER-KR 
didomain [71] (Figure 9B) from multi-modular PKSs are compatible with this 
model. Therefore, a similar architecture for multi-modular PKSs possessing a full β-
carbon processing part was envisioned by the authors [71]. They also propose that a 
putative interaction between the KS domain and the structural KR domain (KRS) 
would explain the absence of this DE in the remaining ~50% of the KR-reducing PKS 
modules [86]. 
 
2. ACP ACTIVATION AND 4’-
PHOSPHOPANTETHEINYL 
TRANSFERASES 
 
Polyketide as well as fatty acid and non-ribosomal peptide intermediates, are 
not covalently bound to an amino-acid residue on ACPs but are instead tethered via a 
thioester linkage on the post-translationally added P-pant moeity. This residue 
extends the reach of the CP to present the polyketide intermediates it shuttles to the 
other domains. The PPTase enzyme superfamily, responsible for the transfer of P-
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pant to CPs, has been described in the mid-1990s by the Walsh group who has later 
greatly contributed to their characterization [17]. 
 
a) Transfer of the 4’-Phosphopantetheine 
Moiety 
 
PPTases catalyze the transfer of the essential prosthetic P-pant from CoA to an 
invariant serine residue contained within the conserved sequence motif 
Gx(D/H)S(L/I)(D/K) of all CPs [87] (Figure 15). The transfer results in a 
phosphoester linkage of the P-pant moiety onto the solvent-exposed serine and 
provides a 20 Å flexible arm to the CP. It allows the thioester attachment of the 
growing intermediate at the opposite side of the flexible arm to present it to the other 
catalytic domains. 
Along with CoA, a divalent metal ion is required for the transfer. To date, three 
different cations have been found to allow the transfer of P-pant. Mg2+ and Ca2+ 
ions have been identified in structures of PPTases produced in E. coli and have been 
demonstrated as essential for the in vitro transfer of P-pant [88], [89], [90]. In the 
case of the Bacillus subtilis Sfp, Mn2+ allows for an enhanced catalytic activity [91] 
compared to Mg2+ [88]. However, whether the metal ion is necessary for binding of 
CoA remains unclear [92]. 
 
b) PPTases Classification 
 
PPTases can exist as distinct proteins or be part of the megasynthase they 
activate [93]. They also possess different specificity toward CPs. Enzymes that 
activate primary metabolism ACPs (fatty acid biosynthesis) are referred as Acp 
synthases (AcpS) whereas PPTases involved in secondary metabolism (polyketide and 
non-ribosomal peptide biosynthesis) are Sfp-like enzymes. However, some PPTases 
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show broader specificity and can activate CPs from both FASs and PKSs [94]. Despite 
the absolute requirement for PPTases in a wide range of important biosynthetic 
pathways, these enzymes have remained elusive for a long time due to their low 
sequence identity and lack of proximity to their respective biosynthetic clusters. The 
absence of characterized PPTases has hampered many efforts to produce polyketide 
and nonribosomal peptide products in heterologous host systems utilizing E. coli, 
largely due to the inability of E. coli PPTases to activate foreign substrates. 
We are now able to identify and classify PPTases on the basis of sequence 
motifs and structural features [95]. PPTases partition into three major groups, 
depending on their length, structural architecture and CP substrate specificity. Group 
I is represented by bacterial transferases of ~120 residues, acting on the ACP of 
bacterial FASs. Structure determinations of AcpS from B. subtilis [90] and 
Streptococcus pneumoniae [96] reveal a trimeric arrangement of an α/β fold domain 
containing a β1α3β2 motif (Figure 16A). The active site is located in the cleft between 
the different subunits, resulting in three active sites per trimer. 
Group II PPTases are exemplified by the monomeric ~240 residues Sfp protein 
from B. subtilis, which transfers a P-pant moiety on the non-ribosomal PCP domain 
of bacterial surfactin synthetase [88], [91]. This group can be identified using specific 
sequence motifs (Figure 15B). It may have evolved from the AcpS family by gene 
duplication [89] with subsequent diversification into two sub-families [87]. Indeed, 
the structure determination of Sfp [97] reveals a two-domain enzyme with intrinsic 
pseudo 2-fold symmetry, however, with similar domain architecture as the trimeric 
AcpS (Figure 16A). Sfp is particularly interesting for its broad specificity toward 
both CoA-derivatives and CPs. Indeed, it is able to transfer prosthetic groups from 
non-physiological substrates such as acetyl-CoA or benzoyl-CoA [88] and has been 
early used for polyketide or non-ribosomal peptide production in heterologous hosts 
[98], [99]. 
Finally, Group III PPTases comprise transferases that are an integral part of 
the heteromeric yeast and fungal FAS, and probably share the same trimeric 
arrangement than Group I PPTases [100]. However, no structure of a group III 
PPTase is yet available although the structural determination of the fungal FAS from 
Thermomyces lanuginosus brought light onto its possible location inside the 
megasynthase [101].  
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c) Coenzyme A Binding and Catalytic 
Mechanism 
 
In Sfp [97], CoA is bound in a cleft formed by the two domains, and the 
structure reveals basic principles of Mg2+ and CoA binding. CoA is bound in a bent 
conformation within a pocket delineated at the bottom by residues from strands β2 
and β4. No defined conformation is observed for the pantetheinyl moiety of CoA 
(apart from the β-phosphate) in the electron density map probably because it does 
not interact with Sfp. This feature is in good agreement with the broad-substrate 
specificity of Sfp, since the pantetheinyl part can be replaced or fused to an acyl 
without disturbing the CoA-derivative binding in the Sfp pocket [88]. In contrast, the 
ADP moiety and the pyrophosphate are stabilized by a myriad of polar interactions 
involving a dozen residues from Sfp (Figure 16B). Both α- and β-phosphates 
participate in the complexation of an Mg2+ ion whose additional ligands are the 
carboxylate groups of Asp107, Glu109 and Glu151 and one water molecule. 
Interestingly, this CoA binding mode is not universal among group II PPTases. 
Indeed, in contrast to Sfp, the pantetheine moiety is buried in a hydrophobic cavity in 
the human PPTase (hAcpS) structure [92] (Figure 16B), that probably enhances the 
specificity toward CoA and prevents CoA-derivatives from binding. 
The structure of a ternary complex involving hAcpS, the ACP domain of 
human FAS (hACP), and CoA has been determined and a detailed mechanism 
describing the substrate binding and catalytic process has been proposed [92] 
(Figure 16C). In this complex the hACP catalytic serine had been mutated to an 
alanine (S2156A) to inhibit P-pant transfer and facilitate the observation of the 
hAcpS-hACP complex. The catalytic mechanism would start with the abstraction of a 
proton from the hydroxyl group of the hACP catalytic serine S2156 by the neighboring 
E151 from hAcpS. The resulting hydroxylate would then carry out a nucleophilic 
attack on the CoA β-phosphate, and after protonation by K195, the pyrophosphate is 
cleaved, and the products dissociate from the enzyme. The putative role of E151 and 
K195 as key acid/base catalysts is also strongly supported by the observed significant 
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loss of activity for the associated alanine mutant proteins for both residues. This 
proposed mechanism for human PPTase is similar to the one suggested for Sfp [91] 
but significantly different from the group I AcpS mechanism, where a metal-ion-
activated water molecule is proposed to be responsible for the abstraction of the 
proton from the acceptor hydroxyl group [90]. 
PPTases are potential drug targets since they are required to enable any PKS-, 
FAS- or NRPS-based biosynthesis. They have been shown to be essential for the 
survival of numerous organisms [96], [102], [103], [104]. 
 
3. PKS ROLE IN PRODUCING 
ORGANISMS 
 
Complex polyketide biosynthesis involving several PKSs and other enzymes to 
further modify, transport and possibly excrete polyketides, is energy demanding. For 
example, to produce erythromycin [105], Saccharopolyspora erythraea, devotes 
some 60 kb of its DNA to make this macrolide from propionate units by an assembly-
line process involving no less than 28 active sites arranged along three PKSs, followed 
by hydroxylation and glycosylation involving 18 further proteins, and then has to 
protect its ribosomes from the highly specific toxicity of the antibiotic by an equally 
specific methylation of a site on the ribosomal RNA . Evolution has then mostly 
selected polyketide-synthesizing complex machineries that represent a competitive 
advantage for their producing organisms [106], [107]. Indeed, the ability to produce 
erythromycin gives S. erythraea a strong selective advantage in nutrient poor 
environments by poisoning neighboring organisms. 
Polyketides possess a wide range of activity including inhibition or killing of 
other microorganisms but also toxicity to multicellular organisms, hormone-like 
roles, metal transport, virulence of pathogens, photo-protection, coloration, extra-
cellular communication and probably even more activities that remain to be 
characterized [107]. 
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The actinomycetes, a diverse order of Gram-positive bacteria which include S. 
erythraea, synthesize most of all known polyketides. These are often secondary 
metabolites that give a selective advantage to these non-motile bacteria over other 
species [106], [108], [109]. Inside the actinomycetes order, Mycobacterium 
tuberculosis (Mtb) has chosen another path since it does not produce any secondary 
metabolites, instead, Mtb uses polyketides to enhance its virulence. Indeed, an 
important part of the Mtb virulence is mediated by polyketide-derived lipids or at 
least lipids whose biosynthesis involves PKSs. In a context of growing appearance of 
multidrug- and even totally drug-resistant Mtb strains, this feature makes PKSs very 
promising targets for the development of new drugs against this wide-killer 
bacterium. 
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C. TUBERCULOSIS 
 
 
1. TUBERCULOSIS: THE DISEASE 
 
a) History and State of the Art 
 
“Tuberculosis” (TB) is a very old disease, whose history is closely related to 
that of mankind. Its causative agent, Mycobacterium tuberculosis, have killed more 
persons than any other microbial pathogen [110]. It is presumed that an early 
progenitor of Mtb was probably contemporaneous with early hominids in East Africa, 
three million years ago, and co-evolved with them [111]. TB was documented in 
Egypt, India and China as early as 5,000, 3,000, and 2,300 years ago, respectively. 
Mycobacterial DNA was detected in a human skeleton from the Iron Age (400-230 
BC) found in the United Kingdom [112]. Around 460 BC, Hippocrates used the term 
“phthisis” to describe the wasting away of patient's body caused by the most 
widespread pulmonary disease in Ancient Greece. The beginning of the 17th century 
coincided with the arrival of an epidemic known as the “Great White Plague” (for the 
extreme paleness of people suffering from TB) in Europe that continued for the next 
200 years. At that time, precise pathological and anatomical descriptions of the 
disease began to appear. In his “Opera Medica” (1679), Franciscus Sylvius de la Böe 
was the first to identify the presence of tumor-like nodules in the lungs and other 
areas of the patients, the so-called “tubercles”. But it was not until 1834 when Johann 
Lukas Schölnlein established the current name “tuberculosis” to describe diseases 
with tubercles. 
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In 1865, the French military surgeon Jean Antoine Villemin demonstrated that 
tuberculosis could be transmitted from humans or cattle to rabbits (Figure 17). In 
the light of this revolutionary evidence, he postulated that a specific microorganism 
caused the disease. On March 24th 1882, Robert Koch made his famous presentation 
“Die Äetiologie der Tuberkulose”. He demonstrated the infectious nature of TB. The 
introduction of sanatorium cures in the late 19th century provided the first widely 
practiced approach to anti-TB treatment. In 1854, Hermann Brehmer presented his 
medical dissertation “Tuberculosis is a curable disease” and then opened an in-
patient hospital where patients were continuously exposed to fresh air. He 
emphasized a regimen of rest, rich diet, and exercise with encouraging results [113]. 
This became the model for all subsequent sanatoria. With Edward Jenner’s successful 
discovery, showing that infection with cowpox would give immunity against smallpox 
in humans, many doctors placed their hopes on the use of Mycobacterium bovis – 
the agent that causes bovine TB – for the development of a vaccine against human 
TB. From 1908 until 1919, Albert Calmette and Camille Guérin serially passed a 
pathogenic strain of M. bovis 230 times, resulting in an attenuated strain called 
“Bacille Calmette-Guérin” (BCG). The resulting strain was avirulent, but still able to 
stimulate the immune system of different animal models, thus protecting them 
against TB infection. BCG was first administered to humans in 1921 and it was still 
widely used until the beginning of the 21th century [114]. Then, in the middle of World 
War II, antiobiotics represented the final breakthrough in the treatment of the 
bacterium. In 1943, streptomycin, a compound with antibiotic activity, was purified 
from Streptomyces griseus by Selman A. Waksman, who obtained, in 1952, the Nobel 
Prize in medicine for this discovery. When this therapy was used on TB patients a 
considerable improvement was observed. The discovery of a series of new anti-TB 
drugs: para-aminosalicylic acid (1949), isoniazid (1952), pyrazinamide (1954), 
ethambutol (1962) and rifampicin (1963) further enhanced the treatment. 
Unfortunately, this initial optimism was soon tempered by the development of the 
first resistant strains to anti-TB drugs, although it was later demonstrated that 
cocktails treatment involving several drugs could overcome this problem [113]. 
General improvement in public health and success of antibiotic therapy 
resulted in a pronounced reduction of infection and death rates in Europe and in the 
USA. In the 1980s, elimination of TB was thus envisioned to 2010 [CDC, A strategic 
plan for the elimination of tuberculosis in the United States]. Nevertheless, around 
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1985, cases of TB began to rise again in industrialized countries. The decline in TB 
control activities – TB programs had become loose in industrialized countries 
because the disease was considered close to elimination – and the acquired 
immunodeficiency syndrome (AIDS) epidemic were the major factors in the 
reemergence of TB. The World Health Organization (WHO) declared TB a global 
health emergency in 1994 [WHO, TB: a global emergency). 
TB is today the second major cause of death from any infectious disease, and 
furthermore, the first cause of death coming from a unique pathogen. In 2012, 8.7 
million new cases of TB occurred and 1.4 million people died, and it is estimated that 
one third of population is infected with Mtb [WHO, Global Tuberculosis Report, 
2012]. The worldwide tuberculosis incidence rates are estimated to have peaked in 
2004 and to have decreased at a rate of less than 1% per year since that time. Most 
cases are in Asia and Africa, with smaller proportions of cases in the eastern 
Mediterranean region, European region, and the Americas (Figure 18). Tuberculosis 
remains a disease of poverty that is inextricably associated with overcrowding and 
under-nutrition. 
 
b) Prevention and Treatment 
 
(1) PREVENTION 
 
The primary worldwide mean of fight against tuberculosis, whose first use 
occurred in 1921, was the BCG vaccine. It has been given to 4 billion people so far and 
to more than 90% of the children in the world today, making it the most widely used 
vaccine in the world. Nevertheless, immunity it induces to TB, decreases after about 
ten years. While it is effectively treating disseminated forms of TB (meningitis and 
military) in childhood, its protection against contracting pulmonary TB in both 
childhood and adulthood is rather inconsistent (Table 2) and it has done little to 
contain the tuberculosis pandemic [115]. However, an effective vaccination regimen 
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would be the most efficient way to control the epidemic and this strategy has not been 
abandoned. New vaccine candidates are indeed being tested (for review [116]). 
Nowadays, the most powerful treatment remains by far, the antibiotic therapy. It has 
been used since the early 1950’s and further developed with the discovery of novel 
classes of antibiotics and the generation of drug cocktails. 
 
(2) FIRST-LINE TREATMENT 
 
Current TB treatment requires a combination of drugs and obeys to two 
phases: an initial intensive phase of treatment (2 months) with isoniazid (INH), 
rifampicin (RIF), pyrazinamide (PAZ) and ethambutol (EMB) designed to kill actively 
growing and semi-dormant bacilli; followed by a continuation phase (4 months) with 
INH and RIF only, to eliminate most persistent bacilli and reduce the number of 
relapses [WHO, Treatement of tuberculosis, 2009]. The drugs features are presented 
in Table 3. Interestingly, isoniazid targets the type-II FAS enoyl-reductase which is a 
functional homolog of type-I PKS ER domains. This illustrates the druggability of this 
family of enzymes. 
Treatment completion is critical to reduce development of acquired drug 
resistance, therefore, trained personnel supervises that each dose of medication is 
properly taken by the patient. This strategy is known as directly observed treatment 
short-course (DOTS) and was promoted as the official policy of the WHO in 1991 
[WHO, What is DOTS?]. 
 
(3) RESISTANCE AND SECOND-LINE TREATMENT 
 
Another major challenge is the ever-increasing resistance to anti-TB drugs. 
Mtb strains that possess drug resistance have been classified into three categories. 
Multidrug-resistant TB (MDR-TB) refers to TB caused by M. tuberculosis isolates 
that are resistant to the most effective drugs, INH and RIF. Infection by MDR strains 

'UXJV 0ROHFXODUWDUJHWV
%LRORJLFDO
FRQVHTXHQFHV
*HQHVLPSOLFDWHGLQ
UHVLVWDQFH
)UHTXHQWVLGH
HIIHFWV
,VRQLD]LG )$6,,(5
,QKLELWLRQRIORQJFKDLQ
IDWW\DFLGVDQGP\FROLF
DFLGVELRV\QWKHVLV
NDW*FDWDODVHUHTXLUHGIRU
DFWLYDWLRQRILVRQLD]LGLQK$
SURPRWHUDQG25)
0RVWO\KHSDWRWR[LFLW\
5LIDPSLFLQ $51SRO\PHUDVHɴVXEXQLW5SR%
,QKLELWLRQRI
WUDQVFULSWLRQ USR% 0RVWO\KHSDWRWR[LFLW\
3\UD]LQDPLGH 5LERVRPDOSURWHLQ65SV$
,QKLELWLRQRIWUDQV
WUDGXFWLRQ
USV$SQF$S\UD]LQGDPLGDVH
UHTXLUHGIRUDFWLYDWLRQRI
S\UD]LQDPLGH
+HSDWRWR[LFLW\
DUWKUDOJLD
(WKDPEXWRO
$UDELQRV\O
WUDQVIHUDVHV
(PE%(PE&
,QKLELWLRQRIFHOOZDOO
ELRV\QWKHVLV HPE%HPE&
$UWKUDOJLDRSWLF
QHXULWLV
7DEOH)LUVWOLQHGUXJVXVHGLQ7%WUHDWPHQW
 

'UXJV 0ROHFXODUWDUJHWV
%LRORJLFDO
FRQVHTXHQFHV
*HQHVLPSOLFDWHGLQ
UHVLVWDQFH
)UHTXHQWVLGH
HIIHFWV
$PLQRJO\FRVLGHV
NDQDP\FLQ
DPLNDFLQ
VWUHSWRP\FLQ
$516 ,QKLELWLRQRIWUDQVODWLRQ
UUV$516USV/
ULERVRPDOSURWHLQ6JLG%
$516PHWK\OWUDQVIHUDVH
2WRWR[LFLW\NLGQH\
GDPDJH
&\FOLFSHSWLGHV
FDSUHRP\FLQ
YLRP\FLQ
$516$51
6
,QKLELWLRQRI
WUDQVODWLRQ
UUVWO\$$51U
PHWK\OWUDQVIHUDVH
2WRWR[LFLW\NLGQH\
GDPDJH
'F\FORVHULQH
$OU'DODQLQH
UDFHPDVH'GO
'DOD'DOD
OLJDVH
,QKLELWLRQRI
SHSWLGRJO\FDQ
ELRV\QWKHVLV
DOU'DODQLQHUDFHPDVH 3V\FKLDWULFGLVRUGHUVSV\FKRVLVFRQYXOVLRQV
)OXRURTXLQRORQHV
FLSURIOR[DFLQH
RIOR[DFLQH
$'1J\UDVH
,QKLELWLRQRI'1$
WUDQVFULSWLRQ
UHSOLFDWLRQDQG
UHSDUDWLRQ
J\U$J\U%$'1J\UDVHV
OIUDHIIOX[SXPSPSID
SHQWDSHSWLGHUHSHDWVSURWHLQ
3V\FKLDWULFGLVRUGHUV
WHQGRQWR[LFLW\
7KLRDPLGHV
HWKLRQDPLGH
SURWKLRQDPLGH
,QK$)$6,,(5
,QKLELWLRQRIORQJIDWW\
DFLGVDQGP\FROLFDFLGV
ELRV\QWKHVLV
LQK$)$6,,(5
$JUDQXORF\WRVLV
KHSDWLWLVYDVFXOLWLV
DQGWKURPERF\WRSHQLD
7DEOH6HFRQGOLQHGUXJVXVHGLQGUXJUHVLVWDQW7%WUHDWPHQW

 




)LJXUH;'57%FDVHVUHSRUW
;'57%LQIHFWLRQVKDYHEHHQHQFRXQWHUHGLQFRXQWULHVLQ)URP:+2
 

 
 
is longer to treat (18-24 months) and requires second-line drugs, which are more 
expensive, less potent and have more adverse side-effects, including hepatitis, 
depression, and hallucinations (Table 4). Extensively drug-resistant (XDR-TB) 
infection can only be treated with the most efficient second-line drugs, 
fluoroquinolones and injection drugs such as kanamycin and capreomycin. In 2010, 
58 countries had confirmed at least one case of XDR-TB [WHO, Multidrug and 
extensively drug-resistant TB] (Figure 19). Finally, even more alarming is the 
emergence of deadly “Totally drug-resistant” TB (TDR-TB), defined as XDR-TB 
additionally resistant to treatment with any fluoroquinolones and any of the second-
line anti-TB injection drugs. Although it has been observed in India, Iran, and Italy 
[117], [118], TDR-TB is poorly documented and so far, remains untreatable. 
 
(4) NEW TREATMENTS 
 
First-line treatment is efficient on non-resistant TB and, except for 
pyrazinamide, side effects are rather mild and rare [119]. If properly taken, second-
line treatment is also efficient on resistant TB but induces side-effects on 70% of 
treated individuals and forces 56% to withdraw at least one drug from the treatment 
regimen [120]. While ototoxicity is the most frequent side effects among second line 
drugs, more crippling ones may appear such as psychiatric disorders, central nervous 
system damage and leukopenia. Drugs toxicity and treatment duration have become a 
problem for the DOTS program, as they decrease patient compliance who then tend 
to quit their regimen thus increasing the possibilities for the bacterium to develop 
new resistances. Drugs that would shorten the treatment course, possess minor side-
effects, and help treat XDR- and TDR-TB are then urgently required. While most of 
the drugs that compose the arsenal of the TB treatment were discovered during the 
1950’s and the 60’s, new drugs, derived from known compounds, have entered 
clinical trials in the last decade and might partially respond to this emergency [121] 
(Figure 20). However, there is still a crucial need for new drugs targeting new 
pathways, thus implying a fundamental comprehension of the mechanisms used by 
Mtb to survive, develop and infect host. 
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2. TUBERCULOSIS: THE BACTERIUM 
 
a) Main Features 
 
Within the G+C rich gram-positive Actinobacteria phyllum, the genus 
Mycobacterium belongs to the order of Actinomycetales, suborder of 
Corynebacterineae, a taxon characterized by a multilayered cell envelope extremely 
rich in uncommon lipids [122]. To date, more than 100 species of mycobacteria have 
been described [123], mostly environmental saprophytes. Phylogenetic analyses and 
phenotypic characteristics, such as growth rate and pigmentation, can be used to 
classify these species. The classical distinction between rapid and slow growing 
species is based on the ability of strains to develop visible colonies in less or more 
than 7 days, respectively. Interestingly, the slow growing mycobacteria comprise 
most of the pathogenic species, including M. tuberculosis. The various etiologic 
agents of TB are clustered in the M. tuberculosis complex (MTBC), which currently 
includes seven species: M. tuberculosis, M. africanum, M. canettii, M. bovis 
(primarily a pathogen of cattle), M. caprae (a pathogen of goats), M. microti (a 
pathogen of voles) and M. pinipedii (a pathogen of seals and sea lions) [124]. 
Mycobacteria grouped in MTBC are characterized by 99.9% similarity at the 
nucleotide level and identical 16S rRNA [125]. Phenotypically M. tuberculosis is an 
aerobic bacillus, catalase and nitrate reductase positive, non-motile and 
nonsporulated of 2-5 μm in length and 0.2-0.5 μm in width. 
The first complete genome sequenced was that of M. tuberculosis H37Rv 
[126], the reference laboratory strain in TB research. It comprises 4,411,532 bp with a 
G+C content of 65.6%. The last re-annotation identified 4,044 genes thought to 
encode 3,994 proteins and 50 stable RNAs [127]. The most striking feature in the Mtb 
genome is the complex repertoire of genes involved in lipid metabolism which 
represents about 9% of the coding capacity of the genome. These biosynthesized 
lipids are encountered in the atypical envelope of mycobacteria. 
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b) The Mycobacterial Cell Envelope 
 
The envelope of M. tuberculosis differs considerably from cell walls of both 
Gram-positive and Gram-negative bacteria. Although they are structurally more 
closely related to Gram-positive bacteria, mycobacteria do not fit into this category as 
the molecules attached to the cell wall are distinctively lipids rather than proteins or 
polysaccharides. The high lipid content of the envelope makes it a natural barrier to 
most antibiotics and chemical agents. Frequently, they do not retain the crystal violet 
and appear as “ghosts” after Gram staining. Mtb can rather be observed using the 
acid fastness staining technique. 
The mycobacterial envelope is unique, both in molecular composition and in 
the architectural arrangement of its constituents. Schematically, the cell envelope of 
the bacterium, from the inside to the outside, comprises a typical bacterial plasma 
membrane, a cell wall and an external capsule, which contains proteins, 
polysaccharides and lipids [128] (Figure 21). Recently, new electron microscopy 
techniques have enabled the identification of a periplasmic space [129]. The cell wall 
consists of a peptidoglycan (PG) covalently attached to the hetero-polysaccharide 
arabinogalactan (AG), which is in turn esterified by very long-chain (C60–C90) fatty 
acids called mycolic acids. The outer layer of the cell wall presents various non-
covalently attached lipids and glycolipids esterified with multimethyl-branched 
longchain fatty acids [130], [131]. These complex lipids are restricted, with few 
exceptions, to pathogenic mycobacteria; therefore, it has been thought that they may 
play important roles in the virulence of Mtb. In Mtb, these lipids include the 
phthiocerol dimycocerosates (DIM) and the closely related phenolic glycolipids (PGL, 
not present in all Mtb strains), the trehalose ester families that include sulfolipids 
(SL), diacyltrehaloses (DAT) and polyacyltrehaloses (PAT), and the family of 
mannosyl-β-1-phosphomycoketides (MPM). Interestingly, the biosynthesis pathways 
of all these pathogenicity-related lipids, involve PKSs. 
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3. POLYKETIDE-DERIVED LIPIDS AND 
VIRULENCE 
 
Sequencing of Mycobacterium tuberculosis H37Rv revealed the existence of 
23 ORF potentially coding PKSs [126]. However, several ORF code non-functional 
enzymes, while others code functional enzymes in only a few Mtb strains, and yet 
others code enzymes that are functional in vitro but the corresponding polyketides 
have never been isolated from mycobacteria. These data are summarized in Table 5. 
In this chapter, only well characterized polyketide-derived lipids (Figure 21) involve 
in Mtb virulence are discussed. In addition, the cell wall iron transporters 
mycobactins, which are also synthesized by PKSs, will be discussed. Structures of the 
following molecules are presented in. 
 
a) Mycolic Acids and Derivatives 
 
Mycolic acids are essential to the survival of mycobacteria [132] and hence 
their biosynthesis is the target of widely used drugs such as isoniazid and ethambutol. 
These α-branched and β-hydroxylated long-chain fatty acids indeed play a major role 
in the envelope structure. They are located in the inner membrane of the 
mycomembrane and are covalently attached to the AG, on one side, and interact with 
other lipids in the outer membrane part, on the other side. In addition to their 
essential structural properties, mycolic acid derivatives also play a role in the 
virulence of Mtb. Esterified forms of trehalose called trehalose monomycolates 
(TMM) and trehalose dimycolates (TDM) specifically interact with host cell receptors 
and induce a pro-inflammatory response from the host immune system [133] 
The complex biosynthesis of mycolic acids involves multiple pathways. Briefly, 
type-I FAS first synthesizes fatty acid precursors, type-II FAS elongates other 
precursors coming from FAS-I and finally the key step resides in the condensation of 
the fatty acid chains to yield mycolic acids. This condensation is realized by a 
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specialized PKS called Pks13, which is essential to mycolic acids biosynthesis [134]. 
Interestingly, Pks13 is composed by the core KS and AT domains, but also two ACP 
domains in accordance with the two fatty acid chains to condensate, and a TE domain 
thought to release the final product. One fatty acid chain is selected by the AT domain 
[135], and is then transferred onto the C-terminus ACP, whereas the other one is 
directly loaded on the N-terminus ACP by a dedicated fatty acid AMP ligase (FAAL), 
FadD32 [136]. Such loading of precursors by a dedicated enzyme is a common feature 
of several PKSs in Mtb. 
 
b) Sulfolipids 
 
Sulfolipids (SL) are multiacylated trehalose-containing lipids that belong to 
the extractable lipids group of the mycobacterial envelope. SL interact non-covalently 
with mycolic acids in the outer membrane and their expression is restricted to Mtb 
and Mycobacterium. canetti. They are present in the cell envelope of M. tuberculosis 
under different forms. The main form is tetra-acylated with a palmitic acid, a 
phtioceranic acid and two hydroxyphthioceranic acids. Other forms can be found, 
especially diacylated form which is an intermediary in the synthesis of the tetra-
acylated one. The role of SL in the virulence of Mtb was a matter of debate because of 
the absence of any phenotype in vivo, although these lipids seemed to be involved in 
the survival of the bacillus within macrophages as observed using in vitro 
experiments [137]. However, a recent study has demonstrated a role of these lipids in 
the virulence of M. tuberculosis both in vivo in a mouse model, and in vitro in human 
macrophages [138]. 
The biosynthesis of SL starts by the transfer of a sulfate onto a trehalose 
molecule, catalyzed by the sulfotransferase Sft0 [139]. In parallel, the polyketide 
synthase Pks2 synthesizes the methyl-branched phtioceranic and 
hydroxyphthioceranic chains [140]. The acyltransferases PapA1 & PapA2 are then 
responsible for the transfer of the acyl chains onto the trehalose-2-sulfate which 
generate a diacylated SL [141], [142]. Chp1 is responsible for the transfer of the two 
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remaining acyl chains, and Mmpl8 and Sap are thought to be responsible for the 
transfer of the SL to the mycomembrane [143]. 
 
c) Diacyl Trehalose and Polyacyl Trehalose 
 
Like sulfolipids, diacyltrehaloses (DAT) and polyacyltrehaloses (PAT) are 
extractable lipids only expressed by M. tuberculosis & M. canettii. DAT & PAT are 
lipids constitutionally composed by a trehalose, acylated by a palmitic acid. Other 
acylations may occur to form a variety of lipids. Thereby, two forms of DAT exist: 
DAT1 composed by a palmitic acid and a mycosanoïc acid, and DAT2 composed by a 
palmitic acid and a mycolipanolic acid. DAT & PAT are not involved in the structure 
of the mycobacterial envelope but seem to play a role in the membrane permeability. 
It has been demonstrated, both in vitro [144], [145] and in vivo [138], that DAT & 
PAT are implicated in the virulence of M. tuberculosis, in particular by inhibiting T 
lymphocytes proliferation. They are also involved in the bacterial survival within 
human macrophages [146]. 
The biosynthesis pathway of DAT & PAT remains unclear. PapA3 is thought to 
transfer a palmitic acid onto a trehalose molecule to form a trehalose-2-palmitate 
[147]. PapA3 also seems to be involved in the acylation of the trehalose-2-palmitate 
with the product of the polyketide synthases Pks3/4 to form a diacyltrehalose [148]. 
Then, this lipid may be exported to the surface of the mycobacterial envelope by 
Mmpl10 [148], or used as an intermediary in the polyacyltrehalose biosynthesis 
pathway. 
 
d) Mycobactins 
 
Mtb synthesizes two structurally related siderophore compounds named 
mycobactin and carboxymycobactin to bind iron from the external medium. The 
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main functional difference between them is that carboxymycobactin is secreted into 
external medium whereas mycobactin is associated to the plasma membrane. In host 
cells, iron concentration is 1011 to 1012 fold lower than the concentration required for 
Mtb to survive. Mycobactins have been demonstrated to play a major role in such 
environments [149], [150]. Indeed, Mtb mutant strains deficient for the biosynthesis 
of these compounds hardly multiplicate in these conditions. Also, when either mice or 
isolated macrophages are infected by Mtb, the transcription level of genes coding the 
biosynthesis pathway of mycobactins is increased [151], [152]. 
Mycobactins are mixed “polyketides/peptides” compounds and thus are 
biosynthesized by PKSs and NRPSs. Genes encoding these enzymes are located in the 
mtb 24kb cluster, and include three NRPSs (mtbB, mtbE and mtbF) and two PKSs 
(mtbC and mtbD) [126], [153]. 
 
e) Phtiocerol Dimycocerosates 
 
(1) A MAJOR ROLE IN MYCOBACTERIUM 
TUBERCULOSIS VIRULENCE 
 
As early as 1974, it was recognized that a DIM-deficient spontaneously arising 
variant of the laboratory strain H37Rv was attenuated in a guinea pig model of 
infection [154]. Two years later, it was shown that the in vivo survival of an avirulent 
Mtb strain was enhanced by coating the bacteria with cholesterol oleate and purified 
DIM [155]. Yet, it took a quarter century to clearly establish a link between DIM 
biosynthesis and virulence. Indeed, in the late 90’s, two independent signature-
tagged transposon mutagenesis studies led to the isolation of Mtb mutants with a 
severe growth defect in mice [156], [157]. These transposons have inserted into the 
large chromosomal locus where enzymes responsible for biosynthesis and transport 
of DIM are coded, thus leading to a defect in DIM production or translocation. 
Furthermore, strains deficient in DIM are markedly attenuated for growth in the 
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lungs of infected mice and in macrophages [156], [158], [159]. DIM have been shown 
to be responsible for a strong decrease in phagosome acidification [160], and for 
resistance against both reactive nitric intermediate (RNI) toxic radicals produced by 
macrophages [159], and INF-γ-dependent host cell mechanism [161]. A more 
comprehensive analysis of the effect of DIM presence in Mtb has revealed that DIM 
participates in receptor-dependent phagocytosis through a mechanism involving host 
plasma membrane reorganization [162]. DIM would insert in the plasma membrane 
to facilitate phagocytosis and inhibit phagosome acidification, thus creating a 
protecting niche for Mtb. Additionally, DIM seem to play an important role in the 
impermeability of the mycobacterial cell wall since a defect in these lipids lowers 
mycobacteria resistance to SDS by a 100 fold [158]. Interestingly, in a recent study on 
the roles of SL, DAT/PAT and DIM in Mtb virulence, it has been shown that a 
hierarchical order exists between these lipids, in which DIM have arisen as the 
prevalent one [138]. 
While Euro-American Mtb strains, including H37Rv, only produce DIM, highly 
virulent Asian strains such as Beijing strains, produce both DIM and 
phenoglycolipids (PGL), a structural variant of DIM. PGL production has then been 
associated with hyper-virulent phenotypes in mice models, since it inhibits several 
pro-inflammatory cytokines (TNFα, IL-12, IL-6) implied in the regulation of Mtb 
infection [163], [164]. In human macrophage infection, PGL induces the production 
of IL-4 and IL-13, which are cytokines that deactivate phagocytes. In accordance to 
this feature, human monocytes incubated with lipid extract not containing PGL, 
produce IL-12 [165]. Additionally, PGL is also implicated in dissemination and 
virulence of Mtb in the context of central nervous system infection in rabbit 
meningitis tuberculosis [166]. 
 
(2) STRUCTURE AND BIOSYNTHESIS 
 
DIM are composed of a C33-C41 long β-diol chain called phthiocerol, esterified 
on C9 and C11 by mycocerosic acids which are C27-C31 long methyl-branched chains. 
As shown in Figure 22, different forms of DIM exist depending on (1) phtiocerol and 
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mycocerosic acids chain length, (2) presence of a methoxyl (DIM A, major form) or a 
hydroxyl group instead of the ketone on C3 (DIM B, minor form), (3) presence of an 
additional methyl moiety on C1 (DIM A’ or DIM B’). PGL additionally include a p-
hydroxyphenylalkanoic acid linked to sugars. In Mtb, the major form is known as 
“PGL-tb” and the sugar part corresponds to a 2,3,4-tri-O-methyl L-furanosyl α(1o3) 
L-rhamnopyranose α(1o3) 2-O-methyl L-rhamnopyranose. 
Enzymes responsible for the production of DIM and PGL are coded in a 70kb 
cluster referred to as the “DIM-PGL” cluster. These include six PKSs for DIM 
biosynthesis (Figure 22) and an additional one for PGL biosynthesis. Other enzymes 
are responsible for precursor recruitment and transfer, polyketide condensation and 
modification, and transport to the external part of the mycomembrane (not shown in 
Figure 22). PpsA, PpsB, PpsC, PpsD and PpsE are type-I mono-modular PKSs 
(Figure 22, compared to DEBS multi-modular PKS in Figure 5), which catalyze the 
formation of the phthiocerol moiety (or phenol-phtiocerol moiety for PGL 
biosynthesis). Mas is a type-I iterative PKS which catalyze the formation of 
mycocerosic acids [167]. Pks15/1 is a type-I iterative PKS implied in PGL biosynthesis 
that it responsible for the elongation of p-hydroxybenzoic acid (formed by the 
Rv2949c pyruvate lyase [168]) to p-hydroxyphenylalkanoic acid with malonyl-CoA as 
elongation unit [169]. A 7bp deletion in the pks15/1 gene is responsible for the defect 
in PGL for several Euro-American laboratory strains (H37Rv, Mt103, CDC1551, 
Erdman) [169]. 
Phtiocerol biosynthesis starts with the transfer of a C20-C22 fatty acid 
precursor (or p-hydroxyphenylalkanoic acid in the case of PGL biosynthesis) on the 
ACP domain of PpsA by the FadD26 FAAL [170] (Figure 22). PpsA catalyzes the 
condensation of the precursor with a malonyl-CoA elongation unit and reduce the β-
ketone with the help of its KR domain [167]. The growing polyketide is then 
transferred to the ACP domain of PpsB to undergo the same treatment. Next, PpsC 
and PpsD elongate it using a malonyl- and methylmalonyl-CoA, respectively. They 
also catalyze the complete reduction of the previously incorporated β-ketones using 
their full set of β-carbon processing domains (KR, DH, and ER). Finally PpsE 
catalyzes the condensation with either a malonyl- or a methylmalonyl-CoA without 
further modification, to form the phthiocerol chain.  
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In parallel, mycocerosic acid biosynthesis starts with the transfer of a C16-C20 
by FadD28 FAAL [170] onto the ACP domain of Mas, which then iteratively elongates 
and processes the polyketide, with methylmalonyl-CoA as elongation unit [167]. 
Resulting mycocerosic acids are then transferred onto the (phenol-)phtiocerol moiety 
by the PapA5 acyltransferase [171]. This enzyme has been shown to be essential to 
DIM biosynthesis and since it interacts with PpsE, it has been suggested that it would 
be responsible for the DIM release from the C-terminus condensase domain (C) of 
PpsE [172]. Finally, the condensation product (DIM B) can be reduced on the 
(phenol-)phtiocerol C3 by Rv2951c [173], and then methylated by Rv2952 [174] to 
yield DIM A (or PGL-tb precursor). In the case of PGL, additional 
glycosyltransferases Rv2962, Rv2958c, Rv2957 and the methyltransferase Rv2959c 
are required to add and methylate sugar moieties, respectively, [174] to yield PGL-tb. 
 
(3) TRANSPORT 
 
DIM and PGL biosyntheses require cofactors such as NADPH and ATP which 
are only present in the cytosol, thus suggesting that it occurs in the cytoplasm. DIM 
transfer in the outer part of the mycomembrane is poorly understood, nonetheless, 
several enzymes have been shown to participate to DIM transport. For example, it 
has been demonstrated that Mmpl7 is essential to the presence of DIM in the Mtb 
envelope [156], [158]. In addition, two-hybrid screening and GST pull-down 
experiments have shown that Mmpl7 interact with PpsE. Mmpl7 being a resistance 
nodulation cell division (RND) permease transporter, authors have proposed a model 
in which the whole biosynthetic machinery would be recruited by Mmpl7 in close 
proximity to the cytoplasmic membrane to facilitate transfer [175]. DrrC, a subunit of 
the ABC (ATP Binding Cassette) transporter also involving DrrA and DrrB, has also 
been shown to be implicated in DIM transport, since an Mtb strain mutated on drrC 
produces DIM, but these are not present in the envelope [158]. Finally, the 
lipoprotein LppX would also be involved in DIM transport. Indeed, inactivation of 
lppX in Mtb, induces an accumulation of DIM in both cell wall and plasma 
membrane, but not in the mycomembrane [176]. 
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All the studies revealing a potential role of transporters in DIM transfer have 
been realized on strains that do not produce PGL. However, structural similarities 
between these lipids suggest that they are transported by the same proteins. This 
hypothesis has gained further credibility with the demonstration of the essentiality of 
mmpl7 to the presence of PGL-tb in the envelope of the PGL-producing HN878 strain 
[163]. 
 
f) Activation of the Mycobacterial Polyketide 
Synthases 
 
In Mtb, two putative PPTases have been identified: Rv2553c (AcpS) which 
would be a 130 residue-long group I PPTase, and Rv2794c (PptT) which would be a 
227 residue-long group II PPTase involved in mycobactin biosynthesis [126], [153]. In 
a study using the fast-growing Mycobacterium smegmatis, both AcpS and PptT have 
been shown to be essential for the growth of the bacterium [103] 
AcpS is responsible for the activation of ACPs of both FAS systems (FAS-I ACP 
domain [104] and FAS-II AcpM [177], [178]). Its solution structure has been 
determined [179] and has confirmed the trimeric arrangement with an α/β fold of the 
protein, a typical feature of group I PPTases. The ACP binding site is a flexible loop 
that would allow the enzyme to adapt to both the FAS-I ACP domain and AcpM. 
PptT is assumed to be responsible for the activation of all the PKSs and NRPSs 
in Mtb [103], [153]. Indeed, in vivo activation of PpsA, PpsB, PpsC, PpsD, Mas and 
Pks13 [103], and in vitro activation of MbtB and MbtE [153] have been demonstrated. 
PptT is therefore required for the biosynthesis of sulfolipids, DAT & PAT, 
mycobactins, phtiocerol dimycocerosates, and mycolic acids [103]. Using an Mtb 
conditional expression mutant of PptT, our collaborators in the Guilhot’s group at the 
Institut de Pharmacologie et de Biologie Structurale in Toulouse, have recently 
established that PptT is required for mycobacterial survival in various environments, 
including those encountered in macrophages, and during the various phases of 
infection in an animal model. More specifically, they have demonstrated that PptT is 
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required for the replication of Mtb both in vitro and in vivo during the acute and 
chronic phases of infection in immunocompetent mice [104]. The impaired survival 
of Mtb in mice during the chronic phase was probably not solely due to disrupted 
mycolic acids biosynthesis, since in chronic tuberculosis, mycobacteria are thought to 
have low level of replication and therefore mycolic acid synthesis is probably low. As 
antibiotics affecting the synthesis of mycolic acids have only poor bactericidal activity 
during the chronic phase of infection in mice, the requirement of PptT for Mtb 
replication may be the consequence of additive effects. Indeed, PptT is required for 
the expression of mycobactins, DIM, PGL, SL, DAT/PAT which are all involved in 
Mtb virulence. Moreover, DIM also contribute to the permeability barrier role of the 
mycobacterial cell envelope [158], and their absence increase Mtb sensitivity to the 
bactericidal activities of phagocytes [159]. 
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II. RESULTS 
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A. PROJECT I: STUDY OF A 
TYPE-I MONO-MODULAR 
POLYKETIDE SYNTHASE 
 
 
1. PROJECT 
 
a) Significance 
 
Polyketides have been shown to be of great value in numerous pharmaceutical 
applications (see section I.A.1), and interest is rising on the design and production 
of new polyketide compounds. Enzymes responsible for their biosynthesis, the 
polyketide synthases, are complex molecular machineries that consist in a set of 
catalytic domains designed to work in synergy in order to produce a large panel of 
possible compounds. New approaches implying the modification of PKSs to 
synthesize new polyketides require a precise understanding of these complex 
machineries to gain efficiency. In an attempt to better characterize polyketide 
biosynthesis and address some outstanding issues (described in section I.B.1.b) 
about the structural features that determine the function of PKSs, we have decided to 
undertake a functional and structural study on PpsC, a mono-modular type-I PKS. 
Tuberculosis is the second greatest killer disease worldwide, after AIDS, due to 
a single infectious agent [WHO, 2011]. The low BCG vaccine efficiency, in addition to 
the emergence of multi-drug resistant strains contaminating nearly half a million 
people per year underlies the failure of the actual therapies. Now that the 
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determinants of Mtb pathogenicity begin to be precisely defined, a novel approach 
consisting in the rational design of Mtb drugs has arisen. In this context, several 
studies have shown that some polyketide-derived lipids greatly contribute to Mtb 
virulence. More specifically, DIM have been shown to be required for Mtb to possess 
its fully virulent phenotype and therefore their biosynthesis pathway represents a 
promising target candidate for drug design. Such approach being greatly facilitated 
by the knowledge of the tridimensional structure of the protein target, we have been 
interested in determining the high-resolution structure of a PKS essential for DIM 
biosynthesis. 
The aim of this project is to structurally and functionally characterize the 
polyketide synthase PpsC from Mtb. Among the six PKSs that participate in DIM 
biosynthesis, PpsC has been chosen for three main reasons. First, it is a modular PKS, 
the most promising class of PKSs for the production of new drug-active polyketides. 
Second, between all PpsA-E PKSs, PpsC is the only one to possess a full set of β-
carbon processing domains (Figure 23) and thus represents a model for the study of 
this cluster of enzymes. We were also interested in deciphering the overall 
architecture of a PKS in order to understand how the domains assemble together and 
compare it to the structurally- and functionally-related mFAS. Finally, at the 
beginning of this project, PpsC, along with PpsB and Mas, were the only enzymes that 
had been demonstrated as strictly essential to DIM biosynthesis [180], [181], an 
indispensable character for rational drug design approaches. 
It is noteworthy to mention that our group is also interested in the 
characterization of the PpsA and Mas enzymes. The functional and structural study of 
these enzymes, in addition to PpsC, is part of a global project (XPKS-MYCO) 
involving several groups in our institute (IPBS, Toulouse, France), whose focus is the 
characterization of PKSs essential for the virulence of Mtb 
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b) Strategy 
 
Due to their length and flexibility, PKSs are thought to be very difficult to 
crystallize in their entire form. Moreover, no structure of a full-length PKS has ever 
been reported. Structural information on PKSs has then arisen from protein 
fragments representing one or rarely two domains of a given enzyme. Taking this into 
account, we have decided to study individual fragments representing one or more 
domains of PpsC. 
PpsC is a 231 kDa mono-modular PKS that possess six catalytic domains: KS, 
AT, DH, ER, KR and ACP, separated by linkers (Figure 23). Our strategy first relied 
on identifying soluble fragments representing one or more domains of the enzyme 
using the recently developed domain trapping strategy. These fragments were then 
subjected to a specific protocol developed to produce and purify them in large 
amounts. Pure and stable fragments were then selected for crystallization trials and 
further characterized using enzymatic tests and biophysical methods. 
 
2. APPLICATION OF THE DOMAIN 
TRAPPING METHOD 
 
In order to structurally and functionally characterize PpsC, our first goal has 
been to identify soluble fragments, representing each catalytic domain. The most 
commonly used approach to this problem is limited proteolysis. However, this 
method has several drawbacks including the low diversity in fragment space and 
possible issues concerning the solubility of the fragments. Not to mention the many 
other limitations inherent to this methodology, achieving it for every six domains that 
compose PpsC would have been too much time-consuming and labor-intensive. 
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Instead, we have chosen to use the domain trapping strategy, recently 
developed by J.D. Pédelacq in collaboration with researchers from the Los Alamos 
National Laboratory. This methodology relies on two independent technologies which 
aim at identifying suitable protein fragments for downstream structural and 
functional characterization. Briefly, randomly-cut gene fragments of the gene coding 
the protein of interest are cloned and expressed in two separate vectors for in-vivo 
selection of (1) in-frame fragments using an insertion dihydrofolate reductase 
(DHFR) vector and (2) soluble fragments using the previously developed split-GFP 
technology [182], [183]. Finally, an inverse polymerase chain reaction (iPCR) step is 
used to create domain-focused sub-libraries of soluble fragments. 
This methodology has first been used on the p85α subunit of the 
phosphoinositide-3-kinase to demonstrate its efficiency. It has then been successfully 
applied to the polyketide synthase PpsC, allowing us to obtain libraries of E. coli-
expressed soluble fragments centered on each catalytic domain of the enzyme. These 
fragment libraries represented the starting point of my work on this project. Some of 
the results I have obtained for PpsC, i.e. the crystallization of the AT, DH, and ER 
domains, have been included in the following publication and will also be discussed 
in the next chapter:  
 
J.-D. Pedelacq, H. B. Nguyen, S. Cabantous, B. L. Mark, P. Listwan, C. Bell, N. 
Friedland, M. Lockard, A. Faille, L. Mourey, T. C. Terwilliger, and G. S. Waldo, 
“Experimental mapping of soluble protein domains using a hierarchical approach.”, 
Nucleic acids research, vol. 39, no. 18, p. e125, Oct. 2011. 
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ABSTRACT
Exploring the function and 3D space of large
multidomain protein targets often requires
sophisticated experimentation to obtain the
targets in a form suitable for structure determin-
ation. Screening methods capable of selecting
well-expressed, soluble fragments from DNA
libraries exist, but require the use of automation
to maximize chances of picking a few good
candidates. Here, we describe the use of an inser-
tion dihydrofolate reductase (DHFR) vector to select
in-frame fragments and a split-GFP assay technol-
ogy to filter-out constructs that express insoluble
protein fragments. With the incorporation of an
IPCR step to create high density, focused
sublibraries of fragments, this cost-effective
method can be performed manually with no a
priori knowledge of domain boundaries while
permitting single amino acid resolution boundary
mapping. We used it on the well-characterized
p85a subunit of the phosphoinositide-3-kinase to
demonstrate the robustness and efficiency of our
methodology. We then successfully tested it onto
the polyketide synthase PpsC from Mycobacterium
tuberculosis, a potential drug target involved in the
biosynthesis of complex lipids in the cell envelope.
X-ray quality crystals from the acyl-transferase (AT),
dehydratase (DH) and enoyl-reductase (ER) domains
have been obtained.
INTRODUCTION
Over the past 10 years, the Mycobacterium tuberculosis
Structural Genomics Consortium (http://www.doe-mbi
.ucla.edu/TB/), a large-scale center funded by the
National Institutes of General Medical Sciences
(NIGMS), has cloned more than 1400 protein targets for
cell-based production in Escherichia coli. Only half of
the proteins expressed have been produced in a soluble
form. Other structural genomics initiatives also con-
ﬁrmed this step to be one major bottleneck in structural
biology. Screening approaches for improved folding
and stability of protein targets have brought new
insights into solving structures of single-domain proteins
(1,2). However, structure determination of multidomain
proteins has been found to be more challenging due to
their larger size and increased instability. In addition,
domain boundaries are not always straightforward to
predict (3). In this respect, high-throughput approaches
of generating libraries of truncated DNA fragments (4)
combined with a colony ﬁltration immunoblot using
antibody detection of tagged constructs (5,6), the detec-
tion of a ﬂuorescent fused GFP phenotype (7,8) or a
fused C-terminal biotin acceptor peptide (9) have proven
to be successful in identifying constructs potentially
amenable to functional and structural characterization.
Unfortunately, all these approaches lack a ﬁltering
strategy to effectively eliminate DNA fragments, which
do not encode authentic protein domains. Instead, fully
automated strategies have been implemented to effectively
screen the thousands of clones and pick a few good can-
didates (10).
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Eliminating frame-shifted fragments from DNA
libraries has become a key step to addressing the construc-
tion of expression plasmid libraries that produce protein
domains in-frame with the target gene. Existing systems
involve expressing fragments as N-terminal fusions to
murine dihydrofolate reductase (mDHFR) (11), kanamy-
cin (12) or b-lactamase (13). However these technologies
yield false positives originating from translation initiation
at internal ribosome binding sites (IRBS). A number of
bipartite selection systems have also been developed in an
attempt to overcome these limitations. In these systems,
the DNA sequence of interest is inserted between the two
halves of the reporter, which are both required to give an
observable phenotype (14–18).
In this article, we describe a novel approach that uses a
two-body E. coli dihydrofolate reductase (DHFR) (19)
scaffold for selecting in-frame DNA sequences from a
random library of a fragmented gene, combined with the
split-GFP technology (20) to identify soluble candidates.
We used the regulatory subunit p85a of the class IA
phosphoinositide 3-kinase (PI3K) as a benchmark to
validate our method. We then tested it onto the polyketide
synthase PpsC from M. tuberculosis. This 230 kDa
mega-synthase plays a key role in the virulence of this
microbial pathogen through the synthesis of phtiocerol
dimycocerosates, a family of lipids located in the cell
envelope. With the incorporation of an inverse polymerase
chain reaction (PCR) step to increase population density
in fragments within domains, X-ray quality crystals
from the acyl-transferase (AT), dehydratase (DH) and
enoyl-reductase (ER) domains have been obtained.
MATERIALS AND METHODS
Gene cloning and fragmentation
The p85 and Ppsc genes fromM. tuberculosis were cloned
into the NdeI/BamHI and NdeI/SpeI sites of a pET26b
plasmid (Novagen, Madison, WI, USA), respectively, and
PCR ampliﬁed using gene-speciﬁc primers
(Supplementary Data 2). DNA fragmentation conditions
of the p85 gene were optimized using small aliquots of
concentrated PCR products incubated with a serial 2-fold
dilutions of a DNase I stock solution at 1U/ml
(Invitrogen, Carlsbad, CA, USA). Best condition corres-
ponded to a 24-fold dilution from a 1 ml stock solution of
DNase I with 20 ml of 10mM Tris–Hcl pH=7.4 and 3 ml
of 10mg/ml Bovine Serine Albumine (BSA). Cleaned PCR
product of 50 ml was mixed with 6 ml of 0.5M Tris–Hcl
pH=7.4 and 1ml of 100mM CoCl2. Both solutions
were pre-incubated in a PCR block at 15C for 5min
before mixing. Two libraries were generated by adding
6 ml of the 24-fold DNase I solution to the PCR mixture:
a 250–400 bp DNA library (small size) and a 400–750 bp
DNA library (large size) with incubation times of 5 and
2min, respectively. Digestion reactions were stopped by
adding 650ml of PB buffer before cleaning through a
Qiaquick PCR puriﬁcation column (Qiagen Inc. USA,
Valencia, CA, USA). In the case of Ppsc, small size
(400–850 kb) and large size (850–1650 kb) DNA libraries
were obtained from 160 ml of cleaned PCR product using
a HydroShear device from Genomics Solutions
(Ann Arbor, MI, USA) applying 25 cycles at speed codes
8 and 13, respectively. Extremities of the fragments were
polished using 30-50-exonuclease activity of Vent polymer-
ase (New England Biolabs, Beverly, MA, USA) at 72C for
20min. Double-stranded DNAs were resolved by agarose
gel electrophoresis and visualized by ethidium bromide
staining. A slab of gel containing DNA fragments with
desired size was then excised and recovered with a
QIAquick gel extraction kit (Qiagen Inc. USA, Valencia,
CA, USA). DNA fragments designed for the screening of
BCR domain constructs were ampliﬁed using gene-speciﬁc
primers (Supplementary Data 2) and ligated into the NdeI/
BamHI of pTET ColE1 GFP 11 vector.
Construction of insertion DHFR library
Blunt fragments were ligated in a StuI-digested insertion
DHFR (iDHFR) pET vector (Supplementary Data 1) for
12 h at 16C, and ligated plasmids were transformed into
electro-competent E. coli DH10B cells (Invitrogen,
Carlsbad, CA, USA) to increase efﬁciency. Starting with
5 106 clones/library, transformed cells were plated onto
Luria-Bertani (LB) agar plates containing 35 mg/ml kana-
mycin, allowing the E. coli cells lawn to grow overnight at
37C. Overnight colonies from lawns of 3 105 clones,
estimated by dilution plates, were washed off and used
for plasmid preparation prior to transformation into
chemically competent E. coli BL21 (DE3) Tuner cells.
Following overnight growth at 32C on LB/kanamycin
medium, cells were diluted in LB containing 20%
glycerol to OD600 nm=1.0 for 80C freezer stocks.
Forty microliter of the 1.0 OD freezer stock were used
to seed a 3ml LB/kanamycin culture. Cells were
propagated until OD600 nm=0.5 was reached, and then
induced with 20 mM IPTG for an additional 2–3 h. Cells
were diluted in 1ml LB to OD600 nm=2.0, yielding
10 108 cells/ml, and plated on LB medium containing
6 mg/ml trimethoprim (TMP) and 20 mM IPTG. To
compare the colony-forming unit (CFU), numbers in the
presence or absence of TMP, cells were further diluted to
1/16000 and plated out on two LB/agar plates containing
20 mM IPTG in the presence or absence of TMP. All plates
were incubated overnight at 32C.
Inverse PCRs
Recovered iDHFR libraries were diluted for plasmid prep-
aration. NdeI/BamHI and NdeI/SpeI restrictions sites
were used to release fragments from p85 and Ppsc, re-
spectively. Gel extracted and cleaned inserts were ligated
into their corresponding digested pTET ColE1 GFP 11
vector. Inverse PCRs were performed following the
protocol by Hoskins and colleagues (21). For each p85
and Ppsc targeted domain, phosphorylated forward and
reverse primers were designed (Supplementary Data 2).
Brieﬂy, 100 ml inverse PCRs (IPCRs) were conducted
with Phusion DNA polymerase (Finnzymes) according
to the manufacturer’s instructions. Following a
self-ligation with T4 DNA ligase in a 100 ml volume at
16C overnight and a digestion with DpnI enzyme at
37C for 2 h 30min, ligated pTET ColE1 GFP 11
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vectors containing targeted inserts were transformed into
chemically competent BL21 (DE3) pET GFP 1–10 cells.
Solubility screens using the split-GFP assay
In vivo solubility screenings were performed as previously
described (22). Brieﬂy, cells were grown to saturation in
LB containing 35 mg/ml kanamycin and 75 mg/ml spectino-
mycin, and diluted in 20% glycerol to OD600 nm=1.0 for
80C freezer stocks. Frozen cells were thawed at 0C,
400-fold diluted (twice) in LB and plated onto a nitrocel-
lulose membrane with selective LB-agar containing the
same antibiotics (approximately 3000 colonies). After
overnight growth at 32C, the membrane was transferred
onto a pre-warmed plate containing 250 ng/ml AnTet for
2 h, and rested back onto its original LB-Kan-Spec plate
for 1 h. Following induction with 1mM IPTG at 37C for
1 h, the induced colonies were illuminated using an
Illumatool Lighting System (LightTools Research),
equipped with a 488 nm excitation ﬁlter. An ensemble of
96 clones with decreasing levels of in vivo ﬂuorescence
intensities were picked for each library. Columns 1–3 of
the tissue culture plate correspond to only bright clones,
columns 4–9 present a range in ﬂuorescence intensity
levels from medium bright to faint and columns 10–12
only correspond to very faint clones. As a control, a
total of 96 clones were picked randomly by hand,
transferred to 96-well plates and grown before sequencing.
All the clones were used as starter cultures on 96-well
tissue culture plates for in vitro complementation
split-GFP assays using our in-house automated,
high-throughput, liquid-handling platform (23).
Identiﬁcation of fragments boundaries
Individually picked clones were grown overnight at 30C
in a 96-well tissue culture plate containing 7.5% glycerol
in LB-Kan-Spec medium. Plasmid ampliﬁcation at the
Los Alamos genome sequencing facility using
rolling-circle ampliﬁcation in the presence of a forward
primer speciﬁc of tet-promoter and a reverse primer
speciﬁc of GFP 11 (Supplementary Data 2) yield
high-quality sequence. DNA sequences were analyzed
using BioEdit software. Sequence alignments were per-
formed by aligning individual fragments onto the
full-length parent gene to determine the exact boundaries
from the forward (start of the fragment) and reverse
sequence (end of the fragment). Based on the in vitro solu-
bility assays, fragments were color-coded black, light
green and bright green, where the black side of the
spectrum identiﬁes the least soluble protein fragments
and the bright green side corresponds to the top 25% of
the most soluble ones. Fraction of color-coded black and
light green fragments varies from 25% and 50% for a
full-length gene mapping to 37.5% in the case of IPCRs.
Small scale expression and solubility tests
An ensemble of 10 fragments spanning the PpsC polypep-
tide chain were selected and subcloned from the
pTET-GFP, 11 plasmid into a N6–HIS or C6–HIS pET
vector. The resulting clones were grown at 37C in 1ml
cultures using 35 mg/ml kananycin. Cells were induced in
exponential phase with 1mM IPTG for 3 h. Cell culture
pellets of 1ml of each fragment were separately resus-
pended in 40 ml 150mM NaCl, 100mM Tris–HCl
pH=7.5, 10% (v/v) glycerol (TNG buffer) and sonicated.
The lysate was fractionated by centrifugation to yield the
soluble and pellet fractions. The pellet fraction was
washed twice with 100 ml TNG, centrifuged and resus-
pended in the same starting volume. Samples correspond-
ing to the soluble (S) and pellet (P) fractions were resolved
on a 4–20% gradient Criterion SDS–PAGE gel (Bio-Rad,
Hercules, CA, USA). Protein samples were stained using
Gel Code Blue stain reagent (Pierce, Rockford, IL) and
imaged using a GS-800 Calibrated Densitometer (Biorad,
Hercules, CA, USA).
Metal afﬁnity resin puriﬁcation of selected fragments
Five hundred milliliter cultures of BL21(DE3) cells ex-
pressing selected protein fragments were grown to OD
(600 nm) 0.5–0.7 in LB medium supplemented with
1mM kanamycin, induced with 0.5mM IPTG for 5 h at
32C, pelleted by centrifugation, resuspended in 15ml
100mM Tris–Hcl pH=8.1 containing 150mM NaCl
and sonicated. The soluble extract of 15ml was mixed
with an equal volume of 50% v/v slurry of metal afﬁnity
resin beads (Talon resin, Clontech, Palo Alto, CA, USA)
in TNG buffer for 10min and centrifuged brieﬂy. The
unbound fraction was removed by pipetting and the
beads were washed twice with 10 volumes of TNG
loading buffer. After an additional wash with TNG
buffer supplemented with 10mM imidazole, His-tagged
proteins were eluted with 250mM imidazole in TNG
buffer. For each puriﬁcation step, the proteins elution
samples were resolved on a 4–20% gradient Criterion
SDS–PAGE gel (Bio-Rad, Hercules, CA, USA) and
stained using the same procedure described above. Using
this procedure, 98% pure AT (4mg), DH (20mg) and
ER (5mg) proteins were obtained. The absence of ag-
gregates in the samples and polydispersity levels of <10%
were conﬁrmed using a DynaProTM Dynamic Light
Scattering (DLS) Instrument from Wyatt Technology.
15N–Protein labeling and sample preparation for
NMR spectroscopy
Protein expression level in minimal media was enhanced
by increasing cell density using a 4:1 cell concentrating
method (24). For 15N uniform labeling, cells from 2 l of
LB media were grown at 37C until an OD600 of 0.5–0.7
was reached, then harvested and resuspended in 500ml of
M9 minimal media containing 0.5 g 15NH4Cl. Following
an additional 30min of shaking, cells were induced with
0.5mM IPTG for 7 h at 25C. Proteins were puriﬁed as
described above using Talon resin and dialyzed against
50mM Na phosphate buffer pH=7, 1mM DTT, 1mM
EDTA overnight at 4C to remove imidazole and salt
from elution buffer. Protein solution was concentrated
using an Amicon Ultra-15 centrifugal ﬁlter device
(10 kDa cutoff; Millipore). Final NMR samples usually
contain 0.5–1mM protein in 50mM Na phosphate
buffer pH=7, 1mM DTT, 1mM EDTA and 10%
D2O. 1H–15N HSQC spectra were recorded at 298K on
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Varian Inova 720MHz spectrometer using a conventional
probe. Complex points of 1024 in the direct dimension
(1H) and 256 complex points in the indirect dimension
(15N) were collected. All spectra were processed using
nmrPipe (25) and analyzed by the Sparky software
(Goddard and Kneller, University of California, San
Francisco). Chemical shifts were referenced to 4,4-
dimethyl-4-silapentane-1-sulfonic acid (26).
RESULTS
Selection of in-frame, well-expressed and soluble
fragments
Our strategy has four distinct steps, where selection
pressure forces the false positives at any given step to be
effectively eliminated and the number of false negatives to
be reduced. First, a library of 5 106 clones expressing
DNA fragments is created by fragmentation of a PCR
ampliﬁed gene using DNase I or mechanical shearing
(Figure 1). Fragments of the desired size are excised
from preparative agarose gel, blunt-ended with
50-30-exonuclease, and then cloned between the two
halves of bacterial DHFR at a permissive site between
amino acids 86 and 87 in the presence of TMP
(Supplementary Data 1). We found that 3–6mg/ml TMP
killed DH10B E. coli cells, but allowed clones expressing
inserts without stop codons to subsist. Under this selective
antibiotic pressure, approximately 1 in 18 cells survive,
corresponding to fragments translated in the same
reading frame as the parent open reading frame (ORF)
and in-frame with the reporter destination vector (8).
This leads to 3 105 clones recovered at this step
(Figure 1), a number to compare with the few hundreds
in-frame clones from published methods (5,6,11). Only
fully automated platforms capable of picking and
assaying tens of thousands of clones in parallel for expres-
sion and solubility can compete with our approach. In this
respect, Expression of Soluble Proteins by Random
Incremental Truncation (ESPRIT) (9) has led to remark-
able results on several challenging targets (10,27–30). In
the third step, in-frame fragments are subcloned into the
split-GFP system. At this point, full-length libraries can be
screened for solubility after in vivo sequential induction of
the GFP 11-tagged protein fragments and the complemen-
tary GFP 1–10 detector (22). Clones displaying a wide
Figure 1. The GFP-enabled domain trapping strategy. The PCR-ampliﬁed gene is fragmented by chemical or mechanical means and DNA fragments
of desired size are excised from agarose gel. Blunt-end fragments are cloned into the iDHFR ORF ﬁlter, where only the in-frame ones permitting the
expression of the second half of DHFR will survive. Inserts from the recovered plasmids are cloned into the split-GFP vector and used for IPCR to
create high density, focused sublibraries of fragments prior to the split-GFP assay. A range of ﬂuorescent clones are picked and grown in 96-well
liquid cultures for in vitro quantiﬁcation of the soluble and insoluble protein fractions. Clones are sequenced and the fragments are aligned onto the
full parent gene. Fragments can be directly tested for expression or subcloned without the S11 tag into a pET vector. Numbers to the left indicate the
approximate library size at the different steps.
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range of ﬂuorescence are picked from the agar plates and
grown in 96-well liquid culture plates (Figure 2). Within
each library, we picked a total of 384 clones in four 96-well
plates with ﬂuorescence intensity levels from bright to
faint (see Methods in Supplementary Data). As an alter-
native, IPCR (21) can ﬁrst be used to create high density,
focused sublibraries of fragments prior to the split-GFP
assay. In this case, 96 clones were picked per sublibrary of
fragments to ensure maximum coverage (Figure 1). For
in vitro quantiﬁcation, E. coli cells were ﬁrst induced with
anhydrotetracycline (AnTET) to overexpress the GFP
11-tagged proteins. Soluble lysates and insoluble fractions
were assayed by adding the GFP 1–10 detector fragment,
as previously described (22). In the ﬁnal step, DNA
sequencing was used to determine the boundaries of
each fragment by reference to the parent gene. In silico,
all fragment sequences within a library were aligned onto
the parent gene and color-coded by solubility levels.
We used the color scheme black/light green/bright
green, where the black side of the spectrum identiﬁes the
least soluble fragments and the bright-green color
identiﬁes the most soluble ones. This provides a visual
tool to correlate fragment boundaries with solubility
levels and makes it easy to identify the most compact
and soluble fragments for downstream functional and
structural characterization.
p85a as a benchmark for testing our domain
trapping strategy
The structural organization of the regulatory subunit p85a
of the class IA PI3K has been very well studied. Except for
the two coiled-coil regions CC1 and CC2, the documented
structures of the well-folded SH3 (31), BCR (32), N–SH2
(33) and C–SH2 (34) make p85a a good benchmark for
demonstrating the feasibility and efﬁciency of domain
trapping strategies.
Large quantities of PCR ampliﬁed target DNA (1–2mg)
were produced using either the Platinum Taq DNA
Polymerase High Fidelity (Invitrogen, Carlsbad, CA,
USA) or the Phusion High-Fidelity DNA polymerase
(NEB, Ipswich, MA, USA). Since DNA ligation efﬁciency
varies inversely with the size of the insert, and to avoid
biased ligation of small fragments, two individual libraries
of fragments were created: from 250 to 500 bp and from
350 to 750 bp. Indeed, the larger size fragment library
would let us ‘ﬁsh’ soluble fragments encompassing the
larger BCR domain (550 bp), whereas the smaller size
fragment library would favor the selection of smaller
soluble fragments from the SH3 domain (252 bp) and
the two SH2 domains (345 and 324 bp for N–SH2 and
C–SH2, respectively). DNase I reaction conditions were
optimized to narrow the window of highly concentrated
DNA fragments in the desired size range (see Methods in
Supplementary Data).
Figure 2. Screening clones using the split-GFP reassembly assay. Images showing cell colony ﬂuorescence from agar plates after sequential induction
(solubility reporter) and co-induction (expression reporter) of the GFP 11-tagged protein fragments and its complementary GFP 1–10 detector.
Clones displaying a wide range of ﬂuorescence are visible after sequential induction.
Nucleic Acids Research, 2011 5
 at S
C
D
 - U
niversite Toulouse III on S
eptem
ber 6, 2011
nar.oxfordjournals.org
D
ow
nloaded from
 

The two independent pools of blunted p85 fragments
were cloned into the iDHFR vector and transformed into
E. coli DH10B electro-competent cells (Invitrogen,
Carlsbad, CA, USA). Transformation of the recovered
plasmids into E. coli BL21 Tuner TM(DE3) competent
cells (Novagen, San Diego, CA, USA) containing the
lacY permease mutation allowed the uniform induction
of the cells by IPTG during the subsequent selection of
in-frame clones. To ensure that the selection process is
consistent with the theoretical 1 in 18 clones expected to
survive after the ORF-ﬁlter step, each library was diluted
and plated on medium in the presence and absence of
TMP for fast and accurate colony counting.
Initially, pools of ‘in-frame’ DNA fragments were
subcloned into the pTET-GFP 11 solubility vector using
NdeI and BamHI sites (Supplementary Data 1), and
transformed into BL21 (DE3) cells containing the pET
GFP 1–10 plasmid to screen for soluble expression (20).
After sequential induction of the GFP 11-tagged frag-
ments, we could take advantage of the split-GFP comple-
mentation assay to screen thousands of clones in vivo by
visual assessment of their intrinsic ﬂuorescence, which is
well correlated with the amount of soluble protein ex-
pressed (Figure 2). Both fragment libraries displayed sub-
stantial phenotypic variability as observed from the wide
distribution of ﬂuorescence intensities. Even though
sequencing information was missing for some of the 384
manually picked clones (79 for the small size and 16 for
the large size library), probably due to cross contamin-
ation with nearby faint or black clones, only a limited
number of the sequenced fragments were not in the au-
thentic reading frame (9 out of 305 for the small size and
2 out of 368 for the large size library), thus illustrating the
efﬁciency of selection process. Despite the fact that most
p85a domains are well represented, with the exception of
the BCR domain, we noticed a bias in the distribution of
fragments towards the second-half of the gene, from the
N–SH2 domain to the C-terminal end of the gene
(Supplementary Figure S1). In contrast, the distribution
of randomly picked fragments is more homogeneous, as
no information concerning ﬂuorescence intensity levels
was taken into consideration (data not shown).
Figure 3. Mapping of the IPCR p85a targeted fragments. IPCRs using oppositely directed primers were used to generate sublibraries of fragments.
For each sublibrary, an ensemble of 96 clones with a wide range of in vivo ﬂuorescence intensities were picked and grown in 96-well liquid culture
plates for in vitro split-GFP solubility screen. Only the correctly sequenced in-frame fragments are represented. Based on the in vitro solubility assays,
fragments were color-coded black, light green and bright green, where the black side of the spectrum identiﬁes the bottom 20% least soluble protein
fragments and the bright green side corresponds to the top 20% most soluble ones. IPCRs within p85a were used to generate four large-size
sublibraries (350–750 kb) centered onto the SH3, BCR, N–SH2 and C–SH2 domains. Within each library, solubility values from three or more
identical fragments were averaged in order to keep the color-coded representation as clear as possible. Boundaries of structure solved domains are
indicated in red and the junction at amino acid position 9 is indicated in blue.
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We reasoned that the bias may originate from our
multistep selection process that favors the selection of ex-
tremely well-behaved fragments to the detriment of less
soluble ones. To circumvent this representation artifact
and starting with the same original library of in-frame
fragments (following iDHFR selection), we used the
IPCR (21) technique to selectively enrich for DNA se-
quences in regions of p85. Phosphorylated primers were
designed (Supplementary Data 2) to generate three
small-size sublibraries (250–400 bp) centered on the SH3,
N–SH2 and C–SH2 domains and one large-size sublibrary
(400–750 bp) centered onto the BCR domain (Figure 3).
We noticed that cutting into the N-terminal region of the
SH3 and N–SH2 domains had a dramatic effect onto the
solubility levels of the selected fragments. Also, the in-
corporation of amino acid residues from the CC2
domain and linker region drastically improved the solu-
bility of the C–SH2 centered fragments, a somewhat
surprising and difﬁcult result to predict considering the
unstructured nature of these regions.
Fragments can occasionally be used as a starting point
to identify more compact and soluble constructs with a
clear objective of maximizing the chances of 3D structure
(35). As illustrated in Figure 3, IPCR sublibrary centered
on the BCR domain contains three soluble fragments
(110–294, 110–297 and 110–300) with C-terminal positions
slightly shorter than the structurally characterized frag-
ments 105–319 (PDB code: 1PBW). We note that the
low solubility of another BCR fragment (117–297) from
the full-length p85 library could be attributed to its
shorter N-terminal end (Supplementary Figure S1b). In
an effort to rationalize the effect of N- and C-terminal
truncations in the BCR region, we cloned an ensemble
of 144 constructs corresponding to a 10 amino acids
walk from positions 55 and 369 (Figure 4 and
Supplementary Data 2). Protein solubility levels were
assessed both in vivo and in vitro using the split-GFP
assay (20). Figure 4 illustrates the expression and solubil-
ity levels of all 144 constructs, respectively. As expected,
fragments are soluble when the BCR core domain is
Figure 4. PCR-directed truncations of the p85a BCR domain. (a) Schematic representation of all 144 constructs aligned onto the p85a amino-acid
sequence. N- and C-terminal positions are indicated. Fragments are organized in groups of 12 with identical N-terminal positions. (b) Expression
(left) and solubility (right) levels of E. coli BL21(DE3) cells expressing the corresponding fragments in fusion with S11 following complementation
with GFP 1–10. Orange dashed lines mark boundaries, where dramatic changes in expression and solubility levels were observed. (c) In addition to
105–319 for which the X-ray structure is known (PDB code: 1PBW), well-expressed and soluble fragments were selected for downstream NMR
studies. HSQC spectra of fragments 105–299 (blue), 105–309 (red), 105–319 (black with corresponding white rectangle in the solubility screen) and
115–299 (green) are represented.
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present. As truncations within the core proceed, protein
solubility levels fall. Approximate boundaries of soluble
fragments range between positions 115 and 125 in the
N-terminal region, and positions 289 and 299 in the
C-terminal region. A ﬁner screening using one amino
acid incremental truncation from the N-terminal
(116–123) and C-terminal (290–297) regions was then per-
formed (Supplementary Figure S2). Based on the ﬂuores-
cence intensity ratios of solubility over expression, the
fragments 116–294 is the shortest most soluble fragment
of the BCR domain. Interestingly, cutting into the
C-terminal end of helix a10, from positions 297 to 294,
did not seem to have an effect on the solubility of the last
three fragments within the group. The addition of a three
residue linker (Gly–Ser–Asp) to the C-terminus of the
protein as a result of molecular cloning site in the
pTET-GFP 11 (20) vector may compensate for residues
Ser–Thr–Glu of the real protein sequence, thus making
truncated variants more stable. A total of six most
compact soluble protein fragments, including the structur-
ally characterized fragments 105–319 (PDB code: 1PBW),
were selected and puriﬁed for 2D NMR experiments.
1H–15N HSQC spectra are well resolved and dispersed,
thus indicating that all protein fragments are well folded
(Figure 4c and Supplementary Figure S2). These spectra
overlay each other, thus suggesting that the extra tails at
both N- and C-terminal ends do not affect the domain
core structure.
Application to the polyketide synthase PpsC from
M. tuberculosis
Polyketides comprise natural compounds that are essen-
tial for the virulence of major human mycobacterial
pathogens, namely M. tuberculosis (36,37) and other
emerging infectious agents. Polyketide biosynthesis is ac-
complished by polyketide synthases (PKS), which are
giant and multifunctional enzymes. PpsC belongs to the
family of type I PKS with six domains present on a single
polypeptide chain.
Information on the 3D structure of full-length
type I PKS is not available and the current data col-
lected worldwide on fatty acid synthases (FAS) and the
6-deoxyerythronolide B synthase (DEBS) from
Saccharopolyspora erythraea, the most studied modular
PKS, only allow rough modeling of their molecular archi-
tectures, thus providing only a low-resolution picture.
High-resolution structural information is needed to
describe at the atomic level each individual domain in
order to understand the full-length PKS catalytic machin-
ery. Dedicated software for the analysis of PKS, MAPSI
Figure 5. Mapping of the IPCR PpsC targeted fragments. Five large-size sublibraries of fragments (850–1650 kb) centered onto the KS, AT, DH, ER
and ACP domains were generated. Picking and color coding of fragments follow the same rules as in Figure 3. Red dots indicate the fragments
selected for downstream biochemical and structural characterization.
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(http://gate.smallsoft.co.kr:8008/pks/mapsitools/index.pl)
and SEARCHPKS (http://www.nii.res.in/searchpks.html)
were used to identify approximate boundaries for each
individual domain. Only in the case of the DH domain,
the identiﬁcation of C-terminal boundaries differs sub-
stantially for the methods used in the two approaches
(1093 with SEARCHPKS and 1221 with MAPSI).
We used a hydrodynamic point-sink shearing method
(38) to create large-size (850–1650 kb) DNA libraries of
Ppsc fragments. Compared to enzymatic digestion with
DNase I, the resulting DNA fragment libraries were
tightly distributed in size (data not shown). For each
targeted domain, IPCR was used to generate focused
sublibraries of fragments, as shown in Figure 5. Initially,
phosphorylated forward and reverse IPCR primers were
designed to the center of the KS, AT, DH, ER and ACP
domains (Supplementary Data 1). Multiple priming sites
originating from the high GC content of the M. tubercu-
losis genome lead to PCR ampliﬁcation failures. To cir-
cumvent this problem, 32-mer primers were blasted
against the full-length gene to ensure priming at a
unique site. An ensemble of 10 fragments covering all
six PpsC domains was selected (Figure 6a) and subcloned
from a pTET-GFP 11 vector using NdeI and SpeI sites
(Supplementary Data 1) into a N6–HIS pET vector.
Selected fragments had to satisfy two main criteria:
(i) N- and C-terminal boundaries should incorporate the
predicted ones and (ii) fragments with different levels of
solubility should be considered if possible. SDS–PAGE of
the soluble and pellet fractions of E. coli BL21 (DE3) cells,
expressing the different fragments, were in good agree-
ment with the in vitro split-GFP solubility screen
(Figure 6b). Crystallization trials have been performed
on 6 out of 10 selected constructs centered on the AT,
DH and ER domains. Diffraction quality crystals have
been obtained for all three domains (Figure 6c).
Analysis of the 3D structure of the fragment 921–1222
centered onto the DH domain clearly indicates that the
typical double-hotdog fold extends from positions 933 to
1216 (A. Faille et al., manuscript in preparation).
DISCUSSION
Our approach to screening libraries of over a million
clones can be of general interest for identifying soluble
constructs of ‘recalcitrant’ proteins, as it does not
require the use of an automated robotic platform. It
simply relies on well-proven technologies capable of ef-
fectively eliminating the unwanted constructs, thus
reducing the population size of fragments to be
analysed. Although E. coli cells expressing self-associated
DHFR in the presence of TMP somewhat forces the se-
lection of inserted in-frame fragments, we noticed the
presence of short antisense peptides devoid of stop
codons and in-frame with both ends of DHFR.
Following the in vivo split-GFP ﬁltration step, the propor-
tion of false positives drops to <3% of the total number of
picked clones. The most plausible explanation is that they
Figure 6. Expression, solubility and crystallization trials of selected PpsC fragments. (a) Ten fragments covering the structural domains of PpsC were
subcloned from the pTET-GFP 11 plasmid into a N6–HIS pET vector for biochemical and biophysical characterization. (b) SDS–PAGE of soluble
(S) and pellet (P) fractions of E. coli BL21 (DE3) cells expressing the different fragments. (c) Pictures of X-ray quality crystals of selected fragments
represented as a black rectangle in (a) are shown. The 3D structures of the AT (545–877), DH (921–1222), and truncated ER (1558–1750) domains
have been recently determined at 1.8, 2.8, and 2.5 A˚ resolutions, respectively.
Nucleic Acids Research, 2011 9
 at S
C
D
 - U
niversite Toulouse III on S
eptem
ber 6, 2011
nar.oxfordjournals.org
D
ow
nloaded from
 

have been eliminated during gel puriﬁcation prior to
subcloning into the GFP S11 vector.
The IPCR step is crucial as it helps remove the bias
originating from the overrepresentation of regions of the
protein that never get ampliﬁed due to the lack of
homology to the IPCR primers. It also permits single
amino acid resolution boundary mapping as seen from
both p85a and PpsC sublibraries of fragments. For
example, in the case of the p85a SH3 domain, two
distinct populations of fragments at the junction between
amino acid positions 6 and 9 were visible (Figure 3).
Detailed examination of the solution structure of the
SH3 domain (31) revealed that Tyr6 is the last amino
acid residue of the N-terminal tail that connects to a
four-residues b-strand central to a triple-stranded antipar-
allel b-sheet. Cutting into this strand would not only have
a destabilizing effect on interactions within the b-sheet,
but also with a parallel b-sheet of two strands crossing
at right angle. In the case of PpsC, single amino acid trun-
cations also have a dramatic impact on the solubility of
the expressed fragments, a result which clearly demon-
strates the potential of our approach in an attempt to
identify potential candidates for downstream functional
and structural applications. To date, only the crystal struc-
ture of a fragment covering partially the ER domain has
been reported (PDB code 1PQW). Thanks to our
approach, we successfully crystallized fragments encom-
passing the AT, DH and ER domains and solved the
X-ray structure of the active AT and DH domains
(Alexandre Faille et al, manuscripts in preparation).
Our domain trapping strategy is also particularly well
adapted to situations, where unstructured regions are es-
sentials for the stability of isolated domains. As seen with
p85a and PpsC, it offers a rapid and easy way to identify
N- and C-terminal boundaries of soluble fragments often
difﬁcult to predict solely by theoretical means. In the near
future, we anticipate our approach will facilitate decipher
structure–function relationships in mechanistically diverse
and complex enzymatic machineries, thus opening the way
to atomic level description of active sites and domain–
domain interactions.
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Domain trapping has proven to be a robust and efficient method for 
identifying soluble fragments from multi-domain proteins. This methodology has 
been successfully applied to PpsC and has resulted in the production of libraries of 
fragments centered on each catalytic domain of this enzyme (J.D. Pedelacq et al., 
Figure 5). 
The most soluble and well-expressed fragments can be efficiently produced in 
a classical expression system involving the fast-growing bacterium E. coli and easy-
to-use pET vectors for downstream applications. As highlighted in this publication, 
crystallization trials have yielded at least one diffraction-quality crystals for 
fragments representing the AT, DH and ER domains of PpsC. Subsequent structural 
analysis of these fragments have then demonstrated that domain trapping is able to 
correctly identify fragments encompassing one functional domain (or sub-domain, in 
the case of the ER domain), without prior knowledge of domain boundaries. 
A summary of all the results obtained from the fragments studied during my 
PhD, including those concerning the AT, DH and ER domains, are presented in the 
next chapter. 
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3. PPSC: A FRAGMENT STUDY 
 
a) Overview of the PpsC Fragment Study 
 
Classical pET vectors, bearing a six histidine tag either in N- or C-terminus, 
have been used to facilitate purification and the resulting constructions were 
produced by Escherichia coli BL21 (DE3). The most soluble ones were selected for 
downstream applications. In most cases, relatively small culture volumes (250 ml to 2 
l) were sufficient to efficiently produce these fragments. Purification consisted in a 
batch affinity step using a cobalt-bound resin followed by dialysis. In some cases, an 
additional size exclusion chromatography on an automated AKTA system was 
needed. A total of 19 different fragments, representing all PpsC domains, have been 
brought to crystallization trials using this methodology (Table 6 and Figure 24). 
Experimental procedures are detailed in section II.A.3.B. 
Diffraction-quality crystals have been obtained for fragments representing the 
AT domain, the DH domain and the nucleotide-binding subdomain of the ER 
domain. However, despite extensive crystallization trials on six different fragments 
representing the full-length ER domain, only low-resolution diffracting crystals could 
be obtained. This is in accordance with the absence of any structure of this domain 
from a PKS when it is expressed alone. The only structure containing the full-length 
ER domain is indeed that of the ER-KR didomain from DEBS module 4 [71]. KR and 
ACP domains also seem to be concerned by this issue, although only four fragments 
have been brought to crystallization in our study. Fragments representing the KS 
domain could only be produced at low temperatures (<20 °C), in small amounts and 
crystallization trials never yielded hits. Likewise, no KS domain expressed alone has 
ever been structurally characterized and all structures available concern KS-AT 
didomains from FASs or PKSs. We were then interested in di- and tri-domain 
fragments to establish the structure of these domains. So far, the most promising 
results have been obtained for fragments encompassing the DH, ER and KR domains. 
Thin protein needles that need to grow bigger and are, so far, not suitable for 
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diffraction data collection, have been recently obtained (fragment 6, see Figure 24). 
To conclude with this study, we have been able to characterize the structures of the 
AT domain, of the DH domain and of the nucleotide-binding subdomain of the ER 
domain. The structure of the AT domain will be part of an article that will also include 
other PKS AT domains, which were structurally characterized in our research group. 
Therefore, it will not be discussed in this manuscript. The following chapter reports 
the functional and structural results obtained for the DH and ER domains. 
 
 
b) Experimental Procedures 
 
CLONING 
All fragments were amplified by PCR using the Phusion High-Fidelity DNA 
polymerase (New England Biolabs), and a ppsC containing vector as matrix. Primers 
consisted in 22-mer complementary sequences bearing 5’-NdeI and 3’-BamHI 
restriction sites. Resulting amplicons were then digested and ligated into a modified 
pET28 plasmid bearing a STOP codon and a six-histidine tag at either side of the 
cloning site. Plasmids were transformed into chemically competent E. coli BL21 
(DE3) cells. 
 
PRODUCTION 
Frozen cells expressing the different fragments were used to start an overnight 
3 ml LB-kanamycin (112 μg/ml) culture at 37 °C prior to inoculation in baffled flasks 
containing 500 ml to 2 l of the same media. Cells were allowed to grow for 
approximately 2 h at 37 °C before temperature was dropped from 37 °C to 30 °C (or 
20 °C in the case of KS-encompassing fragments). When OD600 reached 0.5–0.7, cells 
were induced with IPTG at a final concentration of 1 mM and grown for an additional 
4 h (or 20 h in the case of KS-encompassing fragments) prior to harvesting by 
centrifugation at 4000g for 30 min and storage at −80 °C.  
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PURIFICATION 
Step 1. The pelleted cells, grown in 1 l of LB broth, were suspended in 40 ml of 
buffer A (100 mM Tris, 150 mM NaCl pH 8.0) and lysed by sonication (6 cycles of 30 
s pulse, 50% amplitude, power 5) prior to centrifugation at 40,000g for 30 min. The 
supernatant was poured on 3 ml of dried cobalt Talon Superflow resin (Clontech) 
previously washed with buffer A, and centrifuged at 300g for 5 min. The fragment-
bound resin was then washed 3 times with buffer A by centrifugation. 30 ml of buffer 
A containing 10 mM imidazole was used to elute non-specific interactants, and after 
centrifugation, 5 ml of buffer A containing 250 mM imidazole was used to elute the 
fragment of interest.  
Step 2. The eluted protein was concentrated down to 2 ml using a Vivaspin 20 
centrifugal concentrator (Sartorius), prior to injection into a HiLoad 16/60 Superdex 
75 ((or Superdex 200 for fragments 6 and 7,), (GE Healthcare)) pre-equilibrated with 
buffer B (25 mM Tris, 25 mM NaCl pH 8.0). 
 
CRYSTALLIZATION TRIALS 
Crystallization trials were conducted with concentrated proteins using 
QIAGEN NeXtal commercial kits assisted by a Nanodrop ExtY crystallization robot. 
400 nl drops consisting in 200 nl protein and 200 nl crystallization condition were 
set in Innovadyne Innovaplate SD-2 plates. Crystallization conditions that yielded 
crystals were refined in Linbro 24-well plates with 2 μl drops consisting in 1 μl 
protein and 1 μl crystallization condition. 
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4. THE DEHYDRATASE DOMAIN AND 
THE ASSEMBLY OF THE BETA-CARBON 
PROCESSING DOMAINS 
 
To date, the DH domain substrate specificity and catalytic mechanism have 
been poorly characterized. Indeed, only suicide inhibitors that are not representative 
of a physiological substrate have been structurally identified with stand-alone 
dehydratases from type-II fatty acid synthases (FAS-II). Until now, determinants of 
substrate specificity were unknown with no experimental evidence demonstrating the 
activity of a given substrate, although a few conserved residues have been proposed to 
assist this transient catalytic mechanism. In addition to the X-ray structure of the 
native DH domain of PpsC, we have solved, for the first time, the structure of an 
inactive mutant version (DH-H959F) in complex with the substrate analog crotonyl-
CoA (C4:1-CoA), demonstrated as suitable for (de)hydration by in vitro enzymatic 
tests. We also report the structure of the nucleotide-biding sub-domain of the ER 
domain of PpsC. This structure has helped us model the assembly of the DH and ER 
domains of PpsC using the mammalian FAS (mFAS) as a template. Finally, the 
crotonyl-CoA bears a full-length phosphopantetheinyl moiety whose β-phosphate is 
normally covalently attached to the serine acceptor of the ACP domain. We have imposed a 
of 3 Å constraint between the two atoms to generate a docking model of the ACP 
domain of PpsC onto the DH domain. 
All these results are presented in the following article that we are currently 
writing, which is then a temporary version: 
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Abstract 
 
Dehydration reactions play a crucial role for de novo biosynthesis of fatty acids and a 
wide range of pharmacologically active polyketide natural products with strong emphasis 
in human medicine. Until now, the dehydration mechanism remained poorly documented 
due to the lack of structural studies implying metabolizable substrates. Here, we describe 
the first crystal structure of a dehydratase domain, from the Mycobacterium tuberculosis 
type I polyketide synthase PpsC, in complex with the substrate analog trans-2-butenoyl-
CoA for which activity was confirmed in vitro. Residues essential for binding and 
activity have been identified and a dehydration mechanism has been confirmed. We have 
also determined the X-ray structure of the dimeric nucleotide-binding subdomain of the 
enoylreductase domain that we used to propose an assembly model for the dehydratase, 
enoylreductase and acyl carrier protein domains of PpsC, similar to mammalian fatty acid 
synthase.  
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Polyketides represent the most important class of naturally synthesized 
metabolites in human health with proven antibacterial, anticholesterolemic, 
immunosuppressant, antifungal, anti-cancer, antiparasitic, and insecticide activities1. 
They are biosynthesized by complex machineries, named polyketide synthases (PKS), 
that human pathogens such as M. tuberculosis use in combination with fatty acid 
synthases (FAS) to produce lipid virulence factors. Indeed, these polyketide-derived 
lipids form a permeability barrier within the mycobacterial cell envelope, which 
constitutes the first line of defense against toxic molecules from the host and confers 
intrinsic resistance against treatments2,3. Among these virulence factors, phthiocerol 
dimycocerosates (PDIM) participate directly into the early steps of microbial infection 
through a mechanism of host plasma membrane rearrangement that encourages 
phagocytosis and inhibits phagosome acidification4. More recently, Cambier and 
colleagues have highlighted a central role for PDIM in masking pathogen-associated 
molecular patterns, thus preventing the production of microbicidal reactive nitrogen 
species through the Toll-like receptor recruitment of macrophages5. 
The M. tuberculosis genes involved in the biosynthesis of PDIM and closely 
related phenolic glycolipids (PGL) are clustered in a 73-kb region of the chromosome6. 
Biosynthesis of these components implies the concerted action of an ensemble of six type 
I PKS: five mono-modular phenol phtiocerol synthases (PpsA to E) responsible for the 
elongation of long-chain fatty acid backbones that form the phtiocerol (or 
phenolphtiocerol in the case of PGL biosynthesis) moiety and the mycocerosic acid 
synthase (Mas) for the production of multi-methyl branched mycocerosates7. PDIM result 
from the esterification of two mycocerosic acids onto the hydroxyl groups of the 
phthiocerol, a reaction mediated by the acyltransferase PapA57. 
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Both type I PKS and FAS belong to the superfamily of megasynthases 
characterized by the presence of multiple catalytic domains onto the same polypeptide 
chain. Three domains are essential for their activity: an acyl transferase (AT) domain, 
often referred to as the “gatekeeper”, which catalyzes the transfer of a starter/elongation 
unit to its cognate acyl carrier protein (ACP) domain, and a ketosynthase (KS) domain for 
the condensation of the growing chain with the elongation unit to give an ACP bound ȕ-
keto ester. Optional modification reactions, also referred to as ȕ-carbon processing, 
involve the enzymatic ketoreductase (KR), dehydratase (DH), and enoylreductase (ER) 
domains. First, the ȕ-keto ester undergoes a reduction by the KR domain to yield a 
hydroxyl subsequently dehydrated by the DH domain, thus resulting in carbon-carbon 
double bond formation. The growing chain can also be reduced by the ER domain to 
yield a saturated carbon chain longer than the original one by two methylene units. 
Overall, the catalytic mechanism underlying ȕ-carbon modifications remains poorly 
described as no structure of individual DH, ER and KR domains in complex with their 
physiological substrates is yet available. Only suicide inhibitors in complex with stand-
alone FabA8 and FabZ9 dehydratases from Pseudomonas aeruginosa have been published 
so far. In this paper, we report for the first time the three-dimensional structure of a DH 
domain from the type I mono-modular PKS PpsC in complex with a substrate analog for 
which activity was confirmed in vitro. We also solved the X-ray structure of the PpsC ER 
domain that we used to propose a DH-ER-ACP assembly model in accordance with the 
mammalian FAS structure10. 
Two libraries of fragments centered onto the DH and ER domains of M. 
tuberculosis PpsC were created to select for well-expressed and soluble constructs, using 
the domain trapping method11 (Figure 1a). DH fragments A (884-1231) and B (921-
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1222) could be easily purified and crystallized (Figure 1b). Small crystals of fragment A 
never diffracted beyond 8-10 Å despite the implementation of extensive optimization 
screens. On the other hand, tetragonal bipyramidal crystals of fragment B could grow 
overnight and diffracted to a maximum resolution of 2.7 Å (Supplementary Table 1). 
The ER domain was initially represented by soluble fragments C (1465-1786), D (1470-
1784), E (1477-1784), and F (1477-1781), with N- and C-termini close to the predicted 
boundaries for this domain (Figure 1b). Extensive crystallization attempts failed to 
produce good quality crystals for these fragments, although nice bipyramids could be 
obtained for fragment C. The search for the shorter fragment G (1558-1758) was driven 
by the fact that only the nucleotide-binding subdomain of the ER domain interact with 
DH in the mFAS X-ray structure12. Diffraction quality crystals of fragment G were 
obtained and X-ray data were collected to a maximum resolution of 1.5 Å 
(Supplementary Table 1). 
The DH domain belongs to the hotdog-fold enzyme superfamily whose first 
identified member was the Escherichia coli type II dehydratase FabA9. Unlike FabA, 
which functions as a homodimer with hotdog folds from each monomer associating to 
create an extended ȕ-sheet, the PpsC dehydratase double hotdog occurs in a single 
polypeptide chain. Landmarks include a 13-stranded ȕ-sheet (topology ȕ7-ȕ8-ȕ9-ȕ11-
ȕ12-ȕ13-ȕ10-ȕ3-ȕ6-ȕ5-ȕ4-ȕ2-ȕ1), hotdog helices ĮHD1 and ĮHD2, a cap motif 
comprising helices Ș1, Ș2, and Ș3, a three-stranded ȕ-sheet (ȕ2a, ȕ2b, and ȕ7a), and helix 
ĮC1 (Figures 2a & Supplementary Figure 1a). Residues in loop regions (1049-1063 
and 1144-1158) that connect the two hotdog motifs are missing from the refined X-ray 
structure. The search for structural homologues in the Protein Data Bank 
(http://www.rcsb.org) highlighted some strong similarities with dehydratase domains 
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from the curacin A biosynthetic pathway, CurF being the closest structural homologue13, 
and from mFAS12, with 2.1-2.5 Å root mean square deviation between superimposed CĮ 
atoms. The structural alignment also revealed that ~85% of the DH CĮ atoms could be 
superimposed onto the CurF homologue and ~70% in the case of the mFAS X-ray 
structure, with most structural differences occurring in the cap motif (Supplementary 
Figures 1a,b). 
In an attempt to elucidate the dehydration mechanism of the DH domain, we 
conducted a series of experiments using trans-2-butenoyl-CoA (C4:1-CoA) and trans-2-
octenoyl-CoA (C8:1-CoA), two molecules resembling the natural substrate with an intact 
4’-phosphopantetheine (P-pant) moiety (Figure 2b). We chose to monitor the hydration 
of these substrate analogues since isolated dehydratases preferentially catalyze hydration 
rather than dehydration in vitro14. Disappearance of the C=C double bond at 263 nm 
showed a specific activity of 0.5 μmol.min-1.mg-1 in the presence of either substrate 
(Figure 2c), thus indicating that the reaction rate is not limited by the length of the 
aliphatic carbon chain covalently attached to the P-pant moiety. Neither co-crystallization 
nor soaking of wild-type DH crystals with C4:1-CoA could give rise to the structure of a 
stable complex. Instead, we focused our efforts on engineering an inactive mutant that 
could sequester the substrate within the active site cavity. We relied onto two 
independent studies that had shown that mutating the catalytic His residue into a 
phenylalanine was sufficient to abolish the activity of the DH domains of DEBS15 and the 
picromycin/methymycin synthase16. Using this strategy, crystals of the PpsC DH domain 
bearing the analogous mutation H959F were soaked with C4:1-CoA. The presence of C4:1-
CoA in the active site cavity was confirmed after examination of the 2Fo-Fc and Fo-Fc 
difference Fourier maps (Figure 2a). Hydrogen bond interactions occur between the P-
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pant group and residues G969, R1000, M1002, and P1163 (Figure 2a). The highly 
conserved G969 interacts with the substrate ketone via its main-chain nitrogen and guides 
the substrate towards the active site tunnel (Figures 2a,d). Interestingly, this ketone 
superimposed well with the bound phosphate found in the DH apo structure (Figure 2d). 
The cavity entrance at the junction between the two hotdogs is delineated by two 
stretches of residues located between strands ȕ3 and ȕ4 (positions 999 to 1002) and 
within strand ȕ10 (positions 1162 to 1164) (Figure 2d, top). In the apo structure, V966 
and Q1084 make hydrogen bonds with the catalytic H959 that maintain its side chain in a 
position suitable for hydration of the carbon-carbon double bond (Figure 3a). The strictly 
conserved Y1076 is part of a polar interaction network that probably increase the pKa
value of the carboxylic acid group of D1129, thus allowing it to catalyze dehydration at a 
physiological pH. In the holo form, the D1129 side-chain would facilitate the proton 
transfer to the 3’-hydroxyl of the substrate, while the histidine side-chain nitrogen İ2 
could abstract a proton from C2 of the substrate, thus forming a carbon-carbon double 
bond between C2 and C3 (Figure 3b). This dehydration reaction also generates a water 
molecule that makes interactions with G969 and the side chain of D1129 (Figure 3c). 
This water molecule had previously been hypothesized as the dehydration side product 
for the DEBS module 4 homologue17. 
To date, FAS remains the only megasynthase for which X-ray structures of the 
full-length enzyme have been described10,18,19. mFAS is the closest homologue to type I 
PKS, in terms of module organization10 and sequence and structural similarities. However 
differences in protomer-protomer association exist between isolated DH domains from 
PpsC, CurF13, DEBS module 417 type I PKS and mFAS10. This change is orchestrated by 
the intertwined “crab claw”-like structure at the dimer interface, that slightly opens up in 
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mFAS to adopt a V-shaped structure (Figures 4a,b). Dimerization of the PpsC DH 
domain occurs both in the crystal structure and in solution, for which a molecular weight 
of 75.3 ± 1.2 kDa has been measured by size exclusion chromatography multi-angle laser 
light scattering (SEC-MALLS) experiments (Supplementary Figure 2). Although we 
could not confirm a mFAS-like V-shaped structure of our DH dimer in solution and in the 
crystal structure, evidences that the ȕ-carbon processing DH and ER domains could 
interact similarly as in mFAS (Supplementary Figure 3a) was reinforced by the 
observed variability in the DH dimerization mode in addition to the dimer interface of the 
PpsC ER X-ray structure that may play a key role in stabilizing the complex. Indeed, the 
linear dimerization mediated by an extended 12-stranded ȕ-sheet in the PpsC ER 
structure is also shared by mFAS, whereas the presence of an extra Į-helical segment in 
the multimodular spinosyn PKS structure prevents dimerization (Figure 4c)20. We then 
generated a model of PpsC DH-ER interactions using mFAS as a template, wherea PpsC 
DH protomer was first superimposed onto each of the two protomers constituting the 
mFAS DH dimer, prior to the positioning of the ER dimer (Supplementary Figure 3b). 
We felt confident that the resulting model could provide a fair picture of the PpsC DH-
ER assembly. Indeed, steric clashes were only found between the side-chain of residue 
K810 from the ER domain and G263 from the loop that connects ȕ11 to ȕ12 in the DH 
domain (Supplementary Figure 3c). This loop region may play a major role in 
stabilizing the DH-ER interface as it protrudes from the 12-stranded ȕ-sheet into a cleft 
with potential interactions with main-chain and side-chain atoms of residues from each 
protomer of the ER domain. In an attempt to address how the ACP domain could fit into 
our model of the DH-ER assembly, we first generated a DH-ACP complex by imposing a 
distance constraint of 3 Å between the ȕ-phosphate of the CoA derivative in the active 
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site cavity of the DH domain and the serine acceptor of the ACP domain. Although the 
three-dimensional structure of the PpsC ACP domain is still unknown, a structural 
alignment with homologues from FAS and other type I PKS indicates the conservation of 
a four-helix bundle motif covering the entire domain. We first generated a PpsC ACP 
model based on the module 2 of DEBS, with respect to the criteria of highest sequence 
identity (~37 %) and conservation of key residues in the active site. Modeling of the PpsC 
DH-ACP interface led to only one solution permitting favorable interactions of the ACP 
domain with the ER and DH domains (Supplementary Figures 3c,d). Recently, the X-
ray structure of a crosslinked complex between the dehydratase FabA and the acyl carrier 
protein AcpP involved in the fatty acid biosynthesis pathway of E. coli has been 
determined21. Although the covalently bound probe used for crosslinking follows the 
same route in FabA as in PpsC DH, the orientation of the ACP domain differs 
substantially. Examination of the FabA-AcpP interface highlighted significant differences 
with the mFAS structure and our DH-ACP complex model that would lead to severe 
steric clashes with the ER domain. As suggested by the authors, the interactions observed 
in the FabA-AcpP complex are not relevant to megasynthases for which an atomic level 
description of the interface still remains to be elucidated21. 
In conclusion, we have determined the first structure of a ȕ-carbon processing 
domain from a type I PKS, i.e. the dehydratase domain from PpsC, in complex with the 
non-covalently bound substrate analog trans-2-butenoyl-CoA (C4:1-CoA) whose activity 
has been clearly demonstrated in vitro. To stabilize the complex, the universally 
conserved catalytic histidine residue was mutated into a phenylalanine, an approach that 
can easily be transposed to any dehydratase whether it is part of a megasynthase or a 
stand-alone enzyme. A detailed structural comparison of the PpsC DH domain in its apo 
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form and in complex with trans-2-butenoyl-CoA allowed us to unambiguously identify 
residues implicated in the dehydration mechanism. This should enable the engineering of 
modified DH domains of PKS and FAS to process non-natural substrateswith improved 
or novel pharmacological properties. 
 
 
Methods 
 
PpsC fragment library, ORF selection, and cloning. The open reading frame for the M. 
tuberculosis ppsC gene was amplified by PCR using forward 5’-
GATATACATATGACCGCAGCGACACCAGATCG-3’ and reverse 5’-
AATTCACTAGTTGACTCGCCTCGCGTCGCAGC-3’ primers. The underlined bases 
represent the NdeI and SpeI restriction sites, respectively. A large size DNA library (850-
1650 bp) was created from cleaned PCR product using a HydroShear device from 
Genomics Solutions (Ann Arbor, MI). Extremities of the fragments were polished using 
Vent polymerase (New England Biolabs, Beverly, MA) at 72°C for 20 min. A slab of the 
gel containing the DNA fragments region 850-1650 bp was excised and recovered with a 
QIAquick gel extraction kit (Qiagen). Library screening for open reading frames (ORFs) 
into a permissive site of the E. coli dihydrofolate reductase (DHFR) was conducted as 
previously described11. Recovered DHFR insertion library was diluted for plasmid 
preparation. Gel extracted and cleaned inserts from NdeI/SpeI restriction digests were 
ligated into the pTET ColE1 GFP11 vector and transformed into chemically competent 
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BL21 (DE3), pET GFP 1–10 cells. In vivo solubility screenings were performed as 
previously described 22. 
 
Enzymatic assays. Hydratase activity was monitored at 263 nm using a thermostated 
Uvikon 923 spectrophotometer (Kontron Instruments) in the presence of trans-2-enoyl-
CoA (¨A of 0.67 for a variation of concentration of 100 μM). Kinetic assays were 
performed in a quartz cuvette for 1.5 min at 25°C, in 100 mM sodium phosphate buffer 
pH 7.0 in the presence of trans-2-octenoyl-CoA (C8:1-CoA, 25 μM) or trans-2-butenoyl-
CoA (C4:1-CoA, 10 or 25 μM). After equilibration of the baseline, reactions were started 
by adding purified DH domain (fragment A) at 125 nM or 250 nM. C8:1-CoA was 
synthesized as previously described (Quémard et al., 1995) and C4:1-CoA was purchased 
from Sigma-Aldrich. 
 
Additional Methods. For details on protein production and purification, crystallization 
and structure determination, modeling of the assembly of the DH-ER-ACP domains, 
SEC-MALLS experiments, please see Supporting Information. 
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Figure Legends 
Figure 1. The domain trapping strategy. (a) Our strategy integrates a DHFR filter to 
eliminate the incorrect reading frames and a split-GFP solubility screen to identify the 
soluble constructs. A 850-1500 bp library of fragments was inserted at position 86/87 of 
the DHFR. Inverse PCR focused sub-libraries of fragments helped identifying soluble 
fragments centered onto a specific region of the protein of interest. (b) The top 25% most 
soluble clones centered onto the DH and ER domains of the M. tuberculosis polyketide 
synthase PpsC are represented. Fragments that permitted the X-ray structure 
determination of the DH and ER domains are colored in gray. 
 
Figure 2. Structure and activity of the DH domain of the M. tuberculosis PpsC. (a) 
Ribbon representation of the X-ray structure of the DH domain in complex with trans-2-
butenoyl-CoA. The active site H959 has been mutated into a Phe. The presence of C4:1-
CoA in the active site cavity was confirmed after examination of the difference Fourier 
2Fo-Fc (blue) and Fo-Fc (green) maps contoured at 1ı and 3ı levels, respectively. (b) 
Enzymatic assays were performed using trans-2-butenoyl-CoA (C4:1-CoA) and trans-2-
octenoyl-CoA (C8:1-CoA), two molecules resembling the natural substrate. (c) 
Disappearance of the C=C double bond at 263 nm indicates a specific activity of 0.5 
μmol.min-1.mg-1 in the presence of either C4:1-CoA or C8:1-CoA. (d) Top, the cavity 
entrance is delineated by two stretches of residues located between strands ȕ3 and ȕ4 
(positions 999 to 1002) and within strand ȕ10 (positions 1162 to 1164) with small 
differences in the shape and size between the apo (left) and holo (right) X-ray structures. 
A phosphate molecule is present in the active site of the apo enzyme whereas a water 
molecule (black ball) is at hydrogen bond distance to the thioester group of C4:1-CoA. 
Bottom, orthogonal view around the vertical axis. 
 
Figure 3. Catalytic mechanism of the dehydration reaction. Ball and stick 
representation of residues involved in the dehydration reaction as seen in the structure of 
(a) wild-type apo DH and (b) the DH-H959F mutant in complex with trans-2-butenoyl-
CoA. (c) Proposed dehydration reaction mechanism. 
 
Figure 4. The PpsC DH and ER dimers. (a) Ribbon diagram representation of the DH 
dimer present in the PpsC crystal structure and (b) its comparison with known 
homologues from DEBS module 4 (PDB code 3EL6), CurF (PDB code 3KG6) and 
mFAS (PDB code 2VZ8). Reference molecule in black is in the same orientation. 
Interacting residues at the interface are represented as spheres. (c) X-ray structure of the 
nucleotide-binding subdomain of the ER domains from PpsC (left), mFAS (middle) and 
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
module 2 of the Spinosyn PKS (PDB code 3SLK, right). The extra Į-helical segment in 
the spinosyn PKS structure is represented in red. 
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In this study, we have deciphered the catalytic mechanism of the DH domain 
of PpsC and we have identified key residues for the substrate specificity of 
dehydratases. Using two different substrate analogues, we have demonstrated that 
the chain length is not a determinant in terms of substrate specificity. The approach 
we used to obtain a complex between the DH domain and its substrate analogue can 
easily be transposed to any dehydratase, both stand-alone enzymes and domain from 
a megasynthase. We have also established that the DH dimer is flexible and could 
adopt a “V-shaped” conformation similar to the one seen in the mFAS X-ray 
structure. Indeed, considering that the ER dimer superimposes well with its 
counterpart in mFAS where it plays a major role in stabilizing the bent DH dimer, we 
have modeled the assembly of the DH and ER domains based on the mFAS structure. 
This modeling led to the identification of undocumented flexible loops from the DH 
domain which lies into a cavity in the ER domain and could help form a stable 
complex between these two domains. Finally, the presence of the bound C4:1-CoA in 
the active site cavity of the DH domain has greatly facilitated the docking of the ACP 
domain onto the DH domain. Taken together these results should open the route to a 
more detailed and comprehensive study of the dehydration mechanism, and of the 
assembly of the β-carbon processing domains in type-I mono-modular PKSs. 
We have recently crystallized the DH domain in a different crystalline form 
which, based on preliminary diffraction tests, will allow us to improve resolution. 
Soaking these crystals into a crotonyl-CoA solution will certainly bring a clearer view 
of the interactions than what we are able to observe with the complex structure 
refined at 3.2 Å resolution we had so far. 
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B. PROJECT II: STUDY OF 
AN ESSENTIAL PPTASE 
FROM MYCOBACTERIUM 
TUBERCULOSIS 
 
 
1. PROJECT 
 
PptT has been clearly identified as a new target for the development of 
antituberculosis drugs by our collaborators at the IPBS [103], [104]. PptT is essential 
for the replication and survival of Mtb during acute and especially chronic phases of 
infection in mice, a very encouraging feature for the search for new drugs. Indeed, 
anti-TB drugs usually have only poor bactericidal activity during the chronic phase of 
infection [184], which extend the treatment course and thus indirectly promote 
antibiotic resistance. Moreover, a conserved PptT-encoding gene has been identified 
in all sequenced mycobacterial species, including clinical isolates. Also, PptT may be 
druggable, since submicromolar inhibitors have already been found for its closest 
homologue, the B. subtilis Sfp [185]. Besides, the low amino acid identity (12%) with 
the human AcpS (hAcpS) will certainly allow the design of specific inhibitors for 
PptT, and the availability of the hAcpS structure should enable careful selection of hit 
compounds. 
With this in mind, our collaborators have developed a miniaturized assay 
suitable for the search of inhibitors of PptT by high-throughput screening [104]. In 
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order to help the rational drug design, we have decided to determine the 
tridimensional structure of PptT using X-ray crystallography, in parallel to its 
functional characterization. We hope the structure will help understand the binding 
mechanism of inhibitors and will contribute in a near future to the design of new 
anti-TB drugs. Finally, PptT also represents an invaluable biotechnological tool for 
the activation of mycobacterial PKSs and may help their structural and functional 
study as well. 
When PptT is produced in E. coli using classical pET vectors, only very small 
amounts can be purified and the protein precipitates irreversibly overtime. To 
overcome this problem, our collaborators, on the basis of published results [153], 
have managed to produce and purify PptT N-terminally fused to the maltose binding 
protein (MBP). However, this construction may not be adapted to a structural study 
since flexibility between the two proteins would probably hinder crystallization. 
Furthermore, removing the MBP tag induces precipitation of PptT. In an effort to 
produce PptT expressed alone, we have first explored for a better production strategy 
that led us to develop a new method for the diagnosis of co-factor dependent protein 
expression. Using this strategy, sufficient amounts of stable PptT could be obtained. 
PptT has then been subjected to crystallization trials and characterized using 
biophysical methods. Finally, its 4’-phosphopantetheinyl transferase activity has been 
tested with PpsC ACP domain as its carrier protein substrate. 
 
2. DESIGN OF A SPECIFIC PROTOCOL 
TO RECOVER PPTT 
 
Based on length, activity, and sequence motifs, PptT was thought to belong to 
the group II PPTase class of enzymes, along with hAcpS and the well characterized 
Sfp from B. subtilis. According to the biochemical and structural data accumulated 
for Sfp [88], [97] and hAcpS [89], [92], this group of PPTase would use Mg2+ and CoA 
as cofactors to realize its catalytic activity. 
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Before considering producing PptT in other organisms than E. coli, we have 
sought to determine whether PptT was produced in a soluble form in-vivo using the 
split-GFP technology. We have also generated N- and C-terminally truncated versions 
of the open reading frame in an effort to obtain a soluble and stable fragment of the 
enzyme. Interestingly, the most soluble construction in E. coli was the full-length 
enzyme, although once purified, aggregation occurred overtime in vitro. Our 
knowledge on the catalytic mechanism of group II PPTases have then led us to 
introduce the naturally-occurring co-factors, since they might be required to stabilize 
PptT, even though this feature has never been encountered in any functional 
homologue so far [88], [89]. 
Introducing MgCl2 and CoA all along the purification process, as well as using 
a weaker promoter, have indeed been sufficient to recover large amounts of PptT in a 
soluble and non-aggregated form. The impact of co-factors on PptT stability has 
further been estimated using differential scanning fluorimetry (DSF). We have also 
performed enzymatic tests to verify the in vitro PptT activity and determine its metal-
ion specificity, some homologues being able to catalyze the transfer reaction with 
other divalent cations than Mg2+, like Ca2+ [90], or Mn2+ [91]. To do so, we have 
monitored the transfer of P-pant onto a fragment containing PpsC ACP domain 
isolated by domain trapping, by both PptT and Sfp. 
All these results, along with the methodology developed to diagnosis protein 
requirement for co-factors, are presented in the following paper: 
A. Faille*, K. Rottier*, T. Prudhomme, C. Leblanc, C. Chalut, S. Cabantous, C. 
Guilhot, L. Mourey, and J.-D. Pedelacq, “Detection of soluble co-factor dependent 
protein expression in vivo: application to the 4¶-phosphopantetheinyl transferase 
PptT from Mycobacterium tuberculosis.” Journal of Structural Biology, , vol. 183, 
no. 3, pp 320-8, Sept. 2013. 
*These authors contributed equally to this work. 
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a b s t r a c t
The need for early-on diagnostic tools to assess the folding and solubility of expressed protein constructs
in vivo is of great interest when dealing with recalcitrant proteins. In this paper, we took advantage of the
picomolar sensitivity of thebipartiteGFP1–10/GFP11 system to investigate the solubility of theMycobacterium
tuberculosis 40-phosphopantetheinyl transferase PptT, an enzyme essential for the viability of the tubercle
bacillus. In vivo and in vitro complementation assays clearly showed the improved solubility of the full-length
PptT compared to its N- and C-terminally truncated counterparts. However, initial attempts to purify the full-
length enzyme overexpressed in Escherichia coli cells were hampered by aggregation issues overtime that
caused the protein to precipitate within hours. The fact that the naturally occurring Coenzyme A and Mg2+,
essentials for PptT to carry out its function, could play a role in stabilizing the enzyme was conﬁrmed using
DSF experiments. In vitro activity assays were performed using the ACP substrate from the type I polyketide
synthase PpsC from M. tuberculosis, a 2188 amino-acid enzyme that plays a major role in the virulence and
pathogenicity of this microbial pathogen. We selected the most soluble and compact ACP fragment (2042–
2188), identiﬁed by genetic selection of in-frame fragments from random library experiments, to monitor
the transfer of the P-pant moiety from Coenzyme A onto a conserved serine residue of this ACP domain.
 2013 Elsevier Inc. All rights reserved.
1. Introduction
Ways to reduce the toxicity and improve the solubility of re-
combinant proteins in heterologous hosts have been the subject
of proliﬁc research over the past two decades. Major progresses
have been made with the advent of structural genomics initiatives
and the development of tools to circumvent this major obstacle.
Available strains and expression vectors with different promoters
now make possible parallel approaches to increase the chance of
isolating protein targets in a form suitable for functional and struc-
tural studies. Oftentimes, recombinant proteins partition into
‘‘inclusion bodies’’ as a result of misfolding, aggregation, and intra-
cellular accumulation. With the advent of DNA polymerase-based
error-prone PCR protocols (Cadwell and Joyce, 1994) as well as
Escherichia coli mutator strains (Greener et al., 1997), introducing
mutations that enhance solubility and stability of a target protein
while retaining its activity has now become possible. Wider se-
quence variations introduced by DNA shufﬂing techniques (Stem-
mer, 1994; Zhao et al., 1998) have expanded the functional
diversity and facilitated the identiﬁcation of variants with superior
crystallization propensity (Keenan et al., 2005). Libraries of se-
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quences fused to reporters with speciﬁc marker phenotype (ﬂuo-
rescence in the case of GFP reporters) may be screened to detect
soluble variants. Successful results were obtained with the GFP
(Pedelacq et al., 2002; Waldo, 2003), although the bulky C-termi-
nally fused reporter may affect the solubility of the passenger pro-
tein. Insertion into the GFP scaffolding or fusion to GFP11 prior to
complementation with the large fragment GFP1–10 (Cabantous
et al., 2005) can overcome this limitation.
When a full-length protein fails to maintain in a soluble form,
N- and C-terminal truncations generated by PCR ampliﬁcation
can help identifying variants with increased solubility level
(Pedelacq et al., 2011). Another alternative is to select soluble
fragments encompassing one or several domains. This can be
achieved when domain boundaries are easily predictable from
known homologues. The situation becomes more difﬁcult with
protein targets that have no sequence or structural homologues.
One way to tackle this problem is to generate libraries of trun-
cated DNA fragments coupled with a genetic screen to discrimi-
nate between the thousands of constructs. The expression of
soluble proteins by random incremental truncation (ESPRIT)
(Yumerefendi et al., 2010) and colony ﬁltration (CoFi) blot (Corn-
vik and Dahlroth, 2006) methods have their limits, since they
only permit to truncate unidirectionally one end of the gene.
The bidirectional truncation version of ESPRIT (An et al., 2011)
and the combinatorial domain hunting (CDH) (Reich et al.,
2006) method have no ﬁltering strategy over fragment orienta-
tion and frame selection. Upstream protein fusions to murine
dihydrofolate reductase (mDHFR) (Dyson et al., 2008) or the b-
lactamase (Fisher et al., 2006) can help eliminating incorrect
reading frames. However, false positives were identiﬁed from
translation initiation at internal ribosome binding sites (IRBS).
A number of bipartite selection systems have also been devel-
oped in an attempt to overcome this issue. The DNA sequence
of the target gene is inserted between the two halves of the re-
porter, which are both required to give an observable phenotype
(Cabantous et al., 2008; Daugelat and Jacobs, 1999; Gerth et al.,
2004). Our insertional DHFR system combined with the split-GFP
assay has been successfully applied to identify soluble fragments
from each domain of human p85a and PpsC (Pedelacq et al.,
2011).
In this paper, we adopted a PCR approach and a library screen-
ing strategy to identify soluble constructs of an enzyme and its
protein substrate, respectively. We extend the use of the split-
GFP complementation assay (Cabantous et al., 2005) as a diagnos-
tic tool to investigate the solubility of co-factor dependent pro-
teins expressed in vivo. We applied this system to the
Mycobacterium tuberculosis PptT, an enzyme required for growth
and persistence of the bacteria in vivo (Leblanc et al., 2012). PptT
is responsible for the covalent transfer of the P-pant group of
Coenzyme A (CoA) to a conserved serine residue onto the acyl
carrier protein (ACP) domain of various type I polyketide syn-
thases (PKS) (Quadri et al., 1998a). This post-translational modiﬁ-
cation converts PKS into functional holo enzymes that play a key
role in the biosynthesis of various lipids of the mycobacterial cell
envelope (Chalut et al., 2006). Split-GFP complementation assays
indicated that the full-length enzyme is the most soluble among
all the variants tested. A soluble fragment containing the pre-
dicted boundaries for the PpsC ACP substrate identiﬁed using
our domain trapping method (Pedelacq et al., 2011) was used
for in vitro activity assays. We showed that the natural endoge-
nous CoA and divalent metal ion Mg2+, which play a crucial role
for PptT to carry out its function, are also a prerequisite for its
stability overtime. This easy-to-use split-GFP system can be gen-
eralized to detect soluble co-factor dependent protein expression
in vivo whenever the presence of co-factors is required for folding
and stability.
2. Materials and methods
2.1. PptT small scale expression and solubility tests
The pptT gene from M. tuberculosis was ampliﬁed from genomic
DNA using top and bottom primers listed in Supplementary Table 1.
The NdeI/BamHI digested pptTwas then inserted into commercially
available pET28 vectors (Novagen, Madison, WI, USA) with N- or C-
terminal 6His tag. pET vectors allowing the production of PptT
with MBP (Leblanc et al., 2012) or SUMO (Invitrogen, Carlsbad,
CA, USA) fused to its N-terminus were also tested. Ligated plasmids
were transformed into chemically competent E. coli BL21(DE3)
cells (Invitrogen, Carlsbad, CA, USA). Transformed cells were plated
onto Luria–Bertani (LB) agar plates containing 35 lg/ml kanamy-
cin, allowing them to grow overnight at 32 C. The resulting clones
were grown at 37 C in 1 ml cultures using 35 lg/ml kananycin.
Cells were induced in exponential phase with 1 mM IPTG for 3 h.
Cell culture pellets of 1 ml of each fragment were separately resus-
pended in 40 ll TNG buffer (150 mM NaCl, 100 mM Tris–HCl
pH = 7.5, 10% (v/v) glycerol) and sonicated. The lysate was fraction-
ated by centrifugation to yield the soluble and pellet fractions. The
pellet fraction was washed twice with 100 ll TNG buffer, centri-
fuged and resuspended in the same starting volume. Samples cor-
responding to the soluble (S) and pellet (P) fractions were resolved
on a 4–20% gradient Criterion SDS–PAGE gel (Bio-Rad, Hercules,
CA, USA). Protein samples were stained using Gel Code Blue stain
reagent (Pierce, Rockford, IL, USA) and imaged using a GS-800 Cal-
ibrated Densitometer (Biorad, Hercules, CA, USA).
2.2. Cloning and in vivo split-GFP solubility screen
Full-length and truncated variants of the M. tuberculosis PptT
gene were ampliﬁed by PCR using a series of forward and reverse
primers listed in Supplementary Table 1. Cleaned inserts from
NdeI/SpeI restriction digests were ligated into the pTET ColE1
GFP11 vector and transformed into chemically competent
BL21(DE3) cells containing the pET GFP1–10 plasmid (Cabantous
and Waldo, 2006; Cabantous et al., 2005). Frozen cells were used
to grow 1 mlLuria–Bertani (LB) medium in a 96-well deep-well
plate containing 35 lg/ml kanamycin and 112 lg/ml spectinomy-
cin until OD600 reached 1.0 at 37 C. 50 ll of two successive
400-fold dilutions of the expressed constructs were plated onto a
compartmentalized nitrocellulose membrane and grew overnight
at 32 C. The membrane was transferred to an LB/Agar plate con-
taining the same antibiotics supplemented with 250 ng/ml anhy-
drotetracycline (AnTET) for 2 h at 32 C, and then moved back
onto the original plate for 1 h at the same temperature. Finally,
the membrane was transferred onto a plate with same antibiotics
and 1 mM IPTG to induce the expression of the GFP1–10 fragment
at 32 C. Colonies were illuminated using an Illumatool Bright light
System LT-9900 (http://www.lightools.com/) at excitation and
emission wavelengths of 470 nm and 515 nm, respectively. Pic-
tures were taken after 30 min complementation at 32 C.
2.3. In vitro split-GFP complementation assay
5 ml LB cultures with 112 lg/ml spectinomycin were grown
at 37 C until OD600 reached 0.5–0.7. After induction at 32 C
with AnTET at a ﬁnal concentration of 8 lg/ml and growth for
an additional 4 h, cells were harvested by centrifugation at
20,000g for 20 min. 20 ll of PptT-GFP11 soluble fractions were
mixed with 180 ll of 0.35 mg/ml refolded GFP1–10 in a 96 well
microplate (Nunc-Immuno plate, Nunc, Rochester, NY, USA), as
previously described (Cabantous and Waldo, 2006). Fluorescence
kinetics (kexc = 488 nm/kem = 530 nm) were monitored with a
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FL600 Microplate Fluorescence Reader (Bio-Tek, Winooski, VT,
USA), at 3 min intervals, for 15 h. The background ﬂuorescence
of a blank sample (20 ll E. coli lysate expressing an unrelated
protein without the GFP11 tag, and 180 ll of 0.35 mg/ml
GFP1–10 in TNG buffer) was subtracted from ﬁnal ﬂuorescence
values.
2.4. Full-length PptT production and puriﬁcation
Frozen cells expressing the full-length PptT from a pTet vector
missing the GFP11 tag were used to start an overnight 3 ml LB-
spectinomycin (112 lg/ml) culture at 32 C prior to inoculation
in bafﬂed ﬂasks containing 500 ml of the same media. Cells were
allowed to grow for approximately 2 h at 37 C before temperature
was dropped from 37 C to 20 C. When OD600 reached 0.5–0.7,
cells were induced with AnTET at a ﬁnal concentration of 8 lg/
ml and grown for an additional 18 h prior to harvesting by centri-
fugation at 4000g for 30 min and storage at 80 C. The pelleted
cells were suspended in 40 ml of buffer A (100 mM Tris pH 8.0,
300 mM NaCl, 10 mM MgCl2, 50 lM CoA) and lysed by sonication
(6 cycles of 30 s pulse, 50% amplitude, power 5) prior to centrifuga-
tion at 20,000g for 1 h. The supernatant was ﬁltered (0.2 lm) and
puriﬁed on an ÄKTA puriﬁer system (GE Healthcare) following a
two-step procedure that combined an immobilized metal ion afﬁn-
ity chromatography (IMAC) and a size-exclusion chromatography
(SEC). The lysate was loaded onto a 1 ml HisTrap HP (GE Health-
care) afﬁnity column. The N-terminally His tagged PptT was eluted
from the column with a step of buffer A supplemented with
120 mM imidazole. The eluted protein fractions were pooled and
concentrated down to 2 ml using a Vivaspin 20 centrifugal concen-
trator (Sartorius), prior to injection into a HiLoad 16/60 Superdex
200 (GE Healthcare) pre-equilibrated with buffer B (50 mM Tris
pH 8.0, 50 mM NaCl, 10 mM MgCl2, 50 lM CoA).
2.5. ACP fragment cloning and puriﬁcation
The ppsC gene fromM. tuberculosiswas cloned into the NdeI/SpeI
sites of a pET26b plasmid (Novagen, Madison, WI) and PCR ampli-
ﬁed using gene speciﬁc forward 50-GATATACATATGACCGCAGCGAC
ACCAGATCG-30 and reverse 50-AATTCACTAGTTGACTCGCCTCGCGT
CGCAGC-30 primers. DNA fragmentation, cloning of the DNA library
into the DHFR ORF ﬁlter and the split-GFP solubility reporter
(Cabantous et al., 2005) were conducted as previously described
(Pedelacq et al., 2011). Brieﬂy, a 400 to 850 bp DNA library was cre-
ated by mechanical shearing of the PCR ampliﬁed ppsC gene. Blunt
fragments were ligated in a StuI-digested insertion DHFR pET vec-
tor to select for in-frame fragment in the presence of 6 lg/ml tri-
methoprim. Inverse PCR was performed with fragments ligated
into the pTET ColE1 GFP11 vector using phosphorylated forward
(50-CGACTCGCTGATGGGCCTGGAATTGCGCAATC-30) and reverse
(50-AGTCCCAGGGTTTCCAGCGGTCGGTGGTGATC-30) primers. After
transformation into chemically competent BL21(DE3) pET GFP1–
10 cells, 96 individually picked clones were grown overnight at
30 C in a 96-well tissue culture plate containing 7.5% glycerol in
LB medium with kanamycin and spectinomycin prior to sequenc-
ing. DNA sequences were analyzed using the BioEdit software
(http://www.mbio.ncsu.edu/bioedit/bioedit.html) and aligned
onto the full-length parent gene to determine the exact bound-
aries. Based on the in vitro solubility assays (Cabantous et al.,
2005), fragments were color-coded black, dark gray, and light gray,
where the black side of the spectrum identiﬁes the least soluble
ACP fragments and the light gray side corresponds to the top 25%
most soluble ones. A DNA fragment encompassing the ACP domain
and linker regions of PpsC was ampliﬁed by conventional PCR and
was cloned into the NdeI/BamHI restriction sites of a pET28a plas-
mid (Novagen, Madison, WI, USA) using GATATACATATGCATG
ACTCGGCGGCCCGCAAAA and AATTCGGATCCTGACTCGCCTCGCGTC
GCAGCTT as forward and reverse primers, respectively. The result-
ing plasmid was transformed into chemically competent
BL21(DE3) E. coli cells. Cells expressing the ACP fragment were
grown to OD600  0.6, induced with 0.25 mM IPTG for 4 h at
30 C, pelleted by centrifugation at 4000g for 30 min and stored
at 80 C. The frozen pelleted cells were resuspended in 40 ml of
buffer A and lysed by sonication (6 cycles of 30 s pulse, 50% ampli-
tude, power 5) prior to centrifugation at 45,000g for 30 min. 4 ml of
Talon Superﬂow beads (Talon resin, Clontech, Palo Alto, CA, USA)
conditioned in buffer A were added to the supernatant for 5 min
prior to centrifugation at 1000g for 5 min. The unbound fraction
was removed and the beads were washed twice with 50 ml of buf-
fer A then 30 ml of buffer A supplemented with 10 mM imidazole
to eliminate non-speciﬁc binding to the beads. The N-terminally
His-tagged protein was eluted with 5 ml of buffer A containing
250 mM imidazole. The protein elution sample was resolved on a
4–20% gradient SDS–PAGE gel and stained using a Coomassie Blue
R-250 staining solution. The protein solution was stored at 20 C
after dialysis overnight against 25 mM Tris pH 8.0, 25 mM NaCl
with 10% glycerol.
2.6. DSF experiments
Fluorescence of the SYPRO Orange Protein Gel Stain (Invitrogen,
USA) wasmeasured using the CFX96 real-time PCR detection Sys-
tem (Bio-Rad, Hercules, CA, USA) from 20 C to 90 C in 0.3 C
increments of 3 s. PptT was concentrated to 400 lM in the pres-
ence of buffer A (50 mM Tris pH 8.0, 50 mM NaCl, 10 mM MgCl2,
50 lMCoA) prior to a 10-fold dilution with either buffer A or buffer
B (50 mM Tris pH 8.0, 50 mM NaCl). 20 ll mixtures containing 2 ll
PptT 40 lM and 1 ll Sypro Orange 200X were placed in 96-well
clear-bottom Hard-Shell 96-Well Skirted PCR Plates, Low-Proﬁle
(BioRad). Addition of 17 ll of buffer A or B completes the reaction
mixture. Each condition was realized in triplicate. Melting temper-
atures were then calculated using the BioRad CFX Manager
software.
2.7. Activity assays
PptT at 50 nM was incubated at 30 C with 10 lM of ACP do-
main of PpsC. 20 lM CoA, 25 mM DTT and divalent cations (CaCl2,
MnCl2, or MgCl2) at 10 mM ﬁnal concentration were also present in
the reaction mixture. Reaction was then stopped at different times
with the addition of 100 mM EDTA. The same experiment was con-
ducted with Sfp from Bacillus subtilis (NEB, Ipswich, MA) at the
same concentration, instead of PptT. Samples were then loaded
on a 10% polyacrylamide gel supplemented with 2.5 M urea.
Appropriate positive and negative controls for the transfer of the
P-pant moiety were carried out for one hour at 30 C in the pres-
ence or absence of 200 nM Sfp, respectively.
3. Results
3.1. Expression of PptT in bacterial pET vectors
We ﬁrst cloned pptT into pET28 derived vectors prior to trans-
formation into BL21(DE3) cells. Only in a situation where the his-
tidine tag is present at the N-terminal extremity of the protein
that overexpression of PptT can be achieved. The construct is
poorly soluble and expresses mainly as inclusion bodies after IPTG
induction (Fig. 1). To maximize the amount of soluble protein, one
strategy was to screen conditions where the inclusion bodies could
be refolded in a stable and active conformation. This was achieved
in the presence of 100 mMMES at pH 5.5. Unfortunately, analytical
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gel ﬁltration experiments indicated an aggregated form of the en-
zyme detected in the exclusion volume of the column and the
activity of the enzyme could not be conﬁrmed.
As an alternative, we cloned pptT into pET vectors with fusion
partners maltose binding protein (MBP) (Fox and Waugh, 2003)
and small ubiquitin-related modiﬁer (SUMO) (Mossessova and
Lima, 2000), previously described as solubility enhancers of
passenger proteins (see Section 2). On the one hand, SUMO had no
effect on the solubility of the fusion. On the other hand, the MBP–
PptT fusion was mostly soluble and could be puriﬁed easily follow-
ing a two-step procedure usingmetal-afﬁnity resin followed by size
exclusion chromatography. Unfortunately, the enzyme irreversibly
precipitates after proteolytic cleavage of the N-terminal MBP tag,
which indicates that the MBP fusion maintains PptT in a soluble
form.
3.2. Split-GFP solubility screen of PptT variants
Single amino-acid truncation at the N- or C-terminal extremity
of a protein of interest often has a dramatic effect onto the solubil-
ity level of the expressed variant (Listwan et al., 2010; Pedelacq
et al., 2011). With this in mind, we explored the expression and
solubility levels of an ensemble of 48 constructs in vivo (Fig. 2a
and b), corresponding to the full-length PptT along with N- and
C-terminally truncated variants, using the split-GFP based assay
(Cabantous et al., 2005). In this system, two separately inducible
expression systems are present in the same E. coli cell, one tetracy-
cline-inducible vector bearing the small GFP11 tag N-terminally
fused to the protein of interest while the large complementary
fragment GFP1–10 is located onto a separate IPTG-inducible
expression vector. After sequential induction, only soluble GFP11
fusions can spontaneously bind to GFP1–10, thus restoring the
ﬂuorescence of the full-length GFP. In this system, ﬂuorescent
complementation is directly proportional to the amount of soluble
protein present in the living cells or puriﬁed from cell crude ex-
tracts, with detection levels within the picomole range. In vivo,
the highest ﬂuorescence levels could be attained for the full-length
enzyme and N-terminally truncated variants whereas truncation of
the last C-terminal residue L227 was sufﬁcient to negatively im-
pact the ﬂuorescence intensity of the colonies (Fig. 2b). To conﬁrm
this result, an in vitro split-GFP complementation kinetic assay was
performed by adding a large excess of GFP1–10 to the N- and C-ter-
minally truncated variants in the soluble fraction. After 15 h of
complementation at room temperature, ﬂuorescence intensity
measured for the D227 deletion mutant was reduced by 75%
compared to the full-length enzyme (Fig. 2c). Fluorescence
intensity levels measured for the other six C-terminally truncated
variants, from position 226 to position 220, remained low and
comparable.
3.3. Both CoA and MgCl2 are essential for the stability of PptT
In vivo expression and solubility levels of the recombinant His–
PptT–GFP11 fusion were assessed by comparing the ﬂuorescence
intensities of co-induced and sequentially induced E. coli cell cul-
tures, as previously described (Cabantous and Waldo, 2006).
Approximately one third of the enzyme could be expressed in a
soluble form, a result in accordance with the band intensities mea-
sured on a SDS–PAGE gel (data not shown). A two-step puriﬁcation
procedure using immobilized metal ion afﬁnity chromatography
(IMAC) and size-exclusion chromatography (SEC) indicated that
the protein was mostly aggregated and could precipitate within
hours.
Knowing the essentiality of CoA and Mg2+ for PptT to carry out
its function in vivo (Quadri et al., 1998a), we were wondering if
these compounds could also help maintaining the enzyme in a sta-
ble conformation in vitro. When CoA and MgCl2 are present in a
large molar excess over PptT in the cell lysate and all along the
two-step puriﬁcation strategy, high yields of soluble recombinant
protein can be obtained. We then conducted a series of experi-
ments using the Differential Scanning Fluorimetry (DSF) method
(Niesen et al., 2007) to conﬁrm the importance of the two protag-
onists onto the stability of PptT. We used Sypro Orange to detect
the buried hydrophobic regions of the enzyme that become pro-
gressively exposed to solvent during a linear temperature ramp
from 20 C to 90 C. The low initial ﬂuorescence background and
the high signal-to-noise ﬂuorescence ratios have facilitated an
accurate measurement of the transition midpoint (Tm) values.
High Tm values around 50 C were measured in the presence of
CoA and MgCl2 at a ﬁnal concentration of 50 lM and 10 mM,
respectively, in accordance with the puriﬁcation conditions.
Reducing the concentration of CoA to trace amount (0.5 lM ﬁnal)
while maintaining a 25-fold molar excess of MgCl2 (100 lM ﬁnal)
over PptT profoundly impacted the stability of the full-length en-
zyme, as no Tm values could be measured.
3.4. In vitro enzymatic activity of PptT
PptT catalyzes the covalent transfer of the 40-phosphopantethe-
ine (P-pant) group from CoA onto the ACP domain of various type I
PKS and nonribosomal peptide synthetases (NRPS) (Quadri et al.,
1998a). Issues related to heterologous host expression, folding
and solubility of these large-size multi-domain enzymes forced
us to identify a more compact and stand-alone soluble fragment
encompassing the functional ACP domain. We used our recently
published domain trapping strategy (Pedelacq et al., 2011) to gen-
erate a 400–850 bp fragment library centered onto the ACP domain
of PpsC, a 2188 amino-acid enzyme involved in the biosynthesis of
phtiocerol dimycocerosates (PDIM) (Camacho et al., 2001). These
lipids play a major role in the virulence of M. tuberculosis (Asta-
rie-Dequeker et al., 2009). Our approach combines a two-body
dihydrofolate reductase (DHFR) scaffolding for selecting in frame
DNA sequences from a random library of the fragmented ppsC
1
Mw
(kDa) S P S P S P S P
100
70
55
40
35
25
2 3 4[ [ [ [
Fig.1. SDS–PAGE of soluble (S) and pellet (P) fractions of PptT constructs of E. coli
BL21(DE3) cell cultures carrying a pET28-PptT plasmid allowing expression of PptT
(1) with C-terminal and (2) N-terminal 6His tag, (3) with N-terminally fused SUMO
and (4) MBP proteins. Molecular weight markers (Mw) are also indicated.
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gene, with the split-GFP technology (Cabantous et al., 2005) to
identify soluble candidates centered onto the ACP domain
(Fig. 3). The main advantage of our approach lies in the efﬁciency
of the DHFR step to ﬁlter-out 95% of the constructs present in
the original DNA library and the use of an inverse PCR step to select
for fragments encompassing a speciﬁc region or domain of a given
protein (Pedelacq et al., 2011). The implementation of the split-GFP
assay to distinguish colonies on the basis of their ﬂuorescence
intensities completes this highly reliable and efﬁcient strategy.
We picked a total of 96 clones with ﬂuorescence intensity levels
varying from bright to faint depending on the solubility of the ex-
pressed fragment. Activity assays were carried out in the presence
of the most soluble and compact ACP fragment 2042–2188 using
either PptT or its closest homologue Sfp from B. subtilis (Quadri
et al., 1998b). We then visualized differences in the migration of
the ACP domain on a 10% native polyacrylamide gel supplemented
with 2.5 M urea (Fig. 4). Knowing that the reaction catalyzed by Sfp
is magnesium- (Reuter et al., 1999) or manganese-dependent
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Fig.2. PCR-directed truncations of pptT and split-GFP complementation reaction. (a) Schematic representation of the 48 constructs aligned onto the PptT amino-acid
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(Moﬁd et al., 2004) whereas the B. subtilis AcpS X-ray structure
revealed the presence of calcium in its active site (Parris et al.,
2000), we then explored the role of all three divalent metal ions
onto the activity of PptT. No activation of the ACP domain was
detected in the presence of 10 mM CaCl2 with either PptT or Sfp.
When replacing CaCl2 with MnCl2, activation of the ACP was
noticeable after 30 min incubation, only in the presence of
PptT. At 10 mM MgCl2, approximately half of the ACP domain
was activated by the transfer of the P-pant moiety after 5 and
20 min incubation with PptT and Sfp, respectively. In conclusion,
Mg2+ resulted in the highest activity among the divalent ions
tested followed by Mn2+, while Ca2+ has no effect on the activity
of the enzyme.
4. Discussion
The main goal of this study was to examine the use of the GFP1–
10/GFP11 system (Cabantous et al., 2005) as a diagnostic tool to as-
sess the solubility of co-factor dependent protein targets in vivo. We
have demonstrated the feasibility of our approach on the M. tuber-
culosis PptT whose essentiality for growth and persistence of the
bacteria in vivomakes it a potential candidate for the development
of anti-tuberculosis drugs (Leblanc et al., 2012). Therefore, identify-
ing a functional and soluble construct of this enzyme is a prerequi-
site for high-throughput screening (HTS) of inhibitors and
structure-based rational design of novel hit compounds. Until
now, the solubleMBP–PptT fusionwas used for the implementation
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Screen in vivo 
Colony picking 
Screen in vitro 
Split-GFP assay 
2188 2042 
DNA fragmentation 
and library selection 
Fragment library 
DHFR ORF filter 
KS ACP 
GFP1-10 
L 
+ 
GFP11 
Position 86/87 
Fig.3. The domain trapping strategy. Our strategy integrates a DHFR ﬁlter to eliminate the incorrect reading frames and a split-GFP solubility screen to identify the soluble
constructs. 450–850 bp generated library of fragments was inserted at position 86/87 of the DHFR. Inverse PCR focused sub-libraries of fragments helped identifying a soluble
fragment (indicated by an arrow) centered onto the ACP domain of the M. tuberculosis polyketide synthase PpsC. Clones are picked and grown in 96-well liquid cultures for
in vitro quantiﬁcation of the soluble and insoluble protein fractions. We used the color scheme gray – light gray – bright gray, to distinguish between the least and most soluble
ACP fragments.
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Fig.4. Activation time-course of the ACP domain by PptT and the Sfp from B. subtilis. The transfer of the P-pant group from CoA to the ACP domain of PpsC is visualized on a
10% native polyacrylamide gel supplemented with 2.5 M urea in the presence of CaCl2 (left), MnCl2 (middle) and MgCl2 (right) at different time intervals (5, 10, 15, 20, 30 and
60 min). Negative () and positive (+) controls correspond to the inactivated and activated forms of the ACP domain, respectively.
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of an enzymatic assay suitable for HTS assays (Leblanc et al., 2012).
E. coli expression of PptT alone using pET vectors was hampered by
solubility issues that caused the protein to partition exclusively into
inclusion bodies (Fig. 1). Here, we took advantage of the weak
AnTet-inducible promoter of the GFP11 vector (Cabantous et al.,
2005) to investigate the solubility levels of the full-length PptT from
M. tuberculosis in addition to N- and C-terminally truncated vari-
ants. The picomolar detection level of the split-GFP system helped
differentiating between the different constructs according to
ﬂuorescence intensity of the reconstituted GFP moiety. Interest-
ingly, the full-length enzyme appeared to be the most soluble pro-
tein construct after sequential induction in vivo (Fig. 2). Although
the in vitro experiments followed the same trend, aggregation of
the protein over time ultimately led to its precipitation within
hours.
We then evaluated the contribution of Mg2+ and CoA onto the
stability and function of the full-length PptT in vitro. A series of
experiments using the DSF method was performed. High quality
and reproducible ﬂuorescent melting curves with Tm values of
50 C could be measured only when CoA and MgCl2 were
maintained in a large molar excess over PptT, at concentrations
equivalent to the puriﬁcation conditions. Essentiality of these
two co-factors for PptT to carry out its function was also
demonstrated using a soluble fragment encompassing the ACP do-
main of the polyketide synthase PpsC (Fig. 3). We opted for a do-
main trapping strategy (Pedelacq et al., 2011) to effectively
identify soluble fragments encompassing the predicted boundaries
for this ACP domain (2062–2145). All 96 selected fragments
incorporated the C-terminus of PpsC, probably as a result of less
efﬁcient mechanical breakage at the 30 and 50 extremities of the
DNA molecule. The most compact and soluble ACP fragment
(2042–2188) was selected to maximize the chances of monitoring
the transfer of the P-pant moiety onto its conserved Ser2105 using
either PptT or its closest homologue Sfp from B. subtilis (Reuter
et al., 1999). Activation of the ACP fragment was conﬁrmed in
the presence of Mg2+ and, to a lesser extent, in the presence of
Mn2+. Surprisingly, activity of the B. subtilis Sfp was not detected
in the presence of Mn2+, a result not in accordance with the work
published by Moﬁd et al. (2004), although the reaction mixture
was incubated at 37 C instead of 30 C in our assay.
Fig.5. Sequence alignment of PptT with known homologues. (a) Structure-based sequence alignment of the B. subtilis Sfp (Uniprot code P39135) and the human AcpS (Uniprot
code Q9NRN7) extended to PptT with respect to the conservation of sequence motifs with key residues important for the activity and interactions with CoA. Secondary
structure elements deduced from the X-ray structure of Sfp (PDB code 1QR0) and the human AcpS (PDB code 2C43) are shown at the bottom of the aligned sequences in light
and dark gray, respectively. Sequence similarities are highlighted in red; sequence identities are shown as white letters on a red background. Strictly conserved catalytic
residues D114 and E157 are indicated with brown triangles. The ﬁgure was produced with ESPript (Gouet and Courcelle, 2002). Ribbon representation of the X-ray structure
of the B. subtilis Sfp (b) and the human AcpS (c). CoA is shown in a ball-and-stick representation. N- and C-terminal ends are colored in green and orange in the X-ray
structures and the sequence alignment. The side-chains of residues Tyr4 and Arg57 are indicated.
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In an effort to rationalize the effect of N- and C-terminal trunca-
tions onto the solubiity of the expressed PptT constructs, we gen-
erated a structure-based sequence alignment between the
homologues Sfp from B. subtilis (PDB code 1QR0, (Reuter et al.,
1999)) and the human AcpS (PDB code 2c43, (Bunkoczi et al.,
2007)), that we further extended to PptT with respect to the con-
servation of sequence motifs with key residues important for the
activity and stability of CoA (Fig. 5a). In the Sfp X-ray structure,
N-terminal residues 2 to 7 form the outermost strand of a
three-stranded antiparallel b-sheet, at the opposite side of CoA
(Fig. 5b). This N-terminal b-strand also interacts with the 26-resi-
due long C-terminal region through hydrogen bond interactions
that involve the main-chain nitrogen and oxygen atoms of Ile3
and Gly5. Tyr4 also contributes to the stabilization of the adjacent
helix through interactions with Arg57. Disrupting all these interac-
tions would have a dramatic impact onto the stability of the en-
zyme. In the human AcpS structure, the N-terminal domain is
mostly disordered and unstructured with the ﬁrst residue identi-
ﬁed at position 8 in the X-ray structure and strand b1 starting at
position 17 (Fig. 5c). We then anticipated that the N-terminal re-
gion of PptT adopts an unstructured conformation similar to the
one observed for the human AcpS, in accordance with the sequence
alignment presented in Fig. 5a. Surprisingly, deletion of C-terminal
residues has a dramatic effect on the solubility of PptT, as illustrat-
edby the ﬂuorescence drop to 75% for the truncated variant miss-
ing the C-terminus residue L227. In the Sfp and AcpS structures,
this highly variable and poorly structured region wraps around
the a/b core of the protein (Fig. 5b and c). Stabilization occurs
through numerous hydrophobic and van der Waals contacts and
a constellation of hydrogen bond interactions that involve the
main-chain and side-chain atoms of residues all along the C-termi-
nal region. At this stage, considering the low level of amino-acid
sequence similarity between the three enzymes, questions about
the role of L227 onto the stability of PptT are difﬁcult to answer
as no NMR or X-ray structure is yet available. We are conﬁdent that
our efforts to overcome this major solubility bottleneck will help
determining the three-dimensional structure of PptT, which in turn
will serve as a basis for the structure-based rational design of a
selective PptT inhibitor.
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In this paper, we have used the split-GFP technology to design a general 
protocol to assess the solubility of co-factor dependent protein expression in vivo. We 
have applied this protocol to PptT and PptT truncated versions, and we have 
identified the full-length construction as the most soluble one as estimated by the 
fluorescence of the GFP. We have then demonstrated the role of MgCl2 and coenzyme 
A to help stabilize PptT during the extraction and purification process. This role has 
been further confirmed by the increased stability of the enzyme in presence of these 
co-factors as monitored by DSF. We have also verified that PptT was able to transfer a 
P-pant moiety from CoA onto the ACP domain of PpsC. The ACP domain of PpsC 
could be activated in only a few minutes, which is also interesting for our structural 
and functional study of this enzyme. 
We were then able to produce and purify large amounts of the full-length PptT 
in a stable and active form, suitable for crystallization. In an effort to assist the search 
for specific inhibitors of this essential enzyme in the virulence of Mtb, we have 
determined its structure at high resolution using X-ray crystallography. 
Crystallization, structural determination and characterization of PptT are detailed in 
the next chapter. 
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3. STRUCTURAL CHARACTERIZATION 
OF PPTT 
 
a) Crystallization, Data collection, and Phasing 
 
Using the pTet vector construction of PptT missing the GFP11 strand, and 
thanks to Mg2+ and CoA, we have been able to produce and purify large amounts of 
PptT in a stable and active form. Screening a thousand crystallization conditions with 
the help of commercial kits and a crystallization robot, has been sufficient to identify 
a condition that resulted in the formation of thin platelets of PptT. These diffracted 
beyond 2 Å resolution using an in house X-ray source (Agilent PX-Scanner). In order 
to make PptT crystals easier to handle and more reproducible, we adapted a 
microseeding protocol where crushed platelets served as microseeds for the setup of 
new crystallization experiments [186], [187]. Using this protocol, a very similar 
crystallization condition was obtained which resulted in the formation of 
reproducible, individual thick platelets. These have been used to collect an X-ray 
diffraction dataset to 1.4 Å resolution at the PROXIMA 1 beamline at the SOLEIL 
synchrotron in Gif-sur-Yvette, France (Table 7). 
We have first used the structures of B. subtilis Sfp (PDB code: 1QR0) or human 
AcpS (PDB codes: 2BYD or 2C43) as templates for the molecular replacement 
method. Unfortunately, a solution could be found only when using the conserved 
“core” structure as template, but no additional electron density was visible and the 
protein structure could only be partially built. We then took advantage of the 
anomalous signal provided by the 8 sulfur atoms (from 4 cysteines and 4 
methionines) naturally present in PptT in addition to the 3 phosphorus and the sulfur 
atoms from CoA to collect a highly redundant SAD (single anomalous wavelength 
diffraction) dataset at a wavelength of 2Å at the beamline ID-29-1 at the European 
Synchrotron Radiation Facility (ESRF) in Grenoble, France (Table 7). The position 
of 12 atoms could be identified and the structure of PptT has been solved at 2.1 Å 
resolution. We have then used this structure as a molecular replacement template to 
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solve the structure from the native dataset collected at SOLEIL. The final model has 
been refined at 1.4 Å resolution to an R-factor of 0.14 and an R-free of 0.17 (Table 7). 
 
b) Overall Structure of PptT and Comparison 
with its Homologues 
 
PptT folds into a pseudo-dimeric structure, similar to the well-characterized 
Sfp [97] and thUS belongs to the group II PPTases family of enzymes. This family can 
be divided into two sub-families (Figure 15B). Interestingly, PptT possess sequence 
patterns similar to both sub-families (Figure 25), although it lacks the motif 1A 
which is peculiar to the F/KES sub-family. Since members of these two sub-families 
are responsible for the same catalytic activity, and no structure from the F/KES sub-
family is available yet, PptT cannot be unambiguously classified in either one of the 
subfamilies. A search using DALI (http://ekhidna.biocenter.helsinki.fi/dali_server/ )
has yielded only 2 homologues whose structure align with more than 100 of the 224 
residues observed in the PptT structure. These correspond to the human AcpS (rmsd 
3.0 Å on 190 Cα atoms) and the B. subtilis Sfp (rmsd 3.3 Å on 168 Cα atoms), which 
both belong to the W/KEA sub-family of group II PPTases. Other homologues align 
with only a hundred residues though with an average rmsd of about 2.5 Å and 
correspond to group I PPTases. 
Like Sfp, PptT folds into two nearly identical domains connected by a short 
linker region (Figure 26). The N-terminal domain extends from M1 to V108 
whereas the C-terminus domain extends from R109 to L227. The main difference 
between these two domains lies in the first 18 residues of the N-terminus domain that 
are dedicated to the closure of the hydrophobic core formed by the β-sheets of the 
two sub-domains. They are located in a position similar to the β-sheet of the third 
monomer in the trimeric group I PPTase family (Figures 27 and 13A). The first 
residue fulfilling this role is L6 which is stabilized by the side chain of E23 and is 
involved in the short 3/10 helix η1 stacked against the hydrophobic core. 
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When searching for more soluble constructs of PptT, we have tested a 
combination of N- and C-terminally truncated versions of the enzyme (see Rottier, 
Faille et al., Figure 2). Using the split GFP technology, we have established that 
the deletion of the first five residues only slightly hampered PptT solubility. On the 
contrary, deleting the last residue L227 was sufficient to observe a large decrease in 
solubility. These results can easily be interpreted when examining the PptT structure. 
Indeed, the first five residues do not take part into any secondary structure and are 
not involved in any interaction with the remaining part of the protein (Figure 28). 
Deleting the residues L6 and V7 would probably have a more dramatic effect on PptT 
solubility since, in addition to their implication in the hydrogen bonding network 
through the side chain of E23, they prevent solvent from entering the hydrophobic 
core of the protein. The large negative effect on solubility caused by the deletion of 
the last residue L227 can also be explained. The L227 carboxy-terminus is located at 
the extremity of β8 and is part of the C-terminal β-sheet (Figure 29). It also helps 
stabilize the β6-β7 and β3-β4 loops via an extensive hydrogen bond network 
involving R109. 
Interestingly, in Sfp [97] and hAcpS [92], closing of the solvent access to the 
hydrophobic core does not involve any N-terminal residues but instead, 30 C-
terminal residues absent from the PptT sequence (Figures 25 and 27). Other 
structural differences appear when comparing PptT to Sfp and hAcpS. The positions 
of the strands β5 and β6 in PptT, although similar to those in hAcpS (β7 and β8) 
largely differ from those in Sfp (β7 and β8). In PptT, they are stacked against the long 
α4 helix whereas in Sfp they come out of the structure and participate in crystal 
packing by interacting with several symmetry-related molecules. Their position in Sfp 
might not then reflect the solution structure but show the flexibility of this structural 
element, to which no function has been attributed yet. It also illustrates that PptT 
ressembles more hAcpS than Sfp. Finally, PptT also bears a 16 residues insertion 
compared to both Sfp and hAcpS. Located between L196 and R211, this insertion 
creates a small cavity on top of the protein that does not exist in the two homologues. 
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c) Coenzyme A Binding 
 
CoA binds in a cleft delineated by the core elements α1, α4, β2 and β4 and the 
loops α1-β2 (residues 67-86) and α4-β5 (residues 168-175) (Figure 29). It is 
stabilized by numerous polar interactions mainly involving side chains from the core 
elements (Figure 29A). A magnesium ion has been found to coordinate with the 
CoA pyrophosphate in addition to the side chain of D114 and a water molecule 
(wat191), a feature already observed in both Sfp and hAcpS structures. Interestingly, 
in the structures of these homologues, the Mg2+ coordinates with an additional 
glutamic acid. In PptT, E157 lies in a position similar to the glutamic acid in Sfp and 
hAcpS, but it participates to the stabilization of the P-pant moiety. A possible rotamer 
of the E157 side chain would allow the carboxylate to reach the coordination sphere of 
Mg2+ but there is no evidence from electron density that this is the case. Despite the 
low sequence identity between homologues, residues whose sides chains are involved 
in polar interactions with CoA are well conserved (Figure 25). Indeed, to the 
exception of Y160, the five other residues are either similar or identical and 
participate in the same interactions with CoA as in the Sfp and hAcpS structures. A 
conserved lysine residue (K156, Figure 29A) seems to be responsible for the relative 
positioning of the α4 core helix and the loop α4-β5 that form the buried cavity in 
which the P-pant enters in the hAcpS and PptT structures. In the Sfp structure, the P-
pant is not visible in the electron density and probably solvent exposed (Figure 16), 
and no similar buried cavity could be observed. 
CoA binding is also driven by electrostatic patches (Figure 29B-C). Along 
with Mg2+, the P-pant part lies on an electronegative surface, to the exception of the 
bottom of the buried cavity, which is rather electropositive. On the contrary, the 
adenosine phosphate lies on an electropositive surface, especially the 5’-phosphate 
which interacts with the side chains of R48, R56 and K75 (Figure 29A). Only the 
adenosine N6 is stabilized by the side chain of Y160. Similar electronegative and 
electropositive patches are found in Sfp, but in this case the P-pant part of CoA is not 
visible in the structure. Also, the shape of the CoA-binding pocket largely differs from 
that of PptT and is more solvent-exposed. In hAcpS, both shape and electrostatic 
surface are similar to those found in PptT. However, the P-pant moiety is also buried 
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in a cavity but in a different conformation and not stabilized by any polar interaction. 
Also, the electrostatic surface where lies the adenosine moiety is of opposite charge in 
hAcpS compared to PptT. As to why CoA is required for the stability of PptT and not 
for hAcpS, still remains an enigma. 
 
d) Docking of PpsC ACP Domain and PptT 
Catalytic Mechanism 
 
To date the only structure involving a group II PPTase in complex with a CP 
domain, is between hAcpS and the human ACP (hACP). This complex helped the 
authors to describe a detailed mechanism of P-pant transfer (see section I.B.2.c). 
Nonetheless, if the catalytic mechanism involves highly conserved residues and is 
thus probably similar in all group II PPTases, the interaction between hAcpS and the 
ACP may not be universal considering the low amino-acid identity among both group 
II PPTases and CPs. We have therefore modeled a complex between the PpsC ACP 
domain and PptT by computational docking. We used the same PpsC ACP domain 
model generated by MODELLER, as in section II.A.4. In the hAcpS-hACP complex 
(PDB code: 2CG5; Figure 16C) and hAcpS (PDB code: 2C43) structures, the CoA 
positions identically. We therefore used the position of the CoA in our PptT structure 
as a constraint to guide molecular docking. More specifically, in all binding modes 
calculated by PatchDock, the distance between the oxygen atom of the ACP serine 
and the phosphorus of the P-pant phosphate was not allowed to be greater than 5 Å of 
the. After refinement with FireDock, only one docking solution still satisfied this 
unique condition. 
In the resulting complex, the oxygen atom of S2105 is 3.1 Å away from the P-
pant phosphore (Figure 30C). Additional evidences indicate that our docking model 
could be relevant for the description of PptT-ACP interactions. Indeed, the PptT 
glutamic acid (E157), which probably activates the ACP serine (S2105) is 2.7 Å away 
from the serine (Figure 30C) and in a suitable position to catalyze deprotonation, as 
seen in the hAcpS-hACP structure (Figure 16). Furthermore, a putative П-stacking 
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interaction is observed between PptT W170 and W2129 of PpsC ACP (Figure 30A). 
It is noteworthy that in the PptT experimental structure a well-defined imidazole 
positions identically to the pyrrole ring of ACP W2129. Likewise, the main-chain 
oxygen of ACP T2100 which forms a polar interaction with S44 of PptT superposes 
well with the oxygen of a phosphate molecule involved in an interaction with S44 in 
the PptT experimental structure. 
Interestingly, we have found similar interactions in the model of the PptT-ACP 
complex as those occurring in the structure of the hAcpS-hACP. These interactions 
mainly comprise hydrophobic contacts between the α1 and α4 long helices of PptT 
and the α1 and α2 helices of the ACP domain. A few polar interactions also seem to 
participate to PptT-ACP docking, namely G124-T2122, K75-E2099, S44-T2100. PptT 
and the PpsC ACP domain also present electrostatic patches of opposite charges that 
may drive their interaction (Figure 30B). Furthermore, two main contact areas can 
be observed in the PptT-ACP model. One involves a negatively charged patch at the 
C-terminus of PptT and the electropositive ACP helix α2. The other one involves a 
positively charged patch at the N-terminus of PptT and the electronegative α1-α2 loop 
of the ACP domain. 
The group II PPTase catalytic mechanism has been well described for hAcpS 
(Figure 16C). Our PptT-PpsC ACP docking model, which as explained above is 
structurally similar to the hAcpS-hACP structure, is also compatible with the catalytic 
mechanism described for the latter. In hAcpS, this mechanism involves two residues 
playing the role of acid/base catalysts. These two residues are strictly conserved in 
PptT (E157 and K161) and are indeed in a suitable position to catalyze the P-pant 
transfer onto the catalytic S2105 of ACP. As in hAcpS-hACP, S2105 benefits from the 
helix-dipole effect of the α2 helix (Figure 30C), and the side chain of E157, located 
2.7 Å away from the catalytic serine, would abstract a proton from it. K161 would then 
protonate the CoA α-phosphate and the the serine hydroxylate would attack the β-
phosphate, which is only 3.4 Å away from S2105 in our model. It would result in the 
thioester attachment of the P-pant moiety onto the ACP S2105 and the release of an 
adenosine di-phosphate molecule 
 


 
 
e) Experimental Procedures 
 
PRODUCTION AND PURIFICATION 
The protocol described in Rottier, Faille et al., was applied for the 
structural study of PptT: 
Frozen cells expressing the full-length PptT from a pTet vector missing the GFP11 tag 
were used to start an overnight 3 ml LB-spectinomycin (112 μg/ml) culture at 32 °C 
prior to inoculation in baffled flasks containing 500 ml of the same media. Cells were 
allowed to grow for approximately 2 h at 37 °C before temperature was dropped from 
37 °C to 20 °C. When OD600 reached 0.5–0.7, cells were induced with 
anhydrotetracycline at a final concentration of 8 μg/ml and grown for an additional 
18 h prior to harvesting by centrifugation at 4000g for 30 min and storage at −80 °C. 
The pelleted cells were suspended in 40 ml of buffer A (100 mM Tris, 300 mM NaCl, 
10 mM MgCl2, 50 μM CoA pH 8.0) and lysed by sonication (6 cycles of 30 s pulse, 
50% amplitude, power 5) prior to centrifugation at 20,000g for 1 h. The supernatant 
was filtered (0.2 μm) and purified on an ÄKTA purifier system (GE Healthcare) 
following a two-step procedure that combined an immobilized metal ion affinity 
chromatography (IMAC) and a size-exclusion chromatography (SEC). The lysate was 
loaded onto a 1 ml HisTrap HP (GE Healthcare) affinity column. The N-terminally 
His-tagged PptT was eluted from the column with a step of buffer A supplemented 
with 120 mM imidazole. The eluted protein fractions were pooled and concentrated 
down to 2 ml using a Vivaspin 20 centrifugal concentrator (Sartorius), prior to 
injection into a HiLoad 16/60 Superdex 200 (GE Healthcare) pre-equilibrated with 
buffer B (50 mM Tris pH 8.0, 50 mM NaCl, 10 mM MgCl2, 50 μM CoA). 
 
CRYSTALLIZATION 
Initial crystals were obtained from 0.2 M lithium sulfate, 0.1 M phosphate-
citrate pH 4.2, 20% (w/v) PEG 1000 while screening approximately a thousand 
conditions through QIAGEN NeXtal commercial kits using a Nanodrop ExtY 
crystallization robot. Crystallization was further optimized using microseeding 
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techniques in Linbro 24 well plates. Several crystals from the initial condition were 
crushed in 200 μl of reservoir solution and serially diluted. Final crystallization setup 
consisted in 0.5 μl of each dilution, 2 μl protein and 1.5 μl 0.2 M lithium sulfate, 0.1 
M phosphate-citrate pH 4.0, 22% (w/v) PEG 1000 and yielded thick platelets of 0.2-
0.4 mm length. These were then handled in nylon loops and flash frozen in liquid 
nitrogen. All chemicals used were provided by Sigma-Aldrich. 
 
DATA COLLECTION, PHASING AND STRUCTURE 
DETERMINATION 
A native dataset was first collected on PROXIMA 1 beamline at the SOLEIL 
synchrotron in Gif-sur-Yvette, France. As molecular replacement was not efficient to 
obtain the structure of PptT, we collected a highly redundant dataset consisting in 13 
scans of 120° rotation each, on the ID-29-1 beamline at the ESRF in Grenoble, 
France. The diffraction data were collected at a wavelength of 2 Å in order to 
accumulate the anomalous signal from the sulfur and phosphorus atoms. Data were 
processed with XDS, and scans were scaled together with XSCALE. Strong anomalous 
signal was detected and the SHELX software suite allowed us to identify nine of the 
eleven sulfur and phosphorus atoms present in the PptT-CoA complex, and obtain a 
density map using the single wavelength anomalous diffraction (SAD) phasing 
method. PHENIX AutoBuild was then used to automatically build the PptT structure. 
CoA was manually added and the structure was finally refined using REFMAC5 and 
COOT. Statistics of the datasets are detailed in Table 7. 
 
PPTT-ACP DOCKING 
Except from CoA, hetero atoms were first removed from the PptT refined 
structure. The resulting pdb file was then uploaded and set as the receptor molecule 
for molecular docking using the PatchDock webserver 
(http://bioinfo3d.cs.tau.ac.il/PatchDock/). The PpsC ACP domain model generated 
by MODELLER described in section II.A.4 was used as the ligand molecule. A 5 Å 
distance constraint between the side-chain oxygen atom of ACP S64 and the β-
phosphate phosphorus atom of CoA was set and the docking was run with default 
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values. The twenty best results were then streamed to the FireDock webserver 
(http://bioinfo3d.cs.tau.ac.il/FireDock/) and ran with default values. The second 
result in terms of global binding energy (-27.88 kcal/mol) was then considered as the 
most relevant docking model and is the one described in section II.B.3.d. 
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III. CONCLUSION & 
PERSPECTIVES 
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A. CONTEXT 
 
 
Although polyketides are widely used as drug molecules in diverse 
pharmaceutical applications accounting for several millions of dollars in industry, 
many of them remain to be discovered and characterized. The recent availability of 
numerous sequenced genomes should accelerate this process. New challenges also 
concern the direct engineering of polyketide synthases, especially modular polyketide 
synthases. In this exciting research field, advances in biochemical characterization of 
polyketide synthases have recently allowed the synthesis of new polyketide 
compounds. Also, the expensive chemical synthesis of polyketides is beginning to be 
replaced by natural biosynthesis. Nonetheless, in both cases, the lack of details in the 
polyketide biosynthesis mechanism remains the major bottleneck to take these 
strategies one step beyond. For that reason, efforts are now focusing on deciphering 
the complex mechanism used by polyketide synthases and other enzymes to 
synthesize these interesting molecules. Despite great advances during the last decade, 
there are still a number of outstanding issues that need to be addressed, including the 
substrate specificities of each catalytic domain and the architecture of these multi-
domain enzymes. During my PhD thesis, I have undertaken the functional and 
structural characterization of the mono-modular polyketide synthase PpsC and its 
activator PptT. These two enzymes are responsible for the synthesis of polyketide-
derived lipids that provide its virulence to Mycobacterium tuberculosis (Mtb). While 
PpsC is essential for the production of phtiocerol dimycocerosates, PptT catalyzes the 
post-translational modification of all the polyketide synthases and is thus essential to 
the biosynthesis of all polyketide-derived molecules in Mtb. In the long run, this 
study may help understand the mechanism of polyketide biosynthesis and assist the 
design of specific inhibitors of these two enzymes with the hope of developing new 
antituberculosis drugs. 
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B. MAIN RESULTS 
 
 
In this study, we have first used the recently developed domain trapping 
strategy to identify soluble fragments representing each domain of the polyketide 
synthase PpsC from Mycobacterium tuberculosis. These fragments have then been 
produced and purified in Escherichia coli for further structural and functional 
characterization. Crystallization trials realized on 19 fragments spanning the full-
length PpsC have allowed us to obtain crystals for 6 of them and solve the structures 
of the acyltransferase domain, the dehydratase domain, and the nucleotide-binding 
sub-domain of the enoylreductase domain from PpsC. In addition, we have solved the 
structure of the dehydratase domain in complex with crotonyl-coenzyme A that we 
have identified, using enzymatic tests, as a suitable substrate for the catalytic activity 
of this domain. The structure of the acyltransferase domain provides us with useful 
information about substrate specificity. A detailed analysis of the structure and 
function of this domain will be the point of a review together with structures of 
acyltransferases from other PKSs solved in our group. Using the structure of the 
dehydratase/crotonyl-coenzyme A complex, we have characterized the interactions 
that drive the substrate specificity of the dehydratase domain. Finally, both 
enoylreductase and dehydratase structures have helped us understand how the β-
carbon processing domains assemble into a polyketide synthase. Based on functional 
and structural similarities with the previously characterized mammalian fatty acid 
synthase, we have indeed established a model of the assembly of these two domains 
that we extended to the acyl carrier protein domain. We have proposed that type-I 
mono-modular polyketide synthases assemble in a way similar to mammalian fatty 
acid synthases (mFAS), to the contrary of multi-modular polyketide synthases for 
which a different assembly mode seems to prevail. 
In parallel, we applied the split GFP technology to diagnose the importance of 
the co-factors CoA and Mg2+ on the solubility of the Mtb 4’-phosphopantetheinyl 
transferase PptT in vivo and in vitro. We are now able to obtain this enzyme in a 
soluble and stable form without the need for a maltose binding protein fusion. We 


 
 
have also confirmed using biophysical techniques the importance of co-factors for the 
in vitro stability of PptT. Crystallization trials on this enzyme have resulted in the 
formation of clusters of platelets that were further optimized using microseeding 
techniques to yield high resolution diffracting crystals. The PptT structure has then 
been solved using the single anomalous wavelength diffraction method. Analysis of 
the structure led to the classification of PptT in the group-II PPTase family of 
enzymes, represented by the well-characterized Sfp. We have also found an 
interesting docking solution with a model of the acyl carrier protein domain of PpsC 
that allowed us to propose a catalytic mechanism based on the previously described 
complex between the human Acp synthase (AcpS) and the acyl carrier protein 
domain of mFAS. 
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C. PERSPECTIVES 
 
 
1. FURTHER APPLICATIONS OF THE 
DOMAIN TRAPPING  STRATEGY 
 
The domain trapping strategy has allowed us to identify soluble fragments 
representing each domain of PpsC. Our fragment study, along with published results 
on domains of other PKSs, has highlighted the limitations of a structural study on 
individual domains. For example, the KS domain has only been structurally 
characterized when expressed in fusion with the AT domain. The domain trapping 
method should allow the identification of fragments encompassing both the KS and 
the AT domains of PpsC, provided that a DNA library of fragments with a suitable 
size has been generated and that iPCR primers are located in the linker region 
between these two domains. Obviously, such strategy can be envisioned for the other 
domains of PpsC. The successful application of the domain trapping strategy on 
PpsC has also encouraged us to apply it to other PKSs. In particular, such approach 
could be used on PpsB and PpsD, which we believe are interacting with PpsC in order 
to stream the growing polyketide. Our domain trapping method would notably be 
useful to identify the boundaries of the docking domains and help the structural 
study of complexes between the KS and ACP domains of these PKSs. 
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2. SUBSTRATE SPECIFICITY OF 
POLYKETIDE SYNTHASES DOMAINS 
 
Modifying the substrate specificity of the different catalytic domains is a key 
step in an attempt to produce new polyketides from engineered PKSs. In this respect, 
AT domains from several PKSs have been mutated to accommodate malonyl-CoA 
instead of methylmalonyl-CoA. Unfortunately, the residues identified as responsible 
for this specificity switch are not strictly conserved and thus only concern a restricted 
number of PKSs. Another solution to alter elongation unit specificity of a PKS is the 
replacement of its AT domain by another AT domain possessing a different 
specificity, a strategy known as domain swapping, but it often comes at the cost of 
decreased product titres. In most cases, the only remaining solution is to directly 
mutate the AT domain. Therefore, the residues responsible for the specificity of 
additional AT domains must be identified. Preliminary results accumulated in our 
group on the functional and structural study of the AT domains from Mas, PpsA, 
PpsC (unpublished results), and Pks13 [135], indicate that substrate specificity of 
these domains can also be changed when mutating specific residues. Therefore, our 
study will certainly allow deciphering the determinants of elongation unit specificity 
for an increasing number of PKSs. 
We have also participated to the characterization of the dehydratase domain 
specificity. No structural information was available concerning a complex with a 
substrate that could actually be (de)hydrated. Instead, only mechanistic inhibitors 
were co-crystallized with FAS-II dehydratases. Our functional and structural work on 
the dehydratase domain of PpsC and its substrate analogue crotonyl-coenzyme A 
provides useful information on the substrate specificity of dehydratases and their 
catalytic mechanism. Nonetheless, similar experiments should also be carried out 
with substrates that are more similar to the physiological growing polyketides. For 
example, the DH domain of PpsC catalyzes the dehydration of the β-hydroxyl from a 
substrate longer than crotonyl by 20 carbons and which bears two additional 
hydroxyl substitutions at positions C5 and C7. These chemical groups probably 
enhance the substrate affinity for the DH domain through interacting residues that 
need to be characterized. 
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Our strategy for the structural study of the dehydratase domain in complex 
with its substrate can potentially be applied to any dehydratase domain or stand-
alone enzyme. This can be achieved either by co-crystallization or by soaking in a 
solution of commercially available crotonyl-coenzyme A, to the condition that the 
strictly conserved catalytic histidine at position 959 has been mutated into a 
phenylalanine. Applying this strategy to various dehydratases should (i) facilitate the 
identification of residues responsible for the specificity of these enzymes toward their 
substrates and (ii) allow engineering variants of the dehydratase domain that keep a 
high affinity for non-natural substrates, a feature interesting for high-throughput 
production of non-natural polyketides. 
 
3. DOMAIN-DOMAIN INTERACTIONS 
AND ASSEMBLY OF THE BETA-CARBON 
PROCESSING DOMAINS 
 
Very little information is available concerning domain-domain interactions in 
megasynthases. Also, no complex involving an acyl carrier protein domain and 
another catalytic domain from a polyketide synthase has ever been reported. The 
structure of the DH domain of PpsC in complex with crotonyl-coenzyme A has 
allowed us to propose a docking model between holo-ACP and the DH domain. A 
possible way to validate our model could be the mutation of putative interface 
residues. For example, our model helped identifying residues which might be 
involved in hydrogen bonding interactions mediating the binding of the ACP domain 
onto the DH domain. With the possibility of measuring the catalytic activity of the 
DH domain on substrates tethered to the ACP domain, we could compare the activity 
of DH and/or ACP mutants with their corresponding wild-type versions. Another 
perspective for the study of the DH/ACP interaction is to use our docking model as a 
basis for a rational engineering approach to tighten up the two domains by di-sulfide 
cross-linking between residues mutated into cysteines. Using a web program 
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intended to design disulfide bonds from structural information 
[http://cptweb.cpt.wayne.edu/DbD2/], at least two pairs of residues that can fulfill 
this role have been identified. 
We have also used our DH/ACP docking model to generate an assembly model 
of the DH-ER-ACP domains in PpsC, based on the mammalian FAS assembly. In our 
model, the ACP interacts with both the DH and ER domains, thus revealing the 
possibility of obtaining a stable complex between these three domains. To do so, we 
would proceed in two steps: (i) loading of a crotonyl-P-pant molecule onto the ACP 
domain with the help of PptT, and (ii) forming a stable complex with a DH-ER 
fragment bearing an inactive version of the DH domain. In addition, we are still 
working on the optimization of the crystallization conditions of the fragment 6 (DH-
ER-KR tri-domain), whose structure would definitely unravel the mechanism by 
which the β-carbon processing domains assemble in mono-modular PKSs. 
 
4. ANTITUBERCULOSIS DRUG DESIGN 
 
Both PpsC and PptT have arisen as promising drug targets against 
tuberculosis. Indeed, when PpsC is not expressed, DIM are not produced, which 
results in great attenuation of the virulence of Mtb. However, all the PpsC domains 
cannot be considered equally. On the one hand, the domains responsible for 
condensation (i.e. KS and AT) are obviously essential to the activity of the enzyme 
and thus represent potential drug targets. On the other hand, we do not have any 
evidence about the therapeutic value of inhibiting the β-carbon processing domains. 
For example inhibiting the DH domain of PpsC could either result in the formation of 
a DIM variant in which the β-carbon processed by PpsC (C9 for DIM A/B or C10 for 
DIM A’/B’) bears a hydroxyl substitution, or may not be processed by the 
downstream enzymes because of its unusual structure. As far as we know, there is no 
clue indicating how a growing polyketide would be processed in such a pathway. 
Therefore, in our study the structure of the AT domain appears as the most promising 
basis for the rational design of inhibitors. In the context of an ANR funded research 
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project involving several research groups in our institute, whose focus is the 
characterization of PKSs involved in Mtb virulence, AT domains from PpsA, Mas, and 
Pks13 have also been characterized. Preliminary results concerning the search for 
inhibitors of the AT domain of Pks13 indicate that several molecules are able to bind 
this domain and lead to the inhibition of its activity. The results of this project will 
certainly help the design of inhibitors of the AT domains of the PpsA, PpsC, and Mas 
enzymes. Furthermore, the recent development of the PICT platform (“Plateforme 
Intégrée de Criblage de Toulouse”, or Integrated Screening Platform of Toulouse) 
will greatly facilitate the identification, development, and characterization of 
inhibitor compounds. 
Inhibiting PptT would also be of great therapeutic value. Indeed, the study 
performed by our collaborators on the conditional expression of PptT has shown the 
importance of this enzyme for replication of the tubercle bacillus in acute and chronic 
phases of mycobacterial infection. Besides, PptT has the advantage of certainly being 
“druggable”, since several submicromolar inhibitors have already been found for one 
of its closest homologue, B. subtilis Sfp. In an attempt to search for inhibitors of PptT, 
a miniaturized assay suitable for high-throughput screening has been developed. In 
collaboration with the pharmaceutical company Sanofi, this approach has already led 
to the identification of several hit compounds which inhibit PptT activity. In the near 
future, the binding of these molecules onto PptT will be characterized by X-ray 
crystallography using the structure of PptT we have recently solved. The structures of 
the resulting complexes will provide a rational basis for the design of new molecules 
with enhanced efficiency. 
 
  


 
 
 
  
IV. REFERENCES 


 
 
[1] J. N. Collie and W. S. Myers, “The formation of orcinol and other condensation 
products from dehydroacetic acid,” Journal of Chemical Society, no. 63, p. 122, 
1893. 
[2] J. N. Collie, “Derivatives of the multiple keten group,” Journal of Chemical 
Society, vol. 91, p. 1806, 1907. 
[3] A. Birch, R. Massy-Westropp, and C. Moye, “Studies in relation to biosynthesis. 
VII. 2-Hydroxy-6-methylbenzoic acid in Penicillium griseofulvum Dierckx,” 
Australian Journal of Chemistry, vol. 8, p. 539, 1955. 
[4] D. E. Cane and C. C. Yang, “Biosynthetic origin of the carbon skeleton and 
oxygen atoms of nargenicin A1,” Journal of the American Chemical Society, 
vol. 106, no. 3, pp. 784–787, Feb. 1984. 
[5] D. E. Cane, P. C. Prabhakaran, W. Tan, and W. R. Ott, “Macrolide biosynthesis. 
6 Mechanism of polyketide chain elongation,” Tetrahedron Letters, vol. 32, no. 
40, pp. 5457–5460, Sep. 1991. 
[6] X. Xie and Y. Tang, “Efficient synthesis of simvastatin by use of whole-cell 
biocatalysis.,” Applied and environmental microbiology, vol. 73, no. 7, pp. 
2054–60, Apr. 2007. 
[7] J. Cortes, K. E. Wiesmann, G. a Roberts, M. J. Brown, J. Staunton, and P. F. 
Leadlay, “Repositioning of a domain in a modular polyketide synthase to 
promote specific chain cleavage.,” Science (New York, N.Y.), vol. 268, no. 5216, 
pp. 1487–9, Jun. 1995. 
[8] M. Oliynyk, M. J. Brown, J. Cortés, J. Staunton, and P. F. Leadlay, “A hybrid 
modular polyketide synthase obtained by domain swapping.,” Chemistry & 
biology, vol. 3, no. 10, pp. 833–9, Oct. 1996. 
[9] S. Gaisser, L. Kellenberger, A. L. Kaja, A. J. Weston, R. E. Lill, G. Wirtz, S. G. 
Kendrew, L. Low, R. M. Sheridan, B. Wilkinson, I. S. Galloway, K. Stutzman-
Engwall, H. a McArthur, J. Staunton, and P. F. Leadlay, “Direct production of 
ivermectin-like drugs after domain exchange in the avermectin polyketide 
synthase of Streptomyces avermitilis ATCC31272.,” Organic & biomolecular 
chemistry, vol. 1, no. 16, pp. 2840–7, Aug. 2003. 
[10] K. Patel, M. Piagentini, A. Rascher, Z.-Q. Tian, G. O. Buchanan, R. Regentin, Z. 
Hu, C. R. Hutchinson, and R. McDaniel, “Engineered biosynthesis of 
geldanamycin analogs for Hsp90 inhibition.,” Chemistry & biology, vol. 11, no. 
12, pp. 1625–33, Dec. 2004. 
[11] C. M. Starks, Y. Zhou, F. Liu, and P. J. Licari, “Isolation and characterization of 
new epothilone analogues from recombinant Myxococcus xanthus 
fermentations.,” Journal of natural products, vol. 66, no. 10, pp. 1313–7, Oct. 
2003. 

 
 
[12] H. G. Menzella, R. Reid, J. R. Carney, S. S. Chandran, S. J. Reisinger, K. G. 
Patel, D. a Hopwood, and D. V Santi, “Combinatorial polyketide biosynthesis by 
de novo design and rearrangement of modular polyketide synthase genes.,” 
Nature biotechnology, vol. 23, no. 9, pp. 1171–6, Sep. 2005. 
[13] M. Sosio, F. Giusino, C. Cappellano, E. Bossi, a M. Puglia, and S. Donadio, 
“Artificial chromosomes for antibiotic-producing actinomycetes.,” Nature 
biotechnology, vol. 18, no. 3, pp. 343–5, Mar. 2000. 
[14] P. Rugbjerg, M. Naesby, U. H. Mortensen, and R. J. Frandsen, “Reconstruction 
of the biosynthetic pathway for the core fungal polyketide scaffold rubrofusarin 
in Saccharomyces cerevisiae.,” Microbial cell factories, vol. 12, no. 1, p. 31, Apr. 
2013. 
[15] H. S. Raper, “The condensation of acetaldehyde and its relation to the 
biochemical synthesis of fatty acids,” Journal of Chemical Society, vol. 91, p. 
1831, 1907. 
[16] R. S. Flugel, “Holo-(Acyl Carrier Protein) Synthase and Phosphopantetheinyl 
Transfer in Escherichia coli,” Journal of Biological Chemistry, vol. 275, no. 2, 
pp. 959–968, Jan. 2000. 
[17] R. Lambalot, A. Gehring, and R. Flugel, “A new enzyme superfamily—the 
phosphopantetheinyl transferases,” Chemistry & biology, 1996. 
[18] C. T. Walsh, H. C. P. Synthase, and R. H. Lambalot, “Cloning, Overproduction, 
and Characterization of the Escherichia coli Holo-acyl Carrier Protein 
Synthase,” Journal of Biological Chemistry, vol. 270, no. 42, pp. 24658–24661, 
Oct. 1995. 
[19] J. K. Hiltunen, M. S. Schonauer, K. J. Autio, T. M. Mittelmeier, A. J. 
Kastaniotis, and C. L. Dieckmann, “Mitochondrial fatty acid synthesis type II: 
more than just fatty acids.,” The Journal of biological chemistry, vol. 284, no. 
14, pp. 9011–5, Apr. 2009. 
[20] D. Yu, F. Xu, J. Zeng, and J. Zhan, “Type III polyketide synthases in natural 
product biosynthesis.,” IUBMB life, vol. 64, no. 4, pp. 285–95, Apr. 2012. 
[21] C. Hertweck, A. Luzhetskyy, Y. Rebets, and A. Bechthold, “Type II polyketide 
synthases: gaining a deeper insight into enzymatic teamwork.,” Natural 
product reports, vol. 24, no. 1, pp. 162–90, Feb. 2007. 
[22] B. Shen, “Polyketide biosynthesis beyond the type I, II and III polyketide 
synthase paradigms,” Current Opinion in Chemical Biology, vol. 7, no. 2, pp. 
285–295, Apr. 2003. 
[23] J. F. Aparicio, I. Molnár, T. Schwecke, a König, S. F. Haydock, L. E. Khaw, J. 
Staunton, and P. F. Leadlay, “Organization of the biosynthetic gene cluster for 
rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains 
in the modular polyketide synthase.,” Gene, vol. 169, no. 1, pp. 9–16, Feb. 1996. 

 
 
[24] L. Tang, Y. J. Yoon, C. Y. Choi, and C. R. Hutchinson, “Characterization of the 
enzymatic domains in the modular polyketide synthase involved in rifamycin B 
biosynthesis by Amycolatopsis mediterranei.,” Gene, vol. 216, no. 2, pp. 255–
65, Aug. 1998. 
[25] R. Kong, X. Liu, C. Su, C. Ma, R. Qiu, and L. Tang, “Elucidation of the 
biosynthetic gene cluster and the post-PKS modification mechanism for 
fostriecin in Streptomyces pulveraceus.,” Chemistry & biology, vol. 20, no. 1, 
pp. 45–54, Jan. 2013. 
[26] J. Piel, “A polyketide synthase-peptide synthetase gene cluster from an 
uncultured bacterial symbiont of Paederus beetles.,” Proceedings of the 
National Academy of Sciences of the United States of America, vol. 99, no. 22, 
pp. 14002–7, Oct. 2002. 
[27] Y.-Q. Cheng, G.-L. Tang, and B. Shen, “Type I polyketide synthase requiring a 
discrete acyltransferase for polyketide biosynthesis.,” Proceedings of the 
National Academy of Sciences of the United States of America, vol. 100, no. 6, 
pp. 3149–54, Mar. 2003. 
[28] S. L. Ward, Z. Hu, A. Schirmer, R. Reid, W. P. Revill, C. D. Reeves, O. V 
Petrakovsky, S. D. Dong, and L. Katz, “Chalcomycin biosynthesis gene cluster 
from Streptomyces bikiniensis: novel features of an unusual ketolide produced 
through expression of the chm polyketide synthase in Streptomyces fradiae.,” 
Antimicrobial agents and chemotherapy, vol. 48, no. 12, pp. 4703–12, Dec. 
2004. 
[29] N. Palaniappan, B. S. Kim, Y. Sekiyama, H. Osada, and K. a Reynolds, 
“Enhancement and selective production of phoslactomycin B, a protein 
phosphatase IIa inhibitor, through identification and engineering of the 
corresponding biosynthetic gene cluster.,” The Journal of biological chemistry, 
vol. 278, no. 37, pp. 35552–7, Sep. 2003. 
[30] J. Ligon, S. Hill, J. Beck, R. Zirkle, I. Molnár, J. Zawodny, S. Money, and T. 
Schupp, “Characterization of the biosynthetic gene cluster for the antifungal 
polyketide soraphen A from Sorangium cellulosum So ce26.,” Gene, vol. 285, 
no. 1–2, pp. 257–67, Feb. 2002. 
[31] B. Julien, Z.-Q. Tian, R. Reid, and C. D. Reeves, “Analysis of the ambruticin and 
jerangolid gene clusters of Sorangium cellulosum reveals unusual mechanisms 
of polyketide biosynthesis.,” Chemistry & biology, vol. 13, no. 12, pp. 1277–86, 
Dec. 2006. 
[32] R. a Butcher, F. C. Schroeder, M. a Fischbach, P. D. Straight, R. Kolter, C. T. 
Walsh, and J. Clardy, “The identification of bacillaene, the product of the PksX 
megacomplex in Bacillus subtilis.,” Proceedings of the National Academy of 
Sciences of the United States of America, vol. 104, no. 5, pp. 1506–9, Jan. 
2007. 
[33] N. Brendel, L. P. Partida-Martinez, K. Scherlach, and C. Hertweck, “A cryptic 
PKS-NRPS gene locus in the plant commensal Pseudomonas fluorescens Pf-5 

 
 
codes for the biosynthesis of an antimitotic rhizoxin complex.,” Organic & 
biomolecular chemistry, vol. 5, no. 14, pp. 2211–3, Jul. 2007. 
[34] D. Menche, F. Arikan, O. Perlova, N. Horstmann, W. Ahlbrecht, S. C. Wenzel, 
R. Jansen, H. Irschik, and R. Müller, “Stereochemical determination and 
complex biosynthetic assembly of etnangien, a highly potent RNA polymerase 
inhibitor from the myxobacterium Sorangium cellulosum.,” Journal of the 
American Chemical Society, vol. 130, no. 43, pp. 14234–43, Oct. 2008. 
[35] R. Carvalho, R. Reid, N. Viswanathan, H. Gramajo, and B. Julien, “The 
biosynthetic genes for disorazoles, potent cytotoxic compounds that disrupt 
microtubule formation.,” Gene, vol. 359, pp. 91–8, Oct. 2005. 
[36] N. Gaitatzis, B. Silakowski, B. Kunze, G. Nordsiek, H. Blöcker, G. Höfle, and R. 
Müller, “The biosynthesis of the aromatic myxobacterial electron transport 
inhibitor stigmatellin is directed by a novel type of modular polyketide 
synthase.,” The Journal of biological chemistry, vol. 277, no. 15, pp. 13082–90, 
Apr. 2002. 
[37] C. Olano, B. Wilkinson, C. Sánchez, S. J. Moss, R. Sheridan, V. Math, A. J. 
Weston, A. F. Braña, C. J. Martin, M. Oliynyk, C. Méndez, P. F. Leadlay, and J. 
A. Salas, “Biosynthesis of the angiogenesis inhibitor borrelidin by Streptomyces 
parvulus Tü4055: cluster analysis and assignment of functions.,” Chemistry & 
biology, vol. 11, no. 1, pp. 87–97, Jan. 2004. 
[38] A. S. Eustáquio, R. P. McGlinchey, Y. Liu, C. Hazzard, L. L. Beer, G. Florova, M. 
M. Alhamadsheh, A. Lechner, A. J. Kale, Y. Kobayashi, K. a Reynolds, and B. S. 
Moore, “Biosynthesis of the salinosporamide A polyketide synthase substrate 
chloroethylmalonyl-coenzyme A from S-adenosyl-L-methionine.,” Proceedings 
of the National Academy of Sciences of the United States of America, vol. 106, 
no. 30, pp. 12295–300, Jul. 2009. 
[39] S. Rachid, L. Huo, J. Herrmann, M. Stadler, B. Köpcke, J. Bitzer, and R. Müller, 
“Mining the cinnabaramide biosynthetic pathway to generate novel proteasome 
inhibitors.,” Chembiochem᩿: a European journal of chemical biology, vol. 12, 
no. 6, pp. 922–31, Apr. 2011. 
[40] Y. Tang, C.-Y. Kim, I. I. Mathews, D. E. Cane, and C. Khosla, “The 2.7-
Angstrom crystal structure of a 194-kDa homodimeric fragment of the 6-
deoxyerythronolide B synthase.,” Proceedings of the National Academy of 
Sciences of the United States of America, vol. 103, no. 30, pp. 11124–9, Jul. 
2006. 
[41] Y. Tang, A. A. Y. Chen, C. C.-Y. Kim, D. D. E. Cane, C. Khosla, and A. 
Manuscript, “Structural and mechanistic analysis of protein interactions in 
module 3 of the 6-deoxyerythronolide B synthase.,” Chemistry & biology, vol. 
14, no. 8, pp. 931–43, Aug. 2007. 
[42] G. Pappenberger, J. Benz, B. Gsell, M. Hennig, A. Ruf, M. Stihle, R. Thoma, and 
M. G. Rudolph, “Structure of the human fatty acid synthase KS-MAT didomain 

 
 
as a framework for inhibitor design.,” Journal of molecular biology, vol. 397, 
no. 2, pp. 508–19, Mar. 2010. 
[43] A. Witkowski, A. K. Joshi, and S. Smith, “Characterization of the beta-carbon 
processing reactions of the mammalian cytosolic fatty acid synthase: role of the 
central core.,” Biochemistry, vol. 43, no. 32, pp. 10458–66, Aug. 2004. 
[44] A. Witkowski, A. A. K. Joshi, and S. Smith, “Mechanism of the beta-ketoacyl 
synthase reaction catalyzed by the animal fatty acid synthase.,” Biochemistry, 
vol. 41, no. 35, pp. 10877–87, Sep. 2002. 
[45] C. Khosla, R. S. Gokhale, J. R. Jacobsen, and D. E. Cane, “Tolerance and 
specificity of polyketide synthases.,” Annual review of biochemistry, vol. 68, 
pp. 219–53, Jan. 1999. 
[46] T. Maier, M. Leibundgut, and N. Ban, “The crystal structure of a mammalian 
fatty acid synthase.,” Science (New York, N.Y.), vol. 321, no. 5894, pp. 1315–22, 
Sep. 2008. 
[47] S. Kapur, B. Lowry, S. Yuzawa, S. Kenthirapalan, A. Y. Chen, D. E. Cane, and C. 
Khosla, “Reprogramming a module of the 6-deoxyerythronolide B synthase for 
iterative chain elongation.,” Proceedings of the National Academy of Sciences 
of the United States of America, vol. 109, no. 11, pp. 4110–5, Mar. 2012. 
[48] J. Wang, S. M. Soisson, K. Young, W. Shoop, S. Kodali, A. Galgoci, R. Painter, 
G. Parthasarathy, Y. S. Tang, R. Cummings, S. Ha, K. Dorso, M. Motyl, H. 
Jayasuriya, J. Ondeyka, K. Herath, C. Zhang, L. Hernandez, J. Allocco, A. 
Basilio, J. R. Tormo, O. Genilloud, F. Vicente, F. Pelaez, L. Colwell, S. H. Lee, B. 
Michael, T. Felcetto, C. Gill, L. L. Silver, J. D. Hermes, K. Bartizal, J. Barrett, D. 
Schmatz, J. W. Becker, D. Cully, and S. B. Singh, “Platensimycin is a selective 
FabF inhibitor with potent antibiotic properties.,” Nature, vol. 441, no. 7091, 
pp. 358–61, May 2006. 
[49] M. Moche, “Structure of the Complex between the Antibiotic Cerulenin and Its 
Target, beta -Ketoacyl-Acyl Carrier Protein Synthase,” Journal of Biological 
Chemistry, vol. 274, no. 10, pp. 6031–6034, Mar. 1999. 
[50] a C. Price, K. H. Choi, R. J. Heath, Z. Li, S. W. White, and C. O. Rock, 
“Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin 
and cerulenin. Structure and mechanism.,” The Journal of biological 
chemistry, vol. 276, no. 9, pp. 6551–9, Mar. 2001. 
[51] L. Serre, E. C. Verbree, Z. Dauter, A. R. Stuitje, and Z. S. Derewenda, “The 
Escherichia coli malonyl-CoA:acyl carrier protein transacylase at 1.5-A 
resolution. Crystal structure of a fatty acid synthase component.,” The Journal 
of biological chemistry, vol. 270, no. 22, pp. 12961–4, Jun. 1995. 
[52] A. T. Keatinge-Clay, A. a Shelat, D. F. Savage, S. C. Tsai, L. J. W. Miercke, J. D. 
O’Connell, C. Khosla, and R. M. Stroud, “Catalysis, specificity, and ACP docking 

 
 
site of Streptomyces coelicolor malonyl-CoA:ACP transacylase.,” Structure 
(London, England᩿: 1993), vol. 11, no. 2, pp. 147–54, Feb. 2003. 
[53] C. Oefner, H. Schulz, A. D’Arcy, and G. E. Dale, “Mapping the active site of 
Escherichia coli malonyl-CoA-acyl carrier protein transacylase (FabD) by 
protein crystallography.,” Acta crystallographica. Section D, Biological 
crystallography, vol. 62, no. Pt 6, pp. 613–8, Jun. 2006. 
[54] V. Alekseyev, C. Liu, and D. Cane, “Solution structure and proposed domain–
domain recognition interface of an acyl carrier protein domain from a modular 
polyketide synthase,” Protein science, pp. 2093–2107, 2007. 
[55] A. Busche, D. Gottstein, C. Hein, N. Ripin, I. Pader, P. Tufar, E. B. Eisman, L. 
Gu, C. T. Walsh, D. H. Sherman, F. Löhr, P. Güntert, and V. Dötsch, 
“Characterization of molecular interactions between ACP and halogenase 
domains in the Curacin A polyketide synthase.,” ACS chemical biology, vol. 7, 
no. 2, pp. 378–86, Feb. 2012. 
[56] A. Roujeinikova, W. J. Simon, J. Gilroy, D. W. Rice, J. B. Rafferty, and A. R. 
Slabas, “Structural studies of fatty acyl-(acyl carrier protein) thioesters reveal a 
hydrophobic binding cavity that can expand to fit longer substrates.,” Journal 
of molecular biology, vol. 365, no. 1, pp. 135–45, Jan. 2007. 
[57] E. Płoskoń, C. J. Arthur, S. E. Evans, C. Williams, J. Crosby, T. J. Simpson, and 
M. P. Crump, “A mammalian type I fatty acid synthase acyl carrier protein 
domain does not sequester acyl chains.,” The Journal of biological chemistry, 
vol. 283, no. 1, pp. 518–28, Jan. 2008. 
[58] S. Kapur, A. Y. Chen, D. E. Cane, and C. Khosla, “Molecular recognition 
between ketosynthase and acyl carrier protein domains of the 6-
deoxyerythronolide B synthase.,” Proceedings of the National Academy of 
Sciences of the United States of America, vol. 107, no. 51, pp. 22066–71, Dec. 
2010. 
[59] S. Anand and D. Mohanty, “Modeling holo-ACP:DH and holo-ACP:KR 
complexes of modular polyketide synthases: a docking and molecular dynamics 
study.,” BMC structural biology, vol. 12, no. 1, p. 10, Jan. 2012. 
[60] A. Keatinge-clay, “Crystal structure of the erythromycin polyketide synthase 
dehydratase.,” Journal of molecular biology, vol. 384, no. 4, pp. 941–53, Dec. 
2008. 
[61] J. Zheng, C. a Taylor, S. K. Piasecki, and A. T. Keatinge-Clay, “Structural and 
functional analysis of A-type ketoreductases from the amphotericin modular 
polyketide synthase.,” Structure (London, England᩿: 1993), vol. 18, no. 8, pp. 
913–22, Aug. 2010. 
[62] J. Zheng, S. K. Piasecki, and A. T. Keatinge-Clay, “Structural Studies of an A2-
Type Modular Polyketide Synthase Ketoreductase Reveal Features Controlling 
α-Substituent Stereochemistry.,” ACS chemical biology, Jun. 2013. 

 
 
[63] A. T. Keatinge-Clay, “A tylosin ketoreductase reveals how chirality is 
determined in polyketides.,” Chemistry & biology, vol. 14, no. 8, pp. 898–908, 
Aug. 2007. 
[64] A. T. Keatinge-Clay and R. M. Stroud, “The structure of a ketoreductase 
determines the organization of the beta-carbon processing enzymes of modular 
polyketide synthases.,” Structure (London, England᩿: 1993), vol. 14, no. 4, pp. 
737–48, Apr. 2006. 
[65] H. Zhou, Z. Gao, K. Qiao, J. Wang, J. C. Vederas, and Y. Tang, “A fungal 
ketoreductase domain that displays substrate-dependent stereospecificity.,” 
Nature chemical biology, vol. 8, no. 4, pp. 331–3, Apr. 2012. 
[66] D. H. Kwan, M. Tosin, N. Schläger, F. Schulz, and P. F. Leadlay, “Insights into 
the stereospecificity of ketoreduction in a modular polyketide synthase.,” 
Organic & biomolecular chemistry, vol. 9, no. 7, pp. 2053–6, Apr. 2011. 
[67] D. D. L. Akey, J. J. R. Razelun, J. Tehranisa, D. H. Sherman, W. H. Gerwick, 
and J. L. Smith, “Crystal structures of dehydratase domains from the curacin 
polyketide biosynthetic pathway,” Structure, vol. 18, no. 1, pp. 94–105, Jan. 
2010. 
[68] M. Leesong, B. S. Henderson, J. R. Gillig, J. M. Schwab, and J. L. Smith, 
“Structure of a dehydratase-isomerase from the bacterial pathway for 
biosynthesis of unsaturated fatty acids: two catalytic activities in one active 
site.,” Structure (London, England᩿: 1993), vol. 4, no. 3, pp. 253–64, Mar. 
1996. 
[69] B. Kusebauch, B. Busch, K. Scherlach, M. Roth, and C. Hertweck, “Functionally 
distinct modules operate two consecutive alpha,beta-->beta,gamma double-
bond shifts in the rhizoxin polyketide assembly line.,” Angewandte Chemie 
(International ed. in English), vol. 49, no. 8, pp. 1460–4, Feb. 2010. 
[70] E. Nordling, H. Jörnvall, and B. Persson, “Medium-chain 
dehydrogenases/reductases (MDR),” European Journal of Biochemistry, vol. 
269, no. 17, pp. 4267–4276, Sep. 2002. 
[71] J. Zheng, D. C. Gay, B. Demeler, M. a White, and A. T. Keatinge-Clay, 
“Divergence of multimodular polyketide synthases revealed by a didomain 
structure.,” Nature chemical biology, vol. 8, no. 7, pp. 615–21, Jul. 2012. 
[72] B. Ames and C. Nguyen, “Crystal structure and biochemical studies of the 
trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis,” 
Proceedings of the National Academy of Sciences of the United States of 
America, 2012. 
[73] J. Staunton, P. Caffrey, and J. Aparicio, “Evidence for a double-helical structure 
for modular polyketide synthases,” Nature Structural & …, 1996. 

 
 
[74] J. F. Aparicio, P. Caffrey, a F. Marsden, J. Staunton, and P. F. Leadlay, “Limited 
proteolysis and active-site studies of the first multienzyme component of the 
erythromycin-producing polyketide synthase.,” The Journal of biological 
chemistry, vol. 269, no. 11, pp. 8524–8, Mar. 1994. 
[75] I. Fujii, N. Yoshida, S. Shimomaki, H. Oikawa, and Y. Ebizuka, “An iterative 
type I polyketide synthase PKSN catalyzes synthesis of the decaketide 
alternapyrone with regio-specific octa-methylation.,” Chemistry & biology, vol. 
12, no. 12, pp. 1301–9, Dec. 2005. 
[76] D. Edwards, B. Marquez, and L. Nogle, “Structure and Biosynthesis of the 
Jamaicamides, New Mixed Polyketide-Peptide Neurotoxins from the Marine 
Cyanobacterium Lyngbya majuscula,” Chemistry & Biology, vol. 11, pp. 817–
833, 2004. 
[77] E. Brignole, S. Smith, and F. Asturias, “Conformational flexibility of metazoan 
fatty acid synthase enables catalysis,” Nature structural & molecular …, vol. 16, 
no. 2, pp. 190–197, 2009. 
[78] V. S. Rangan, a K. Joshi, and S. Smith, “Mapping the functional topology of the 
animal fatty acid synthase by mutant complementation in vitro.,” 
Biochemistry, vol. 40, no. 36, pp. 10792–9, Sep. 2001. 
[79] a. Witkowski, “Dibromopropanone Cross-linking of the Phosphopantetheine 
and Active-site Cysteine Thiols of the Animal Fatty Acid Synthase Can Occur 
Both Inter- and Intrasubunit. REEVALUATION OF THE SIDE-BY-SIDE, 
ANTIPARALLEL SUBUNIT MODEL,” Journal of Biological Chemistry, vol. 
274, no. 17, pp. 11557–11563, Apr. 1999. 
[80] C. Kao, G. Luo, and L. Katz, “Manipulation of macrolide ring size by directed 
mutagenesis of a modular polyketide synthase,” Journal of the American …, no. 
16, pp. 9105–9106, 1995. 
[81] R. S. R. Gokhale, J. Lau, D. D. E. Cane, and C. Khosla, “Functional orientation 
of the acyltransferase domain in a module of the erythromycin polyketide 
synthase,” Biochemistry, vol. 2960, no. 97, pp. 2524–2528, Feb. 1998. 
[82] R. S. Gokhale, “Dissecting and Exploiting Intermodular Communication in 
Polyketide Synthases,” Science, vol. 284, no. 5413, pp. 482–485, Apr. 1999. 
[83] F. T. Wong, A. Y. Chen, D. E. Cane, and C. Khosla, “Protein-protein recognition 
between acyltransferases and acyl carrier proteins in multimodular polyketide 
synthases.,” Biochemistry, vol. 49, no. 1, pp. 95–102, Jan. 2010. 
[84] P. Kumar, Q. Li, D. E. Cane, and C. Khosla, “Intermodular communication in 
modular polyketide synthases: structural and mutational analysis of linker 
mediated protein-protein recognition.,” Journal of the American Chemical 
Society, vol. 125, no. 14, pp. 4097–102, Apr. 2003. 

 
 
[85] R. Broadhurst and D. Nietlispach, “The structure of docking domains in 
modular polyketide synthases,” Chemistry & biology, vol. 10, pp. 723–731, 
2003. 
[86] J. Zheng, C. D. Fage, B. Demeler, D. W. Hoffman, and A. T. Keatinge-Clay, “The 
Missing Linker: A Dimerization Motif Located within Polyketide Synthase 
Modules.,” ACS chemical biology, Mar. 2013. 
[87] J. Copp and B. Neilan, “The phosphopantetheinyl transferase superfamily: 
phylogenetic analysis and functional implications in cyanobacteria,” Applied 
and environmental microbiology, vol. 72, no. 4, 2006. 
[88] L. E. Quadri, P. H. Weinreb, M. Lei, M. M. Nakano, P. Zuber, and C. T. Walsh, 
“Characterization of Sfp, a Bacillus subtilis phosphopantetheinyl transferase for 
peptidyl carrier protein domains in peptide synthetases.,” Biochemistry, vol. 
37, no. 6, pp. 1585–95, Feb. 1998. 
[89] A. K. Joshi, L. Zhang, V. S. Rangan, and S. Smith, “Cloning, expression, and 
characterization of a human 4’-phosphopantetheinyl transferase with broad 
substrate specificity.,” The Journal of biological chemistry, vol. 278, no. 35, pp. 
33142–9, Aug. 2003. 
[90] K. D. Parris, L. Lin, a Tam, R. Mathew, J. Hixon, M. Stahl, C. C. Fritz, J. Seehra, 
and W. S. Somers, “Crystal structures of substrate binding to Bacillus subtilis 
holo-(acyl carrier protein) synthase reveal a novel trimeric arrangement of 
molecules resulting in three active sites.,” Structure (London, England᩿: 1993), 
vol. 8, no. 8, pp. 883–95, Aug. 2000. 
[91] M. R. Mofid, R. Finking, L. O. Essen, and M. a Marahiel, “Structure-based 
mutational analysis of the 4’-phosphopantetheinyl transferases Sfp from 
Bacillus subtilis: carrier protein recognition and reaction mechanism.,” 
Biochemistry, vol. 43, no. 14, pp. 4128–36, Apr. 2004. 
[92] G. Bunkoczi, S. Pasta, A. Joshi, X. Wu, K. L. Kavanagh, S. Smith, and U. 
Oppermann, “Mechanism and substrate recognition of human holo ACP 
synthase,” Chemistry & biology, vol. 14, no. 11, pp. 1243–1253, Nov. 2007. 
[93] C. T. Walsh, a M. Gehring, P. H. Weinreb, L. E. Quadri, and R. S. Flugel, “Post-
translational modification of polyketide and nonribosomal peptide synthases.,” 
Current opinion in chemical biology, vol. 1, no. 3, pp. 309–15, Oct. 1997. 
[94] N. Barekzi, “Genetic characterization of pcpS, encoding the multifunctional 
phosphopantetheinyl transferase of Pseudomonas aeruginosa,” Microbiology, 
vol. 150, no. 4, pp. 795–803, Apr. 2004. 
[95] H. D. Mootz, R. Finking, and M. a Marahiel, “4’-phosphopantetheine transfer 
in primary and secondary metabolism of Bacillus subtilis.,” The Journal of 
biological chemistry, vol. 276, no. 40, pp. 37289–98, Oct. 2001. 

 
 
[96] N. Y. Chirgadze, S. L. Briggs, K. a McAllister, a S. Fischl, and G. Zhao, “Crystal 
structure of Streptococcus pneumoniae acyl carrier protein synthase: an 
essential enzyme in bacterial fatty acid biosynthesis.,” The EMBO journal, vol. 
19, no. 20, pp. 5281–7, Oct. 2000. 
[97] K. Reuter, M. R. Mofid, M. a Marahiel, and R. Ficner, “Crystal structure of the 
surfactin synthetase-activating enzyme sfp: a prototype of the 4’-
phosphopantetheinyl transferase superfamily.,” The EMBO journal, vol. 18, no. 
23, pp. 6823–31, Dec. 1999. 
[98] J. Ku, R. G. Mirmira, L. Liu, and D. V Santi, “Expression of a functional non-
ribosomal peptide synthetase module in Escherichia coli by coexpression with a 
phosphopantetheinyl transferase.,” Chemistry & biology, vol. 4, no. 3, pp. 203–
7, Mar. 1997. 
[99] J. T. Kealey, L. Liu, D. V Santi, M. C. Betlach, and P. J. Barr, “Production of a 
polyketide natural product in nonpolyketide-producing prokaryotic and 
eukaryotic hosts.,” Proceedings of the National Academy of Sciences of the 
United States of America, vol. 95, no. 2, pp. 505–9, Jan. 1998. 
[100] F. Fichtlscherer, C. Wellein, M. Mittag, and E. Schweizer, “A novel function of 
yeast fatty acid synthase. Subunit alpha is capable of self-pantetheinylation.,” 
European journal of biochemistry / FEBS, vol. 267, no. 9, pp. 2666–71, May 
2000. 
[101] S. Jenni, M. Leibundgut, D. Boehringer, C. Frick, B. Mikolásek, and N. Ban, 
“Structure of fungal fatty acid synthase and implications for iterative substrate 
shuttling.,” Science (New York, N.Y.), vol. 316, no. 5822, pp. 254–61, Apr. 
2007. 
[102] K. a McAllister, R. B. Peery, T. I. Meier, a S. Fischl, and G. Zhao, “Biochemical 
and molecular analyses of the Streptococcus pneumoniae acyl carrier protein 
synthase, an enzyme essential for fatty acid biosynthesis.,” The Journal of 
biological chemistry, vol. 275, no. 40, pp. 30864–72, Oct. 2000. 
[103] C. Chalut, “The nonredundant roles of two 4′-phosphopantetheinyl 
transferases in vital processes of Mycobacteria,” Proceedings of the National 
Academy of Sciences of the United States of America, vol. 103, no. 22, pp. 
8511–8516, 2006. 
[104] C. Leblanc, T. Prudhomme, G. Tabouret, A. Ray, S. Burbaud, S. Cabantous, L. 
Mourey, C. Guilhot, and C. Chalut, “4’-Phosphopantetheinyl transferase PptT, a 
new drug target required for Mycobacterium tuberculosis growth and 
persistence in vivo.,” PLoS pathogens, vol. 8, no. 12, p. e1003097, Dec. 2012. 
[105] S. Donadio, M. Staver, and J. McAlpine, “Modular organization of genes 
required for complex polyketide biosynthesis,” Science, vol. 1, 1991. 
[106] M. Oliynyk, M. Samborskyy, J. B. Lester, T. Mironenko, N. Scott, S. Dickens, S. 
F. Haydock, and P. F. Leadlay, “Complete genome sequence of the 

 
 
erythromycin-producing bacterium Saccharopolyspora erythraea 
NRRL23338.,” Nature biotechnology, vol. 25, no. 4, pp. 447–53, Apr. 2007. 
[107] G. L. Challis and D. a Hopwood, “Synergy and contingency as driving forces for 
the evolution of multiple secondary metabolite production by Streptomyces 
species.,” Proceedings of the National Academy of Sciences of the United 
States of America, vol. 100 Suppl , pp. 14555–61, Nov. 2003. 
[108] S. Omura, H. Ikeda, J. Ishikawa, a Hanamoto, C. Takahashi, M. Shinose, Y. 
Takahashi, H. Horikawa, H. Nakazawa, T. Osonoe, H. Kikuchi, T. Shiba, Y. 
Sakaki, and M. Hattori, “Genome sequence of an industrial microorganism 
Streptomyces avermitilis: deducing the ability of producing secondary 
metabolites.,” Proceedings of the National Academy of Sciences of the United 
States of America, vol. 98, no. 21, pp. 12215–20, Oct. 2001. 
[109] H. Ikeda, J. Ishikawa, A. Hanamoto, M. Shinose, H. Kikuchi, T. Shiba, Y. 
Sakaki, M. Hattori, and S. Omura, “Complete genome sequence and 
comparative analysis of the industrial microorganism Streptomyces 
avermitilis.,” Nature biotechnology, vol. 21, no. 5, pp. 526–31, May 2003. 
[110] T. M. Daniel, “The history of tuberculosis.,” Respiratory medicine, vol. 100, no. 
11, pp. 1862–70, Nov. 2006. 
[111] M. C. Gutierrez, S. Brisse, R. Brosch, M. Fabre, B. Omaïs, M. Marmiesse, P. 
Supply, and V. Vincent, “Ancient origin and gene mosaicism of the progenitor 
of Mycobacterium tuberculosis.,” PLoS pathogens, vol. 1, no. 1, p. e5, Sep. 
2005. 
[112] G. M. Taylor, D. B. Young, and S. A. Mays, “Genotypic analysis of the earliest 
known prehistoric case of tuberculosis in Britain.,” Journal of clinical 
microbiology, vol. 43, no. 5, pp. 2236–40, May 2005. 
[113] H. Herzog, Basel, “History of Tuberculosis,” Respiration, vol. 65, no. 1, pp. 5–
15, 1998. 
[114] M. a Behr, “BCG--different strains, different vaccines?,” The Lancet infectious 
diseases, vol. 2, no. 2, pp. 86–92, Feb. 2002. 
[115] B. B. Trunz, P. Fine, and C. Dye, “Effect of BCG vaccination on childhood 
tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis 
and assessment of cost-effectiveness.,” Lancet, vol. 367, no. 9517, pp. 1173–80, 
Apr. 2006. 
[116] H. McShane, “Tuberculosis vaccines: beyond bacille Calmette-Guerin.,” 
Philosophical transactions of the Royal Society of London. Series B, Biological 
sciences, vol. 366, no. 1579, pp. 2782–9, Oct. 2011. 
[117] A. A. Velayati, M. R. Masjedi, P. Farnia, P. Tabarsi, J. Ghanavi, A. H. Ziazarifi, 
and S. E. Hoffner, “Emergence of new forms of totally drug-resistant 

 
 
tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally 
drug-resistant strains in iran.,” Chest, vol. 136, no. 2, pp. 420–5, Aug. 2009. 
[118] S. Loewenberg, “India reports cases of totally drug-resistant tuberculosis,” The 
Lancet, vol. 379, no. 9812, p. 205, Jan. 2012. 
[119] D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, and D. Menzies, 
“Incidence of serious side effects from first-line antituberculosis drugs among 
patients treated for active tuberculosis.,” American journal of respiratory and 
critical care medicine, vol. 167, no. 11, pp. 1472–7, Jun. 2003. 
[120] T. Törün, G. Güngör, I. Ozmen, Y. Bölükbaşi, E. Maden, B. Biçakçi, G. Ataç, T. 
Sevim, and K. Tahaoğlu, “Side effects associated with the treatment of 
multidrug-resistant tuberculosis.,” The international journal of tuberculosis 
and lung disease᩿: the official journal of the International Union against 
Tuberculosis and Lung Disease, vol. 9, no. 12, pp. 1373–7, Dec. 2005. 
[121] B. Villemagne, C. Crauste, M. Flipo, A. R. Baulard, B. Déprez, and N. Willand, 
“Tuberculosis: the drug development pipeline at a glance.,” European journal 
of medicinal chemistry, vol. 51, pp. 1–16, May 2012. 
[122] E. STACKEBRANDT, F. A. RAINEY, and N. L. WARD-RAINEY, “Proposal for a 
New Hierarchic Classification System, Actinobacteria classis nov.,” 
International Journal of Systematic Bacteriology, vol. 47, no. 2, pp. 479–491, 
Apr. 1997. 
[123] E. Tortoli, “The new mycobacteria: an update.,” FEMS immunology and 
medical microbiology, vol. 48, no. 2, pp. 159–78, Nov. 2006. 
[124] S. Mostowy, J. Inwald, S. Gordon, C. Martin, R. Warren, K. Kremer, D. Cousins, 
and M. A. Behr, “Revisiting the evolution of Mycobacterium bovis.,” Journal of 
bacteriology, vol. 187, no. 18, pp. 6386–95, Sep. 2005. 
[125] R. Brosch, S. V Gordon, T. Garnier, K. Eiglmeier, W. Frigui, P. Valenti, S. Dos 
Santos, S. Duthoy, C. Lacroix, C. Garcia-Pelayo, J. K. Inwald, P. Golby, J. N. 
Garcia, R. G. Hewinson, M. a Behr, M. a Quail, C. Churcher, B. G. Barrell, J. 
Parkhill, and S. T. Cole, “Genome plasticity of BCG and impact on vaccine 
efficacy.,” Proceedings of the National Academy of Sciences of the United 
States of America, vol. 104, no. 13, pp. 5596–601, Mar. 2007. 
[126] S. Cole, R. Brosch, J. Parkhill, and T. Garnier, “Deciphering the biology of 
Mycobacterium tuberculosis from the complete genome sequence,” Nature, vol. 
396, no. NOVEMBER, 1998. 
[127] J.-C. Camus, M. J. Pryor, C. Médigue, and S. T. Cole, “Re-annotation of the 
genome sequence of Mycobacterium tuberculosis H37Rv.,” Microbiology 
(Reading, England), vol. 148, no. Pt 10, pp. 2967–73, Oct. 2002. 

 
 
[128] M. Daffé and P. Draper, “The envelope layers of mycobacteria with reference to 
their pathogenicity,” Advances in Microbial Physiology, vol. 29, pp. 131–203, 
1997. 
[129] B. Zuber, M. Chami, C. Houssin, J. Dubochet, G. Griffiths, and M. Daffé, 
“Direct visualization of the outer membrane of mycobacteria and 
corynebacteria in their native state.,” Journal of bacteriology, vol. 190, no. 16, 
pp. 5672–80, Aug. 2008. 
[130] M. Jackson, G. Stadthagen, and B. Gicquel, “Long-chain multiple methyl-
branched fatty acid-containing lipids of Mycobacterium tuberculosis: 
biosynthesis, transport, regulation and biological activities.,” Tuberculosis 
(Edinburgh, Scotland), vol. 87, no. 2, pp. 78–86, Mar. 2007. 
[131] D. E. Minnikin, L. Kremer, L. G. Dover, and G. S. Besra, “The methyl-branched 
fortifications of Mycobacterium tuberculosis.,” Chemistry & biology, vol. 9, no. 
5, pp. 545–53, May 2002. 
[132] K. Takayama, L. Wang, and H. L. David, “Effect of isoniazid on the in vivo 
mycolic acid synthesis, cell growth, and viability of Mycobacterium 
tuberculosis.,” Antimicrobial agents and chemotherapy, vol. 2, no. 1, pp. 29–
35, Jul. 1972. 
[133] D. M. E. Bowdish, K. Sakamoto, M.-J. Kim, M. Kroos, S. Mukhopadhyay, C. a 
Leifer, K. Tryggvason, S. Gordon, and D. G. Russell, “MARCO, TLR2, and CD14 
are required for macrophage cytokine responses to mycobacterial trehalose 
dimycolate and Mycobacterium tuberculosis.,” PLoS pathogens, vol. 5, no. 6, p. 
e1000474, Jun. 2009. 
[134] D. Portevin, C. De Sousa-D’Auria, C. Houssin, C. Grimaldi, M. Chami, M. Daffé, 
and C. Guilhot, “A polyketide synthase catalyzes the last condensation step of 
mycolic acid biosynthesis in mycobacteria and related organisms.,” 
Proceedings of the National Academy of Sciences of the United States of 
America, vol. 101, no. 1, pp. 314–9, Jan. 2004. 
[135] F. Bergeret, S. Gavalda, C. Chalut, W. Malaga, A. Quémard, J.-D. Pedelacq, M. 
Daffé, C. Guilhot, L. Mourey, and C. Bon, “Biochemical and structural study of 
the atypical acyltransferase domain from the mycobacterial polyketide synthase 
Pks13.,” The Journal of biological chemistry, vol. 287, no. 40, pp. 33675–90, 
Sep. 2012. 
[136] S. Gavalda, M. Léger, B. van der Rest, A. Stella, F. Bardou, H. Montrozier, C. 
Chalut, O. Burlet-Schiltz, H. Marrakchi, M. Daffé, and A. Quémard, “The 
Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in 
Mycobacterium tuberculosis.,” The Journal of biological chemistry, vol. 284, 
no. 29, pp. 19255–64, Jul. 2009. 
[137] P. Brodin, Y. Poquet, F. Levillain, I. Peguillet, G. Larrouy-Maumus, M. Gilleron, 
F. Ewann, T. Christophe, D. Fenistein, J. Jang, M.-S. Jang, S.-J. Park, J. 
Rauzier, J.-P. Carralot, R. Shrimpton, A. Genovesio, J. a Gonzalo-Asensio, G. 
Puzo, C. Martin, R. Brosch, G. R. Stewart, B. Gicquel, and O. Neyrolles, “High 

 
 
content phenotypic cell-based visual screen identifies Mycobacterium 
tuberculosis acyltrehalose-containing glycolipids involved in phagosome 
remodeling.,” PLoS pathogens, vol. 6, no. 9, p. e1001100, Jan. 2010. 
[138] C. Passemar, A. Arbués, W. Malaga, I. Mercier, F. Moreau, L. Lepourry, O. 
Neyrolles, C. Guilhot, and C. Astarie-Dequeker, “Multiple deletions in the 
polyketide synthase gene repertoire of Mycobacterium tuberculosis reveal 
functional overlap of cell envelope lipids in host-pathogen interactions.,” 
Cellular microbiology, vol. 1, Sep. 2013. 
[139] J. D. Mougous, C. J. Petzold, R. H. Senaratne, D. H. Lee, D. L. Akey, F. L. Lin, 
S. E. Munchel, M. R. Pratt, L. W. Riley, J. a Leary, J. M. Berger, and C. R. 
Bertozzi, “Identification, function and structure of the mycobacterial 
sulfotransferase that initiates sulfolipid-1 biosynthesis.,” Nature structural & 
molecular biology, vol. 11, no. 8, pp. 721–9, Aug. 2004. 
[140] T. D. Sirakova, a K. Thirumala, V. S. Dubey, H. Sprecher, and P. E. 
Kolattukudy, “The Mycobacterium tuberculosis pks2 gene encodes the synthase 
for the hepta- and octamethyl-branched fatty acids required for sulfolipid 
synthesis.,” The Journal of biological chemistry, vol. 276, no. 20, pp. 16833–9, 
May 2001. 
[141] K. Bhatt, S. S. Gurcha, A. Bhatt, G. S. Besra, and W. R. Jacobs, “Two polyketide-
synthase-associated acyltransferases are required for sulfolipid biosynthesis in 
Mycobacterium tuberculosis.,” Microbiology (Reading, England), vol. 153, no. 
Pt 2, pp. 513–20, Feb. 2007. 
[142] P. Kumar, M. W. Schelle, M. Jain, F. L. Lin, C. J. Petzold, M. D. Leavell, J. a 
Leary, J. S. Cox, and C. R. Bertozzi, “PapA1 and PapA2 are acyltransferases 
essential for the biosynthesis of the Mycobacterium tuberculosis virulence 
factor sulfolipid-1.,” Proceedings of the National Academy of Sciences of the 
United States of America, vol. 104, no. 27, pp. 11221–6, Jul. 2007. 
[143] J. C. Seeliger, C. M. Holsclaw, M. W. Schelle, Z. Botyanszki, S. a Gilmore, S. E. 
Tully, M. Niederweis, B. F. Cravatt, J. a Leary, and C. R. Bertozzi, “Elucidation 
and chemical modulation of sulfolipid-1 biosynthesis in Mycobacterium 
tuberculosis.,” The Journal of biological chemistry, vol. 287, no. 11, pp. 7990–
8000, Mar. 2012. 
[144] R. Saavedra, E. Segura, R. Leyva, L. A. Esparza, and L. U. Z. M. Lo, 
“Mycobacterial Di- O -Acyl-Trehalose Inhibits Mitogen- and Antigen-Induced 
Proliferation of Murine T Cells In Vitro,” vol. 8, no. 6, pp. 1081–1088, 2001. 
[145] R. Saavedra, E. Segura, E. P. Tenorio, and L. M. López-Marín, “Mycobacterial 
trehalose-containing glycolipid with immunomodulatory activity on human 
CD4+ and CD8+ T-cells.,” Microbes and infection / Institut Pasteur, vol. 8, no. 
2, pp. 533–40, Feb. 2006. 
[146] S. a Gilmore, M. W. Schelle, C. M. Holsclaw, C. D. Leigh, M. Jain, J. S. Cox, J. a 
Leary, and C. R. Bertozzi, “Sulfolipid-1 biosynthesis restricts Mycobacterium 

 
 
tuberculosis growth in human macrophages.,” ACS chemical biology, vol. 7, no. 
5, pp. 863–70, May 2012. 
[147] V. S. Dubey, T. D. Sirakova, and P. E. Kolattukudy, “Disruption of msl3 
abolishes the synthesis of mycolipanoic and mycolipenic acids required for 
polyacyltrehalose synthesis in Mycobacterium tuberculosis H37Rv and causes 
cell aggregation.,” Molecular microbiology, vol. 45, no. 5, pp. 1451–9, Sep. 
2002. 
[148] S. K. Hatzios, M. W. Schelle, C. M. Holsclaw, C. R. Behrens, Z. Botyanszki, F. L. 
Lin, B. L. Carlson, P. Kumar, J. a Leary, and C. R. Bertozzi, “PapA3 is an 
acyltransferase required for polyacyltrehalose biosynthesis in Mycobacterium 
tuberculosis.,” The Journal of biological chemistry, vol. 284, no. 19, pp. 12745–
51, May 2009. 
[149] J. J. De Voss, K. Rutter, B. G. Schroeder, H. Su, Y. Zhu, and C. E. Barry, “The 
salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are 
essential for growth in macrophages.,” Proceedings of the National Academy of 
Sciences of the United States of America, vol. 97, no. 3, pp. 1252–7, Feb. 2000. 
[150] S. C. Andrews, A. K. Robinson, and F. RodrÃguez-QuiÃ±ones, “Bacterial iron 
homeostasis,” FEMS Microbiology Reviews, vol. 27, no. 2–3, pp. 215–237, Jun. 
2003. 
[151] D. Schnappinger, S. Ehrt, M. I. Voskuil, Y. Liu, J. a Mangan, I. M. Monahan, G. 
Dolganov, B. Efron, P. D. Butcher, C. Nathan, and G. K. Schoolnik, 
“Transcriptional Adaptation of Mycobacterium tuberculosis within 
Macrophages: Insights into the Phagosomal Environment.,” The Journal of 
experimental medicine, vol. 198, no. 5, pp. 693–704, Sep. 2003. 
[152] A. M. Talaat, R. Lyons, S. T. Howard, and S. A. Johnston, “The temporal 
expression profile of Mycobacterium tuberculosis infection in mice.,” 
Proceedings of the National Academy of Sciences of the United States of 
America, vol. 101, no. 13, pp. 4602–7, Mar. 2004. 
[153] L. E. Quadri, J. Sello, T. a Keating, P. H. Weinreb, and C. T. Walsh, 
“Identification of a Mycobacterium tuberculosis gene cluster encoding the 
biosynthetic enzymes for assembly of the virulence-conferring siderophore 
mycobactin.,” Chemistry & biology, vol. 5, no. 11, pp. 631–45, Nov. 1998. 
[154] M. Goren, O. Brokl, and W. Schaefer, “Lipids of putative relevance to virulence 
in Mycobacterium tuberculosis: phthiocerol dimycocerosate and the 
attenuation indicator lipid,” Infection and immunity, vol. 9, no. 1, pp. 150–158, 
1974. 
[155] E. Kondo and K. Kanai, “A suggested role of a host-parasite lipid complex in 
mycobacterial infection.,” Japanese journal of medical science & biology, 1976. 
[156] J. S. Cox, B. Chen, M. McNeil, and W. R. Jacobs, “Complex lipid determines 
tissue-specific replication of Mycobacterium tuberculosis in mice.,” Nature, vol. 
402, no. 6757, pp. 79–83, Nov. 1999. 

 
 
[157] L. Camacho and D. Ensergueix, “Identification of a virulence gene cluster of 
Mycobacterium tuberculosis by signatureǦtagged transposon mutagenesis,” 
Molecular …, vol. 34, pp. 257–267, 1999. 
[158] L. R. Camacho, P. Constant, C. Raynaud, M. a Laneelle, J. a Triccas, B. Gicquel, 
M. Daffe, and C. Guilhot, “Analysis of the phthiocerol dimycocerosate locus of 
Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall 
permeability barrier.,” The Journal of biological chemistry, vol. 276, no. 23, 
pp. 19845–54, Jun. 2001. 
[159] C. Rousseau, N. Winter, E. Pivert, Y. Bordat, O. Neyrolles, P. Avé, M. Huerre, B. 
Gicquel, and M. Jackson, “Production of phthiocerol dimycocerosates protects 
Mycobacterium tuberculosis from the cidal activity of reactive nitrogen 
intermediates produced by macrophages and modulates the early immune 
response to infection.,” Cellular microbiology, vol. 6, no. 3, pp. 277–87, Mar. 
2004. 
[160] K. Pethe, D. L. Swenson, S. Alonso, J. Anderson, C. Wang, and D. G. Russell, 
“Isolation of Mycobacterium tuberculosis mutants defective in the arrest of 
phagosome maturation.,” Proceedings of the National Academy of Sciences of 
the United States of America, vol. 101, no. 37, pp. 13642–7, Sep. 2004. 
[161] M. a Kirksey, A. D. Tischler, R. Siméone, K. B. Hisert, S. Uplekar, C. Guilhot, 
and J. D. McKinney, “Spontaneous phthiocerol dimycocerosate-deficient 
variants of Mycobacterium tuberculosis are susceptible to gamma interferon-
mediated immunity.,” Infection and immunity, vol. 79, no. 7, pp. 2829–38, Jul. 
2011. 
[162] C. Astarie-Dequeker, L. Le Guyader, W. Malaga, F.-K. Seaphanh, C. Chalut, A. 
Lopez, and C. Guilhot, “Phthiocerol dimycocerosates of M. tuberculosis 
participate in macrophage invasion by inducing changes in the organization of 
plasma membrane lipids.,” PLoS pathogens, vol. 5, no. 2, p. e1000289, Feb. 
2009. 
[163] M. B. Reed, P. Domenech, C. Manca, H. Su, A. K. Barczak, B. N. Kreiswirth, G. 
Kaplan, and C. E. Barry, “A glycolipid of hypervirulent tuberculosis strains that 
inhibits the innate immune response.,” Nature, vol. 431, no. 7004, pp. 84–7, 
Sep. 2004. 
[164] Z. Hasan, I. Zaidi, B. Jamil, M. A. Khan, A. Kanji, and R. Hussain, “Elevated ex 
vivo monocyte chemotactic protein-1 (CCL2) in pulmonary as compared with 
extra-pulmonary tuberculosis.,” BMC immunology, vol. 6, p. 14, Jan. 2005. 
[165] C. Manca, M. B. Reed, S. Freeman, B. Mathema, B. Kreiswirth, C. E. Barry, and 
G. Kaplan, “Differential monocyte activation underlies strain-specific 
Mycobacterium tuberculosis pathogenesis.,” Infection and immunity, vol. 72, 
no. 9, pp. 5511–4, Sep. 2004. 
[166] L. Tsenova, E. Ellison, R. Harbacheuski, A. L. Moreira, N. Kurepina, M. B. 
Reed, B. Mathema, C. E. Barry, and G. Kaplan, “Virulence of selected 
Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis 

 
 
is dependent on phenolic glycolipid produced by the bacilli.,” The Journal of 
infectious diseases, vol. 192, no. 1, pp. 98–106, Jul. 2005. 
[167] O. a Trivedi, P. Arora, A. Vats, M. Z. Ansari, R. Tickoo, V. Sridharan, D. 
Mohanty, and R. S. Gokhale, “Dissecting the mechanism and assembly of a 
complex virulence mycobacterial lipid.,” Molecular cell, vol. 17, no. 5, pp. 631–
43, Mar. 2005. 
[168] G. Stadthagen, J. Korduláková, R. Griffin, P. Constant, I. Bottová, N. Barilone, 
B. Gicquel, M. Daffé, and M. Jackson, “p-Hydroxybenzoic acid synthesis in 
Mycobacterium tuberculosis.,” The Journal of biological chemistry, vol. 280, 
no. 49, pp. 40699–706, Dec. 2005. 
[169] P. Constant, E. Perez, W. Malaga, M.-A. Lanéelle, O. Saurel, M. Daffé, and C. 
Guilhot, “Role of the pks15/1 gene in the biosynthesis of phenolglycolipids in 
the Mycobacterium tuberculosis complex. Evidence that all strains synthesize 
glycosylated p-hydroxybenzoic methyl esters and that strains devoid of 
phenolglycolipids harbor a frameshift ,” The Journal of biological chemistry, 
vol. 277, no. 41, pp. 38148–58, Oct. 2002. 
[170] O. Trivedi, P. Arora, V. Sridharan, and R. Tickoo, “Enzymic activation and 
transfer of fatty acids as acyl-adenylates in mycobacteria,” Nature, vol. 428, no. 
March, pp. 4–6, 2004. 
[171] K. C. Onwueme, J. a Ferreras, J. Buglino, C. D. Lima, and L. E. N. Quadri, 
“Mycobacterial polyketide-associated proteins are acyltransferases: proof of 
principle with Mycobacterium tuberculosis PapA5.,” Proceedings of the 
National Academy of Sciences of the United States of America, vol. 101, no. 13, 
pp. 4608–13, Mar. 2004. 
[172] a Rao and a Ranganathan, “Interaction studies on proteins encoded by the 
phthiocerol dimycocerosate locus of Mycobacterium tuberculosis.,” Molecular 
genetics and genomics᩿: MGG, vol. 272, no. 5, pp. 571–9, Dec. 2004. 
[173] K. C. Onwueme, C. J. Vos, J. Zurita, C. E. Soll, and L. E. N. Quadri, 
“Identification of phthiodiolone ketoreductase, an enzyme required for 
production of mycobacterial diacyl phthiocerol virulence factors.,” Journal of 
bacteriology, vol. 187, no. 14, pp. 4760–6, Jul. 2005. 
[174] E. Pérez, P. Constant, F. Laval, A. Lemassu, M.-A. Lanéelle, M. Daffé, and C. 
Guilhot, “Molecular dissection of the role of two methyltransferases in the 
biosynthesis of phenolglycolipids and phthiocerol dimycoserosate in the 
Mycobacterium tuberculosis complex.,” The Journal of biological chemistry, 
vol. 279, no. 41, pp. 42584–92, Oct. 2004. 
[175] M. Jain and J. J. S. Cox, “Interaction between polyketide synthase and 
transporter suggests coupled synthesis and export of virulence lipid in M. 
tuberculosis.,” PLoS pathogens, vol. 1, no. 1, p. e2, Sep. 2005. 

 
 
[176] G. Sulzenbacher, S. Canaan, Y. Bordat, O. Neyrolles, G. Stadthagen, V. Roig-
Zamboni, J. Rauzier, D. Maurin, F. Laval, M. Daffé, C. Cambillau, B. Gicquel, Y. 
Bourne, and M. Jackson, “LppX is a lipoprotein required for the translocation 
of phthiocerol dimycocerosates to the surface of Mycobacterium tuberculosis.,” 
The EMBO journal, vol. 25, no. 7, pp. 1436–44, Apr. 2006. 
[177] M. L. Schaeffer, G. Agnihotri, H. Kallender, P. J. Brennan, and J. T. Lonsdale, 
“Expression, purification, and characterization of the Mycobacterium 
tuberculosis acyl carrier protein, AcpM.,” Biochimica et biophysica acta, vol. 
1532, no. 1–2, pp. 67–78, May 2001. 
[178] H. C. Wong, G. Liu, Y.-M. Zhang, C. O. Rock, and J. Zheng, “The solution 
structure of acyl carrier protein from Mycobacterium tuberculosis.,” The 
Journal of biological chemistry, vol. 277, no. 18, pp. 15874–80, May 2002. 
[179] O. Dym, S. Albeck, Y. Peleg, A. Schwarz, Z. Shakked, Y. Burstein, and O. 
Zimhony, “Structure-function analysis of the acyl carrier protein synthase 
(AcpS) from Mycobacterium tuberculosis.,” Journal of molecular biology, vol. 
393, no. 4, pp. 937–50, Nov. 2009. 
[180] a K. Azad, T. D. Sirakova, N. D. Fernandes, and P. E. Kolattukudy, “Gene 
knockout reveals a novel gene cluster for the synthesis of a class of cell wall 
lipids unique to pathogenic mycobacteria.,” The Journal of biological 
chemistry, vol. 272, no. 27, pp. 16741–5, Jul. 1997. 
[181] a K. Azad, T. D. Sirakova, L. M. Rogers, and P. E. Kolattukudy, “Targeted 
replacement of the mycocerosic acid synthase gene in Mycobacterium bovis 
BCG produces a mutant that lacks mycosides.,” Proceedings of the National 
Academy of Sciences of the United States of America, vol. 93, no. 10, pp. 4787–
92, May 1996. 
[182] S. Cabantous and G. Waldo, “In vivo and in vitro protein solubility assays using 
split GFP,” Nature Methods, vol. 3, no. 10, pp. 845–854, 2006. 
[183] S. Cabantous, T. C. Terwilliger, and G. S. Waldo, “Protein tagging and detection 
with engineered self-assembling fragments of green fluorescent protein.,” 
Nature biotechnology, vol. 23, no. 1, pp. 102–7, Jan. 2005. 
[184] R. M. MCCUNE and R. TOMPSETT, “Fate of Mycobacterium tuberculosis in 
mouse tissues as determined by the microbial enumeration technique. I. The 
persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged 
antimicrobial therapy.,” The Journal of experimental medicine, vol. 104, no. 5, 
pp. 737–62, Nov. 1956. 
[185] A. Yasgar, T. Foley, A. Jadhav, J. Inglese, M. Burkart, and A. Simeonov, “A 
Strategy to Discover Inhibitors of Bacillus subtilis Surfactin- type 
Phosphopantetheinyl Transferase,” Molecular biosytems, vol. 6, no. 2, pp. 
365–375, 2010. 
[186] T. Bergfors, “Seeds to crystals,” Journal of Structural Biology, vol. 142, no. 1, 
pp. 66–76, Apr. 2003. 

 
 
[187] J. R. Luft and G. T. DeTitta, “A method to produce microseed stock for use in 
the crystallization of biological macromolecules.,” Acta crystallographica. 
Section D, Biological crystallography, vol. 55, no. Pt 5, pp. 988–93, May 1999.  

